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Abstract
An important role of modern forensic and clinical toxicologists is to monitor the adverse events of novel psychoactive substances (NPS). Following
a prior review from 2013 to 2016, this critical literature review analyzes and evaluates published case reports for NPS from January 2017 through
December 2020. The primary objective of this study is to assist in the assessment and interpretation of these cases as well as provide references
for confirmation methods. Chemistry, pharmacology, adverse events and user profiles (e.g., polypharmacy) for NPS are provided including
case history, clinical symptoms, autopsy findings and analytical results. Literature reviews were performed in PubMed and Google Scholar
for publications using search terms such as NPS specific names, general terms (e.g., ‘designer drugs’ and ‘novel psychoactive substances’),
drug classes (e.g., ‘designer stimulants’) and outcome-based terms (e.g., ‘overdose’ and ‘death’). Government and website drug surveillance
databases and abstracts published by professional forensic science organizations were also searched. Toxicological data and detailed case
information were extracted, tabulated, analyzed and organized by drug category. Case reports included overdose fatalities (378 cases), clinical
treatment and hospitalization (771 cases) and driving under the influence of drugs (170 cases) for a total of 1,319 cases providing details of
adverse events associated with NPS. Confirmed adverse events with associated toxidromes of more than 60 NPS were reported including
synthetic cannabinoid, NPS stimulant, NPS hallucinogen, NPS benzodiazepine and NPS opioid cases. Fifty of these NPS were reported for the
first time in January 2017 through December 2020 as compared to the previous 4 years surveyed. This study provides insight and context of
case findings described in the literature and in digital government surveillance databases and websites during a recent 4-year period. This review
will increase the awareness of adverse events associated with NPS use to better characterize international emerging drug threats.

Introduction
More than a decade after novel psychoactive substances
(NPS) first appeared on the illicit drug market, the appeal
of these drugs persists, requiring forensic investigations and
constant efforts by crime laboratories, public health officials
and law enforcement to stay current with rapidly changing trends. NPS—commonly described as novel, designer or
synthetic drugs—are a global phenomenon. Efforts by manufacturers and distributors to circumvent scheduling laws
and produce drugs with a possibly ambiguous legal status are driving the phenomenon. An additional demand is
fueled by people who use drugs for a novel drug experience or nuanced drug high, with the added benefit of these
drugs remaining undetectable in routine drug testing panels. In the 1980s, the term ‘designer drug’, coined by Gary
Henderson, originally characterized heroin-like derivatives—
such as the fentanyl analogs—but expanded with increasing
3,4-methylenedioxymethamphetamine (MDMA) popularity
to encompass stimulants and hallucinogens, including many

of the drugs described in Alexander Shulgin’s books ‘PiHKAL’
and ‘TiHKAL’ (1–3). Since the early 1980s, hundreds of NPS
have been synthesized and introduced to the national and
international drug markets. By 2005, the European Community adopted the term ‘new psychoactive substances’, defined
as unscheduled ‘narcotic or psychotropic drugs…which may
pose a threat to public health comparable to scheduled substances’ (4). The market continued to proliferate, with NPS
emerging in almost every drug class for which there is a
traditional therapeutic or illicit substance.
Herein, we have further refined the European Community definition of NPS as natural, synthetic or semisynthetic
substances in pure form, mixture or preparation that can be
categorized using at least one of the following criteria:
(i) A substance that has been discovered or synthesized for
the first time since the mid-2000s and is being ingested,
regardless of degree of psychoactive effect (e.g., MDMB4en-PINACA and N-pyrrolidino etonitazene);
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According to the United Nations Office on Drugs and
Crime (UNODC) Early Warning Advisory (EWA) on NPS,
542 total NPS were reported in 2019 compared to 131 total
NPS a decade earlier in 2009. However, trends related to
new substances appearing over the last 5 years showed some
stabilization (5). In the USA, the Drug Enforcement Administration’s (DEA’s) 2019 Annual Emerging Threat Report identified NPS in approximately 2% of the exhibits analyzed by
DEA laboratories, and 17 new substances were first reported
in 2019—or approximately one every 3 weeks (6). More
rapid and comprehensive data from the Center for Forensic
Science Research and Education’s (CFSRE’s) NPS Discovery
show 24 new substances identified for the first time in the USA
in 2020, with the majority being novel opioids, followed by
new synthetic cannabinoids (SC) (7). Consistent with trends
found in Europe, new identifications in the USA decreased in
2020 compared to previous years, which may be attributed
to the COVID-19 pandemic and disruption in distribution
(Figure 1).
This large number of new synthetic substances encompasses diverse chemical groups, many of which were pirated
from medical journals, scientific literature or patent filings and
clandestinely manufactured for illicit use (8). International
and national scheduling actions proved effective in reducing
the supply of NPS that has already emerged; however, new

substances are still quickly introduced to the market as successors to newly scheduled drugs or classes (9, 10). Additional
scheduling efforts have focused on precursor materials used
in the synthesis of NPS, but this has not deterred overall production of new substances. Clandestine chemists have quickly
moved to noncontrolled precursors and/or altered synthesis
routes in response to controls on traditional precursors (5).
The NPS supply chain involves an intricate web of research
chemists, underground laboratories, large-scale manufacturers and global distribution networks. There appears to be
relatively little NPS production in the USA with distribution
focused on final processing, dilution/cutting and packaging of
substances imported from China or other Asian or European
countries (11). The globalization of the NPS problem, including sophisticated and highly networked transnational criminal
organizations, is greatly facilitated by the ease of access via the
web, where illicit substances can be anonymously purchased
online with cryptocurrency and delivered to any destination
in the world (12, 13). People who use drugs post on drug
user forums and social media groups to discuss and debate
the effects and merits of the latest NPS entering the market
and drive demand. These digital forums also provide information related to effects, dosing recommendations, suggested
routes of administration and other user-reported experiences.
The fast-paced NPS market requires clinicians, epidemiologists, drug treatment services, harm-reduction organizations,
government regulators, prosecutors, law enforcement, analytical laboratories, researchers and other stakeholder groups
to constantly monitor numerous data streams to stay abreast
of emerging NPS, their proliferation, decline, health impacts
and the analytical challenges that they pose. We previously
published a comprehensive review of fatalities and adverse
events linked to then-current NPS (from 2013 through 2016)
associated with confirmed NPS ingestions, specifically involving NPS cannabinoids, stimulants, hallucinogens, benzodiazepines and opioids (14). These data were reported from
emergency departments (EDs), medicolegal death investigations, impaired driving and other forensic casework. The
goals of this review are to provide current data (i) for the most
recent emerging drugs in this classification to assist forensic and clinical toxicologists and other previously mentioned
stakeholders in their assessment and response and (ii) for analytical methods that can confirm the presence of NPS. The
initial report is updated and focuses on NPS data reported
during 2017 through 2020.

Methods

Figure 1. NPS reported per year by class in the U.S. (*data through
November 2021 available from NPS Discovery).

Literature reviews were performed in PubMed (National Center for Biotechnology Information, U.S. National Library of
Medicine, Bethesda, MD) and Google Scholar (Google, Inc.,
Mountain View, CA) for publications dated from January
2017 through December 2020. Search terms included specific names of NPS identified in laboratory casework and
published literature, as well as general terms (e.g., ‘designer
drugs’, and ‘novel psychoactive substances’) and drug classes
(e.g., ‘designer benzodiazepines’, ‘novel hallucinogens’ and
‘synthetic cannabinoids’), which were cross-referenced with
outcome-based terms (e.g., ‘overdose’, ‘intoxication’, ‘death’
and ‘hospitalization’). In addition, government reports on
websites discussing data for the years 2017 through 2020
were reviewed, including the National Forensic Laboratory
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(ii) A substance that was previously discovered, synthesized
or reported (e.g., patents, literature and publications) but
has been observed in the current illicit drug supply or identified in toxicological samples for the first time in more
than 10 years (e.g., 2-methyl AP-237 and isotonitazene);
(iii) A substance that since the mid-2000s has been used in a
novel way or differing manner from its originally intended
use (i.e., different dosage form or amount to produce
effects and different preparation) (e.g., loperamide and
xylazine);
(iv) A substance that previously was not well described or
studied but now presents significant challenges or threats
due to an altered toxicological effect profile as a result of
increased use or popularity (e.g., mitragynine) and/or
(v) A substance that is not controlled by the United Nations
drug conventions (1961 Single Convention on Narcotic
Drugs or the 1971 Convention on Psychotropic Substances) but that may pose a public health threat comparable to that posed by substances listed in these conventions
(e.g., quetiapine and O-desmethyl tramadol).

e117

e118

Synthetic Cannabinoids
Introduction
Approximately 280 new SC have entered the worldwide illicit
drug market from January 2009 through January 2020 (22).
Although many of these drugs persist at very low frequencies
for years beyond their initial appearance, there is a consistent pattern of the drugs having a life cycle of 9–18 months.
Once a new SC is identified and its prevalence increases, the
DEA schedules the drug and a new SC typically already in
the markets increases in prevalence to take its place. Only a
few new SC have been introduced each year since 2017. The
following sections provide a brief overview of SC chemistry,
pharmacology, adverse effects and case reports published
since 2017.
An ongoing challenge with SC is the inconsistency in
naming conventions. SC are classified based on their structural attributes (i.e., head, core, tailing and linker); early
examples include naphthoylindoles (JWH-018; Figure 2),
phenylacetylindoles (JWH-250), tetramethylcyclopropylindoles (XLR-11; Figure 2) and indolecarboxylates (5 F-PB-22).
Recently, indazole- and indole-carboxamides (e.g., AB-FUBI
NACA and MDMB-4en-PINACA) and gamma-carbolines
(e.g., Cumyl-CH-MEGACLONE and Cumyl-PEGACLONE)
have increased in popularity. Although structure-based terms
are the norm, new drugs may be titled based on their structural similarity to older drugs that may have been named
inconsistently or according to older naming conventions. The
most commonly used and preferred naming convention for
SC has been coined the modified Uchiyama system (23, 24).
Today, most scientists working in this arena have defaulted
to the naming that principal vendors of analytical standard
reference materials have assigned; these vendors also use the
modified Uchiyama system.

Pharmacology
Minor SC structural modifications do not generally produce
major pharmacological changes. SC are sometimes regarded

as ‘legal’ alternatives to ∆9 -tetrahydrocannabinol (THC), the
major psychoactive drug in Cannabis sativa, an agonist at
the CB1 and CB2 cannabinoid receptors. CB1 agonists generally produce the sought-after euphoria and relaxation effects
of cannabis, while CB2 agonists act on the immune system
and offer novel mechanisms of action for potential pharmacotherapies. Receptor binding studies, functional assays
and in vivo studies such as the mouse tetrad used to characterize SC pharmacology have been described in detail in
previous publications (14, 25–28). SC were usually not studied in vivo when humans began recreational use; toxicologists
and pharmacologists must rely on available in vitro or preclinical studies to suggest if new SC have pharmacological effects
similar to THC. Comparing the binding affinity and activity
of different SC is difficult because studies employ different
evaluation methods (29). Generally, the newer indole- and
indazole-carboxamides such as 5F-MDMB-PICA have been
shown to be more potent than the original drugs such as
JWH-018 and XLR-11. Furthermore, the pharmacokinetics
and pharmacodynamics of SC vary compared to THC and
each other. The paucity of animal and human studies leads
to difficulty with interpreting toxicology results with respect
to when an individual may have ingested an SC or predicting
what specific effects an analyte may have, and toxicologists
must rely on case studies as very few SC clinical studies are
available. Nonetheless, new drugs have appeared each year
during the period of study and evolved within broad general
SC drug subclasses, such as those previously mentioned.
Table I (30–57) summarizes multiple reports describing SC
adverse effects. Publications which included summaries of
large numbers of cases or detailed tables of individual cases
are not included in the table but rather summarized in the text
below (58–62). Further, two recently published exhaustive
review papers on SC include comprehensive case information
not included here (63, 64).
In general, individuals presented to the ED following use
of or exposure to an herbal incense product that resulted in
physiological or psychological distress. Commonly reported
symptoms included agitation, tachycardia, lethargy, loss of
consciousness and psychomotor impairment. Kleis et al. (60)
published a 5F-MDMB-PICA (Figure 1) case series including
five clinical cases, three fatalities and four driving under the
influence of drugs (DUID) cases. 5F-MDMB-PICA serum concentrations in the clinical cases were <0.1–2.5 ng/mL. Three
patients were aggressive, anxious or agitated, and one had a
‘subdued mood’; no mental/behavioral effects were reported
in the fifth case. The four drivers had serum 5F-MDMBPICA concentrations of 0.54–16 ng/mL. Another individual
described as ‘aggressive’ also had a 1.6 ng/mL 4F-MDMBBINACA serum concentration. All patients tested positive for
other drugs including cannabinoids (N = 5), ethanol (N = 4),
amphetamines (N = 2), benzodiazepines (N = 1), methadone
(N = 1), doxylamine (N = 1) and cetirizine (N = 1).
While most clinical cases involved intentional product use,
three unintentional exposure cases were reported. In one case,
two patients reported to the ED approximately 1.5–2 h after
drinking what they believed was winter melon tea (31). One
patient experienced a seizure, was drowsy and was tachycardic at the time of presentation, and the other was unconscious with a low heart rate (67 beats per minute [bpm])
within the normal range. Both patients’ urine specimens were
positive for 5F-MDMB-PICA 3,3-dimethylbutanoic acid, and
the liquid they consumed tested positive for 5F-MDMB-PICA
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Information System (NFLIS) (15), the European Monitoring
Centre from Drugs and Drug Addiction (EMCDDA) (16) and
NPS Discovery (17). Abstracts published by the Society of
Forensic Toxicologists (18) and the American Academy of
Forensic Sciences (19) from 2017 through 2020 were also
investigated.
Only cases that include qualitative or quantitative toxicological confirmation of the NPS in an individual’s body fluids
or tissues or the drug materials at the scene are included in the
review. Drug identification could be in any biological matrix
(e.g., blood, serum/plasma, urine, tissue and oral fluid). Toxicological data and detailed case information were extracted,
tabulated and organized by drug category.
Tables were constructed for synthetic cannabinoid (SC),
NPS stimulant, NPS hallucinogen, NPS benzodiazepine and
NPS opioid cases. Data include case histories, clinical signs
and symptoms, autopsy findings, NPS analytical results and
qualitative and quantitative data for all identified drugs. Citations are included for all published case reports. Structures
were obtained from various in-print and online resources,
including standard reference material manufacturer websites,
Scientific Working Group for the Analysis of Seized Drugs and
ChemSpider (20, 21). All structures were verified by more
than one source.

Mohr et al.

NPS Adverse Effects

e119

and 5Cl-ADAMANTYL-PINACA. An 8-year-old (y/o) male
receiving zonisamide for seizures was given a commercially
available cannabidiol (CBD) oil product by his parents despite
not being diagnosed for Dravet or Lennox–Gastaut syndrome
(40). The child’s neurologist approved treatment with this
product that is not regulated or approved by the Food and
Drug Administration. The first 9 days of CBD treatment were
uneventful; however, later the boy experienced more than
14 tonic-clonic episodes in 24 h. CBD use was discontinued,
and the patient was discharged after 2 days. Analysis of the
CBD product indicated it contained both CBD and the indazole carboxamide SC AB-FUBINACA. Finally, Dobaja et al.
(48) reported three customs inspectors who were occupationally exposed to the gamma-carboline SC Cumyl-PINACA.
They were not wearing gloves and came in contact with a
sticky substance during package examination. They immediately washed their hands but showed signs of an intoxicant exposure approximately 30 min after the exposure. They
arrived at the ED 6 h later confused, lethargic, tachycardic

and weak/numb. All symptoms resolved in 2 days, although
the patients reported some lingering amnesia and slowed
perception of time. Patient blood samples as well as the
liquid the patients came in contact with were positive for
Cumyl-PINACA.
The potentially devastating psychiatric effects of SC were
highlighted by a 2017 report of an individual who stabbed
multiple people, killing one, after using AM-2201 (44). The
accused could not provide any explanation for his actions,
indicating that he did not know why he attacked the individual who later succumbed to her injuries and that he injured the
other two only because he was scared and trying to get away.
No biological testing was performed, but the product tested
positive for AM-2201. A psychiatric evaluation after the event
determined that ‘while performing the acts as charged, the
man was, due to mental defect, totally or partially unable
to appreciate the nature and quality of his acts and be in
control of his conduct’. The accused did not have any history of psychiatric disorders, and the authors opined that the
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Figure 2. Structures of select NPS.

Asphyxiation signs: conjunctival petechiae
and over-inflation/edema of lungs. Brain
edema, massive blood stasis in heart
and circulatory system, enlarged liver,
TSS = 3 for 5F-Cumyl-PEGACLONE.
COD: asphyxia due to SC induced vomiting and aspiration of partially digested
gastric content

33 y/o M found dead in apartment. Hx of
‘spice’ use

HR 111 bpm, RR 21/min, BP 125/52, Temp
36.3◦ C, SpO2 95% on 4 L/min nasal cannula. GCS = 15 ∼4.5 h after ingestion.
Episodic hypotension during 87 h hospital
stay

Macroscopic organ examination unremarkable except for enlarged liver and spleen,
TSS = 2 for 5F-Cumyl-PEGACLONE due
to possible contributory role of pregabalin
and temazepam

36 y/o M found near jail cell

67 y/o F went to ED 1.5–2 h after drinking
yellow fluid from ‘winter melon tea’ bottle
with upward eye rolling and brief limb
jerking ∼45 min after ingestion. Drowsy
with GCS = 6 by EMS

Brain and pulmonary edema, acute blood
stasis in liver and kidneys. COD acute
heroin toxicity with contributory role of
5F-Cumyl-PEGACLONE (TSS = 1)

48 y/o F found dead at home. Hx of
narcotic drugs and ‘spice’ use

Urine: +5F-MDMB-PICA 3,3dimethylbutanoic acid
Seized drug: +5F-MDMB-PICA, +5CLADAMANTYL-PINACA

(30)

Blood (central): 0.07
Blood (femoral): 0.45
9-OH-risperidone 18, trimipramine 250,
+cinnarizine, +diphenhydramine
Brain: 0.03 ng/g
Urine: +5F-Cumyl-PEGACLONE metabolites
(unspecified)
Blood (central): 0.21
Blood (femoral): 0.23
Morphine 297, 6-AM 20, codeine 21,
oxazepam 450, alprazolam 10 and paroxetine
<10
Urine: +5F-Cumyl-PEGACLONE metabolites
(unspecified), 6-AM 12.3, dihydromorphine 29.7, noscapine 16, papaverine 27,
+buprenorphine, +norbuprenorphine,
+4F-MDMB-BINACA metabolites (unspecified),
+AB-FUBINACA/FUB-AMB metabolites
(unspecified)
Blood (central): 0.22
Blood (femoral): 0.12
Pregabalin 6,000, temazepam 230, oxazepam
12, alprazolam 16, lorazepam <5
Urine: +5F-Cumyl-PEGACLONE metabolites
(unspecified)
Blood (central): 0.35
Blood (femoral): 0.09
BZE 107, EME 11, +cocaine, +THC-COOH
Urine: +5F-Cumyl-PEGACLONE metabolites
(unspecified)

(continued)

(31)

(30)

(30)

(30)

Reference

Drug results (ng/mL, unless specified)
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5F-MDMB-PICA and 5ClADAMANTYL-PINACA
(5Cl-APINACA)

Brain and lung edema; bilateral cortical
kidney bleeding, massive subacute stasis
in liver and subcapsular hemorrhages and
acute tubular kidney necrosis, TSS = 3 for
5F-Cumyl-PEGACLONE

37 y/o M found dead in apartment. Hx
of mental health disorders and excessive
cannabis use.

5F-Cumyl-PEGACLONE

Clinical symptoms/Autopsy findings

History

Drug

Table I. SC Receptor Agonists’ Case Histories with Clinical Symptoms, Autopsy Findings and Primary and Additional Drug Concentrations

e120
Mohr et al.

5F-MDMB-PINACA (5F-ADB)

17 y/o F collapsed with foam on mouth
and loss of consciousness after smoking a
herbal mixture

49 y/o M with serious injury after jumping
from second floor after drinking alcohol
and smoking a herbal mixture. Died 6 days
later
26 y/o M driving erratically

8 patients (23–45 y/o; 7 M and 1 F) admitted to ED after IV heroin. Packets at scenes
labeled ‘Santa Muerte’ (4), ‘50 Cal’ (4)
and ‘Nick’ (1). All recovered following ED
admission

N/A

Unmotivated statements, changing moods,
nonsensical statements, glassy eyes,
sluggish, slow pupil response

PM Blood: 0.2
Fentanyl 5.5, quetiapine 11.6, 7-OHquetiapine 8.2, oxycodone 12.7, noroxycodone 2.7, oxymorphone 2.2
Plasma: 0.19
+5F-MDMB-PINACA 3,3-dimethylbutanoic
acid, 5OH-MDMB-PINACA, 5OH-MDMBPINACA 3,3-dimethylbutanoic acid,
4COOH-MDMB-PINACA, and others
Plasma: 0.11

(32)

Blood and Urine: +5F-MDMB-PINACA 3,3dimethylbutanoic acid
+7-amino-nitrazepam, +amphetamine,
+chloroquine, +codeine, +methadone,
+methamphetamine, +nitrazepam,
+nordiazepam
Serum (N = 3): +
+Cocaine (1), +heroin (3), +6-AM (3),
+fentanyl (3), +THC (1), +alprazolam (1)
Seized Drugs (N = 8): +
+Heroin, +fentanyl

Enlarged heart, left ventricular hypertrophy,
significant coronary atherosclerosis but
no infarct. COD mixed drug toxicity with
coronary artery disease

(continued)

(34)

(34)

(34)

(33)

(32)

Antemortem urine (Day 4): +5F-MDMBPINACA 3,3-dimethylbutanoic acid
+7-amino-nitrazepam, +gabapentin

Macroscopic and microscopic examination of brain and lungs confirmed COD
hypoxic ischemic encephalopathy and
pneumonia following SC use

7 of 8 patients admitted to ED with classical opioid toxidrome, including CNS
depression and pinpoint pupils. Following
naloxone administration, patients exhibited severe agitation, combative behavior
and anticholinergic and sympathomimetic
toxidrome. Treated with benzodiazepines
(8) and physostigmine (3)
TSS = 3. COD polytrauma with leading
craniocerebral injury

(31)

Urine: +5F-MDMB-PICA 3,3dimethylbutanoic acid
Seized drug: +5 F-MDMB-PICA, +5CLADAMANTYL-PINACA

HR 67 bpm, RR 20/min, BP 113/71,
Temp 37.0◦ C, SpO2 100% on room air.
GCS = 15 ∼4 h after ingestion

79 y/o F in bed, vomited 1×, became unconscious 1.5–2 h after drinking yellow fluid
from ‘winter melon tea’ bottle. GCS = 7 by
EMS. Transferred to ED

47 y/o M with past hx of heroin and benzodiazepine use admitted to hospital
for numbness and auditory hallucinations. Cardiovascular collapse on
Day 2. Developed hypoxic ischemic
encephalopathy and rhabdomyolysis.
Developed pneumonia and died 11 days
after admission
38 y/o M with hx of drug use arrived home
looking pale. Went to bed and snored.
Discovered cold and unresponsive 3 h later.
Transferred to ED and pronounced dead

Reference

Drug results (ng/mL, unless specified)

Clinical symptoms/Autopsy findings

History

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

Drug

Table I. SC Receptor Agonists’ Case Histories with Clinical Symptoms, Autopsy Findings and Primary and Additional Drug Concentrations
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18 y/o M dead in bed after smoking three
cigarettes containing ‘fake weed’

29 y/o M discovered in cardiac arrest in
office with three packages containing
‘leaves’ found nearby

AB-CHMINACA

21 y/o M transferred to ED due psychomotor agitation and attempted suicide after
smoking ‘spice’

14 y/o F transferred to ED after smoking
‘cherry bomb formula 6A’ and suffering
seizure

17 y/o M (n = 3) transported to ED after
smoking ‘spice’ together

Heavy lungs with severe alveolar effusions,
air bubbles and hemorrhage, systemic
hypoxia. COD AB-CHMINACA induced
pulmonary edema resulting in systemic
hypoxia

Brain edema, acute respiratory distress syndrome, pulmonary edema, acute venous
stasis in liver and spleen. COD acute
respiratory failure due to acute intoxication with 5F-MDMB-PINACA and
MMB-FUBINACA

Agitation, altered language, bradypsychia,
mydriasis and vomiting

Psychomotor agitation, confusion, anxiety, psychosis, tachycardia, amnesia,
temporary loss of consciousness
Hypoactive, altered consciousness and
headache

Dizziness, perception of rotating objects,
incoordination, spasmodic rigidity,
impaired gait, blepharospasm. Symptoms
resolved ∼6 h and was discharged
Driver asleep with car running and lodged
in guard rail, gear in reverse. Responsive
to verbal stimuli, indicated ‘high’. Bilateral
horizontal and vertical nystagmus, WAT
unable to maintain heel-to-toe, lost count,
raised arms; OLS put foot down, hands
for balance; Arrested for operating vehicle
while intoxicated

32 y/o M admitted to ED ∼15 h after taking
what he believed to be ketamine

45 y/o M drove car into oncoming traffic
and swerved into guard rail

Clinical symptoms/Autopsy findings

History

(36)

(37)

Blood: 26.4
+5F-MDMB-PINACA 3,3-dimethylbutanoic
acid

Urine: +5F-MDMB-PINACA 3,3dimethylbutanoic acid, 5OH-MDMBPINACA
Urine: +5F-MDMB-PINACA 3,3dimethylbutanoic acid, 5OH-MDMBPINACA, +5F-MMB-PICA 3-methylbutanoic
acid
Seized drug: +5F-MDMB-PINACA,
+5F-MMB-PICA
Urine: +5F-MDMB-PINACA 3,3dimethylbutanoic acid, 5OH-MDMBPINACA
Herbal blend: +5F-MDMB-PINACA

(39)

Blood: 7.6 ± 0.6
+AB-CHMINACA 3-methylbutanoic acid
56 ± 4, AB-CHMINACA 3-carboxyindazole
2.3 ± 0.1
+5F-MMB-PINACA (5F-AMB), +FUB-PB-22,
+AB-FUBINACA.
Seized Drug Packet 1: + AB-CHMINACA,
+5F-MMB-PICA
Seized Drug Packet 2:
+5F-AB-PINACA
Seized Drug Packet 3:
+4-methyl-N-ethylpentedone

(continued)

(38)

Blood: 3.7 5F-MDMB-PINACA
Seized drug: +5 F-MDMB-PINACA, +MMBFUBINACA

(37)

(37)

(35)

Reference

Plasma: +

Drug results (ng/mL, unless specified)
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5F-MDMB-PINACA (5F-ADB)
and MMB-FUBINACA (FUBAMB)

5F-MDMB-PINACA (5F-ADB)
and 5F-MMB-PICA

Drug
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History

8 y/o M with known seizure disorder
administered CBD oil purchased from
online retailer. After 9 days seizure-free
patient had >14 tonic-clonic episodes in
24 h

24 y/o M admitted to ED with acute confusion, agitation, visual hallucinations and
palpitations after ingesting ‘2 drops’ of ecigarette fluid ‘VapoFi’ mixed with fluid
from unlabeled bottle believed to be ‘liquid
cannabis’

17 y/o M inhaled two puffs of ‘weed’ with
friend. Both immediately began shivering uncontrollably and vomited. Assisted
to home of friend to rest. Discovered
unresponsive and cold to touch 6 h later.
Transferred to ED and pronounced dead
25 y/o M presented to ED with left severe
hemiparesia, left hypesthesia, dysarthria
and visual neglect after smoking ‘Freeze’
prior evening
38 y/o M inmate sent to medical center after
7-day hospitalization for abnormal behavior. Ovoid packets in GI tract (CT scan).
2 packages removed from the rectum, 2
by esophagogastroduodenoscopy and
22 by surgery on Days 7–8. 2 additional
packages found in the rectum on Day 16

18 y/o M stabbed F victim ∼20 times and
injured 2 M witnesses after smoking ‘Mr.
Green’

AB-FUBINACA

AB-FUBINACA and ADBFUBINACA

ADB-FUBINACA

AM-2201

Blood: 0.48
THC-COOH 23
Seized drug: +

(continued)

(44)

(43)

Serum: 34 (Day 6); 17 (Day 8);
+Diphenhydramine, +metoclopramide,
+cocaine, +scopolamine, +midazolam
Seized drug: +

HR 47 bpm, RR 12/min, BP 139/53, SpO2
95% on room air.
Lethargic, unable to answer questions,
shortness of breath, blank stare. Sinus
bradycardia, hypoglycemia, hypotension,
hypopnea, seizures following intubation.
Intermittent hypertension, seizure activity and toxic encephalopathy until Day
16. After final two packets, mental status
returned to baseline within 1 week. Discharged without neurological sequelae
after 1 month
Uncommunicative, calmly detached, sluggish motor movements, pupils slow to
react to light, staggered gait and uncoordinated 1.5 h after incident. Psychiatric
evaluation revealed abnormal personality
and psychotic disorders tempore criminis, cannabis and ‘legal high’ addiction,
and immature personality disorder. Psychiatric legal opinion: while performing
charged acts individual totally or partially
unable to appreciate nature and quality of
acts and not in control of conduct due to
mental defect

(42)

Urine: +
+MDMB-CHMICA
Seized drug: +

Acute ischemic infarction of right middle
cerebral artery, right cerebral edema

(32)

(41)

‘AB-FUBINACA’
Serum: 5.6
‘ADB-FUBINACA’
Serum: 15.6
Seized drug: +AB-FUBINACA, +ADBFUBINACA
Blood: 56

(40)

Reference

Seized drug: +
+CBD

Drug results (ng/mL, unless specified)

At autopsy, internal macroscopic and
microscopic examination of organs unremarkable. No injury or natural disease
noted. COD: ADB-FUBINACA toxicity

HR 169 bpm, RR 20/min, BP 163/93, Temp
36.3◦ C, SpO2 98% on room air. GCS
14/15. Supraventricular tachycardia, sinus
tachycardia with multiple ventricular
beats. Discharged after 22 h

Intermittent agitation, delirium, depressed
mental state, tachycardia, mydriasis.
Returned to baseline and discharged in
2 days

Clinical symptoms/Autopsy findings
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50 y/o M transferred to ED for altered mental status and chest pain after smoking
‘Scooby Snax Limited Edition Blueberry
Potpourri’

29 y/o M transported by EMS for agitation
and depressed consciousness after reported
OD of heroin

MMB-FUBINACA (FUB-AMB)
and PB-22

AMB-PINACA (MMB-PINACA)
and ADB-PINACA

29 y/o M transferred to ED by EMS after
fall at home. 3-day hx of somnolence,
weakness and vomiting

36 y/o F customs inspector developed dry
mouth, blurred vision, dizziness, balance
disorder, weakness, numbness and palpitations 0.5 h after exposure to unknown
viscous and sticky substance at the airport.
Transferred to ED 6 h later
22 y/o M customs inspector developed dizziness and weakness 0.5 h after exposure to
unknown viscous and sticky substance at
the airport. Transferred to ED 6 h later
36 y/o M customs inspector developed
blurred vision, dizziness, balance disorder,
weakness and lethargy 0.5 h after exposure
to unknown viscous and sticky substance
at the airport. Transferred to ED 6 h later

Cumyl-PINACA

Blood: +
Seized drug: +

Blood: +
Seized drug: +

Blood: +
Seized drug: +

HR 110 bpm, BP 145/95; Confused and
mydriasis. Reported amnesia and slowed
perception of time for 2 days
HR 110 bpm, BP 130/80; somnolent and
confused; mydriasis, ataxia; reported
amnesia and slowed perception of time
for 2 days

Serum: 35.5

Serum: +AMB-PINACA,
+ADB-PINACA

(continued)

(48)

(48)

(48)

(47)

(46)

(46)

(45)

Seized drug: +MMB-FUBINACA, +PB-22

Serum: +AMB-PINACA,
+ADB-PINACA

Reference

Drug results (ng/mL, unless specified)

HR 105 bpm, BP 130/88; blurred vision,
numbness, mydriasis, ataxia, somnolence,
lethargy and confusion. 2 days post event
reported amnesia and slowed perception

HR 105 bpm, BP 180/100, RR 22/min,
Temp 39◦ C, SpO2 99% on room air.
Altered mental state, combative, GCS 11.
Nonoliguric kidney failure on Day 4. Mental status improved after dialysis on Days 5
and 6. Left AMA on Day 10

Intubated; HR 75 bpm, RR 14 min, BP
152/0 (palpated), Temp 32.9◦ C, SpO2
100% on 100% inhaled O2 , GCS 3T,
ECG—Osborne waves and prolonged QRS
(124 ms); discharged after 15 h
EMS intubated. At ED HR 85 bpm, RR
14, BP 174/127, Temp 33.7◦ C, SpO2
100% on 100% inhaled O2 , GCS 3T;
normal ECG, EEG ‘mild bilateral cerebral
dysfunction’; discharged after 24 h

HR 52 bpm, RR 16/min, BP 87/52, Temp
36.7◦ C, SpO2 100% on 2 L nasal cannula.
Somnolent, agitated with stimulation,
combative. Intubated. Inferior wall
myocardial infarction. Normal ECG and
troponins on follow-up visits

Clinical symptoms/Autopsy findings
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4-Cyano-Cumyl-BINACA

33 y/o M acting ‘bizarrely’, became unresponsive after tonic-clonic seizure after
reported OD of heroin

History

Drug
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Bradycardia, 13 GCS. Administered naloxone, remained hypercapnic. ABG returned
to normal 24 h post presentation
Administered naloxone and diazepam.
Transferred to ED 70 min later. GCS 3,
pulse 105 bpm, hypercapnic. Discharged
∼24 h after admission
Administered naloxone and diazepam. At
ED, GCS 3, pulse 114 bpm. 3 h post first
episode, suffered tonic-clonic seizure.
Released 24 h post admission

21 y/o M prison inmate presented to ED
with hypercapnia

31 y/o M found dead in apartment.
Postmortem interval ∼ 3 days.

27 y/o M found dead in bed, hx of alcohol
and ‘legal high’ use. COD: acute respiratory failure due to cardiotoxic effects of
MMB-FUBINACA and EMB-FUBINACA

MMB-FUBINACA (FUB-AMB)
and EMB-FUBINACA (5 F-ADB)

Congestion of internal organs; pulmonary
edema, left-sided pleural adhesions

‘Tender’ coronary arteries, cerebral and
pulmonary edema, cyanosis of internal
organs

(52)

‘MMB-FUBINACA’
Blood: ND
Urine: 4.7
Urine (hydrolyzed): 8.2
‘EMB-FUBINACA’
Blood: ND
Urine: 0.2
Urine (hydrolyzed): 0.1
Blood:
+Ethanol, +lorazepam, +haloperidol,
+lidocaine

(continued)

(34)

(51)

(51)

Blood: 0.57
JWH-122 12, diphenhydramine <10,
doxylamine 83
Urine: 232
+5F-MDMB-PINACA 3,3-dimethylbutanoic
acid, 5OH-MDMB-PINACA, +JWH-122
metabolites (unspecified), doxylamine >500

Blood: +
+Quetiapine/metabolite (prescribed),
+promethazine/metabolite, +cocaine, +BZE,
+levamisole
Blood: +
+Olanzapine/metabolite (prescribed)

(50)

Serum: <1.3–86.4 (median = 18.6,
mean = 24.5)
+Diphenidine (1), +methylnaphthidate (1),
+buprenorphine (2), +pregabalin (1), +5Fadamantyl-PINACA
(1), +flubromazepam (1),
+MMB-FUBINACA (1), +THJ-018 (1)
Blood: + +Mirtazapine/metabolites,
+propranolol/metabolites (both prescribed)

(51)

(49)

Reference

Seized drug: +

Drug results (ng/mL, unless specified)
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5F-MDMB-PINACA (5F-ADB)
and JWH-122

43 y/o M prison inmate presented to ED
after collapse and seizure

23 y/o M prison inmate presented to ED
after collapse and seizure

Elevated plasma creatinine (6), dilated
pupils (5), seizure (5), tachycardia (5),
deep unconsciousness (5), respiratory
depression (4), elevated blood and/or
plasma lactate (4), agitation (3), delirium
(3) and vomiting (3)

9 patients presenting to ED. 23–62 y/o; 8 M
and 1 F

MDMB-CHMICA

HR 88 bpm, RR 19/min, BP 130/80; mild
hallucinations, blunted affect, anxiety and
tension. Visual hallucinations and disturbances recurred following extensive
cannabis intake for 4 years

18 y/o M with hx of extensive daily
cannabis use admitted to addiction treatment unit with visual hallucinations after
use of a ‘cannabis-like’ product

JWH-122

Clinical symptoms/Autopsy findings

History

Drug

Table I. SC Receptor Agonists’ Case Histories with Clinical Symptoms, Autopsy Findings and Primary and Additional Drug Concentrations
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43 y/o F found dead in apartment following consumption of a herbal mixture.
Estimated postmortem interval 3 days

19 y/o M acting incoherently after
sniffing/smoking unknown substance

25 y/o M presented to ED with agitation,
double incontinence and incoordination
in movement and speech 5 days after
smoking ‘Black Mamba’

16 y/o M lost consciousness after smoking
cannabis and ‘Bonsai’

19 y/o F presented to ED in status
epilepticus after using ‘space’

MMB-FUBINACA (FUB-AMB)
and 5F-MDMB-PINACA (5FADB)

5F-MMB-PINACA (5F-AMB)

NM-2201

O-2545

UR-144

Seizure activity 3 h, HR 138–150 bpm,
RR 28/min, BP 90/60, Temp 37.1◦ C,
severe biventricular failure; stress cardiomyopathy. Discharged on hospital Day
10
HR 98 bpm, BP 144/84, Temp 36.2◦ C;
Hypoxic on arrival, SpO2 100% on FiO2
0.5; Worsening bilateral alveolar infiltrates
and diffuse alveolar hemorrhage on Day 2.
Discharged 10 days post admission

GCS E1M1V1, dilated pupils, unresponsive to light, tachycardia. Intubated due to
persistent lack of consciousness and transferred to ICU. Discharged after overnight
stay

Admission: GCS = 14, hyperactive agitation, left-sided incoordination, aphasia,
generalized hypertonia, hyperreflexia,
left-sided hemiparesis. Day 4: GCS 10,
no visual tracking, elevated temp 38.7◦ C,
diaphoresis, tachycardia, hypertension and
agitation

BP 120/80; slow movements, slurred speech,
disoriented, lethargic, hyporeflexia, uncoordinated, teeth grinding, fearful, loss of
focus/memory, dry mucus membranes and
tinnitus

Cerebral and pulmonary edema, hyperemia
internal organs

Clinical symptoms/Autopsy findings

(55)

(56)

(57)

Urine: +
+UR-144 metabolites (unspecified)

Blood: +UR-144 5-hydroxypentyl (by ELISA)

(54)

Serum: +
Urine:
+THC-COOH

Seized drug: +

(53)

(34)

Blood: 0.03
+5F-MDMB-PINACA 3,3-dimethylbutanoic
acid, 5OH-MDMB-PINACA, 5OH-MDMBPINACA 3,3-dimethylbutanoic acid,
4COOH-MDMB-PINACA and others, mirtazapine 7.5, +mirtazapine metabolites,
lidocaine 43, 3-MeO-PCP 97
Seized drug: +

Reference

Drug results (ng/mL, unless specified)
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6-AM = 6-monoacetylmorphine, ABG = arterial blood gas, AMA = against medical advice; BP = blood pressure, BZE = benzoylecgonine, CBD = cannabidiol, CNS = central nervous system, CT = computed tomography, ECG = electrocardiogram, EEG = electroencephalogram, EME = ecgonine methyl ester, EMS = emergency medical services, F = female, GI = gastrointestinal, GCS = Glasgow Coma Score, HR = heart
rate, hx = history, M = male, N/A = not available, OLS = one leg stand, PM = postmortem, RR = respiratory rate, SpO2 = oxygen saturation, Temp = temperature, THC-COOH = 11-nor-carboxy-delta-9tetrahydrocannabinol, WAT = walk-and-turn, OD = overdose, ND = none detected, ICU = intensive care unit, ELISA = enzyme linked immunosorbent assay.

27 y/o M with hx of polysubstance use
became unresponsive within 1 h of inhaling
‘K2’. Transported to ED

History

Drug

Table I. SC Receptor Agonists’ Case Histories with Clinical Symptoms, Autopsy Findings and Primary and Additional Drug Concentrations
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NPS Adverse Effects

Cumyl-PEGACLONE. This system evaluates the presence and
concentration of an NPS along with other toxicological and
pathological findings in a case and assigns the NPS a significance value from 1 (low) through 3 (high) (65). In 4 of 5
deaths, the TSS was determined to be ‘high’ (TSS = 3). In
one case, the COD was determined to be acute drug toxicity
(alcohol and Cumyl-PEGACLONE); three cases involved cardiac/coronary disease in the context of Cumyl-PEGACLONE
(two with alcohol) use, and the final death involved positional
asphyxia with Cumyl-PEGACLONE use and obesity. Coronary/cardiac disease, blood stasis, organ edema, hypoxia and
the presence of other drugs are common in postmortem cases.
In general, the toxidrome associated with SC use is nonspecific and inconsistent. In addition, individual cases may have
unusual and inexplicable findings due to concomitant drug
use. This is illustrated by the mass casualty incident reported
by Ershad et al. (Table I) (33). Six heroin users had effects not
typically associated with opioid use, including agitation and
tonic-clonic seizures. The heroin also contained fentanyl and
5F-MDMB-PINACA. In another case, the Centers for Disease
Control and Prevention (CDC) became aware of SC users in
Illinois showing signs and symptoms of anticoagulant exposure. During March–May 2018, 202 cases of suspected SC
used with anticoagulant exposure were identified across nine
states (66). Therefore, relying on investigative clues such as
drug use history, examination of drug paraphernalia or products found with the patient and witness accounts is essential
to determining if the case could involve SC. It is also important to remember that the content of herbal incense products,
pills and potions purchased on the internet change rapidly,
requiring laboratories to ensure assays are testing for the most
current drugs.

Discussion
SC have significant physiological and neurological effects,
with the potential for negative sequelae including death. However, the wide range of reported effects, comorbidities and
co-ingested drugs complicates interpretation of the role that
SC has in clinical, DUID and postmortem casework. Case
reports involving the same drug may mention seemingly contradictory effects. For example, some patients exposed to
ADB-FUBINACA presented with tachycardia and others with
bradycardia. Some patients became agitated/anxious, and
others were somnolent. Based on the cases reviewed, patients
who are transported to the hospital for medical care typically
recover without long-term negative effects. Most postmortem
cases involve individuals who were discovered hours after the
drug exposure, and autopsy findings are often similar to what
is seen in central nervous system (CNS) depressant deaths,
such as pulmonary edema. Table II provides a cumulative
summary of SC’s effects on various anatomical systems based
on the table included in Logan et al. (14).

NPS Stimulants
Introduction
Currently, the most prevalent NPS category is novel stimulants worldwide (67). Many are derived from cathinone, a monoamine alkaloid present in the plant Catha
edulis (Khat) (Figure 2). The methylated analogue of
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psychotropic effects of AM-2201, in combination with the
active component of cannabis, may have played a role in his
actions.
Common signs and symptoms of SC use in drivers include
driving erratically, failing to stay within the lane, crossing into
oncoming traffic and being found asleep behind the wheel.
In addition to the impaired driving cases that Table I summarizes, Kaneko et al. (58) reported on 96 DUID cases that
occurred in 2012–2014, of which 93 involved SC. The 96 incidents were categorized as fatalities (N = 4), injuries (N = 51)
or property damage (N = 41). Immediately following the
collisions, drivers were described as having impaired consciousness (N = 73) and/or being excited/confused (N = 16).
Seventy-three cases included at least one SC, and 20 involved
an SC and a cathinone or the dissociative anesthetic diphenidine. SC identified in blood samples were AM-2232, 5F-PB22, FUB-PB-22, NM-2201, AB-PINACA, NNE-1, 5F-ABPINACA, AB-FUBINACA, 5F-MMB-PINACA (5F-AMB) and
AB-CHMINACA. Kleis et al. reported four drivers in their
case series on 5F-MDMB-PICA (60). Plant cannabinoids and
alcohol were reported in one case in which the driver was
involved in a hit-and-run crash, followed by a car chase. The
driver was unable to stand upright, had slurred speech and
exhibited erratic and confused behavior. The second driver
was stopped after being observed leaving his lane, driving on
the wrong side of the road and braking inappropriately. He
was described as exuberantly happy upon a negative breath
alcohol test but quickly became aggressive. The third driver
was found sleeping in his stopped car (with the engine off)
in the middle of an intersection. After being aroused, he was
disoriented with a subdued mood. No driving behavior was
reported on the final driver, and he was simply described as
having fluttering eyelids and a tremor.
In addition to the nine deceased individuals summarized
in Table I, there are three publications reporting deaths
associated with SC use. In FL, the deaths of 54 prisoners involved a variety of SC, 37 cases had no other drug
classes detected following a comprehensive drug screen. In
cases in which other drugs were detected, only five contained drugs with significant abuse potential (59). Although
blood and urine were initially tested in these early cases, no
drugs were detected in blood leading to analysis of urine
for SC metabolites in the later cases. 5F-MDMB-PINACA
(5F-ADB; Figure 2), MMB-FUBINACA (FUB-AMB), 5FMMB-PINACA (5F-AMB), MDMB-FUBINACA and/or ABCHMINACA were detected in the samples. Morrow et al. (61)
investigated the role of MMB-FUBINACA in nontraumatic
deaths in Auckland, NZ. Following a review of all records
in which ‘AMB-FUBINACA’ (synonyms MMB-FUBINACA
and FUB-AMB) was referenced, 58 cases were identified
that did not have trauma as the cause of death (COD).
MMB-FUBINACA 3-methylbutanoic acid was identified in
all 58 cases, with a mean blood concentration of 229 ng/mL
(median = 140 ng/mL) in 41 cases where it was quantified.
Only 15 cases had positive blood MMB-FUBINACA. MMBFUBINACA toxicity was the primary COD in 42 cases, with
20 involving no other drugs or alcohol. Cumyl-PEGACLONE
was reported in five of 472 deaths over an 18-month period
in Australia’s Northern Territory (62). Postmortem blood
concentrations of 0.73–3.0 ng/mL were reported. Authors
employed the Toxicological Significance Score (TSS) system developed by Elliot et al. to categorize the role of
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Table III. NPS Stimulant Toxicity Profile

Organ system

Symptoms and signs

Organ system

Symptoms and signs

CNS

Agitation, psychosis, irritability,
seizures, sedation, coma, delirium,
hallucinations, paranoia, anxiety,
hypo/hyperreflexia and psychomotor
impairment
Tachycardia, hypertension, acute coronary syndrome, arrhythmia, chest pain
and myocardial infarction
Respiratory depression and hypopnea
Nausea, vomiting, fevers, mydriasis,
blurred vision and acute kidney injury
Organ edema and congestion

CNS

Agitation, psychosis, delusions, aggression, irritability, paranoia, delirium,
hallucinations, sedation, coma, abnormal behavior and altered fluctuating
consciousness
Tachycardia, hypertension and
palpitations
Increased respiration rate
Hypothermia, mydriasis, rhabdomyolysis, compartment syndrome and
sweating
Organ edema and congestion

Cardiovascular

Pulmonary
Other
Postmortem findings

cathinone, methcathinone, was first synthesized in 1929
with reports of abuse as early as the 1990s (68). Since
the early 2000s when 4-methylmethcathinone (mephedrone)
and beta-keto amphetamines (methylenedioxypyrovalerone
[MDPV]) emerged in the UK and Europe, novel stimulants
proliferated and dominated the NPS market (68). By the
late 2000s, novel drugs including methylone and alphapyrrolidinopentiophenone (α-PVP) had also increased in
prevalence. By 2015, substituted methylenedioxyphenethylamines (e.g., ethylone and butylone) had increased in frequency in the USA and Europe. The availability of synthetic
stimulants persists despite scheduling actions internationally
and nationally.
The 2020 European Drug Report on Trends and Developments showed that cathinones accounted for about 36%
of drug seizures, while another 3% of drug seizures were
composed of phenethylamines in 2018 (67). In Europe,
the number of synthetic cathinones identified in powders
has significantly decreased in recent years (67). Following
the appearance of methylone, structurally related analogues
have appeared with varying degrees of popularity with
recent substances including dibutylone, eutylone, pentylone,
N-ethylpentylone (NEP) and N-ethylhexedrone. In the USA,
the DEA’s emerging threat report for the third quarter of
2020 and the CFSRE’s fourth quarter 2020 trend report
showed eutylone as the most frequently encountered cathinone in the USA (69, 70). Similarly, drugs structurally
related to α-PVP, such as alpha-pyrrolidinoheptiophenone
(PV8), alpha-pyrrolidinohexiophenone (α-PHP) and alphapyrrolidinoisohexanophenone (α-PiHP) have proliferated.
Eutylone and NEP accounted for the highest percentages of
reports for NPS in the phenethylamine category at 1.3%
and 0.4%, respectively, as shown in the 2019 NFLIS annual
report (71).
Methylphenidate (MPH) is widely prescribed for attention
deficit hyperactivity disorder but also frequently misused for
cognitive enhancement to improve memory and concentration, control anxiety and stimulate motivation and creativity.
MPH requires a prescription; thus, illegal analogues emerged
on the internet and darknet as cognitive enhancers for their
nootropic and stimulant effects, and this resulted in deaths
in some cases (72–75). Although few analytical methods for
MPH analogs are available and many laboratories do not test
for them, adverse effects were reported for structural derivatives, ethylphenidate (EPH) and 4-fluoromethylphenidate
(4F-MPH).

Cardiovascular
Pulmonary
Other

Postmortem findings

Pharmacology
Synthetic cathinones’ interactions with dopamine transporters
(DATs), serotonin transporters (SERTs) and norepinephrine
transporters (NETs) were documented in in vitro (human cell
lines) and preclinical models (76–80). Ring-substituted cathinones (such as methylone) act as DAT, SERT and NET substrates increasing dopamine, serotonin and norepinephrine
release. The presence of a pyrrolidine ring, as in α-PVP, acts
as a transport blocker (reuptake inhibitor) at DAT (77–80)
increasing affinity and potency with increasing length of the
α-carbon chain (79). Drugs with a higher DAT potency,
including α-pyrrolidinophenones and 4-fluoroamphetamine
(4-FA), exhibit stimulant properties similar to methamphetamine (79); cathinones with similar DAT and SERT
potencies or a higher SERT potency have more empathogenic
activity (e.g., ethylone) (80).
The onset of synthetic cathinone effects occurs within
30–45 min of administration, with desired effects lasting
1–3 h; undesirable effects can last for several days (81).
Reported synthetic cathinone effects include increased energy,
alertness, concentration and euphoria; effects are similar to
those of amphetamine and cocaine (68, 76, 82, 83). Adverse
physiological effects include cerebral edema, diaphoresis,
hyperflexia, hypertension, hyperthermia, dilated pupils,
tachycardia, myocardial infarction, seizures, bruxism, nausea and vomiting. Prominent adverse neuropsychiatric effects
include agitation, aggression, hallucinations, paranoia, psychosis and serotonin syndrome. Hyperthermia, diaphoresis,
tachycardia, agitation and hypertension are indicators of
toxicity and overdose (82). Psychosis may be pronounced,
with patients experiencing paranoia, hallucinations (primarily visual) and delusions. Toxic sequelae can include liver and
kidney failure, rhabdomyolysis and development of increased
pressure in a muscle compartment that can lead to muscle and
nerve damage, blood flow abnormalities and ultimately death
(‘compartment syndrome’) (68, 82). Table III provides a summary of the toxicity profiles related to synthetic stimulants.
Additional information related to adverse effects associated
with NPS stimulant use can be found in Table IV (84–94).
MPH works similarly to amphetamine in competing with
catecholamines in the CNS to block DAT and NET and
elevate synaptic monoamine concentrations (72, 73, 95).
In vitro pharmacology documented more potent DAT than
SERT inhibition by MPH analogues, suggesting predominately stimulant effects with high abuse liability, similar
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Table II. Summary of SC Receptor Agonists’ Toxicity Profiles

Time 1: ED GCS 4, SBP 117 mmHg, DBP
37 mmHg, HR 118 bpm, RR 14/min, 35◦ C,
CT: diffuse bilateral ground glass opacity,
diagnosed diffuse alveolar hemorrhage, admitted ICU and ventilated for 4 days, discharged
on Day 7.
Time 2: Unconscious, bilateral pulmonary
infiltrate recurrence less serious than Time 1.
Discharged on Day 2
GCS 14, HR 101 bpm, SBP 131 bpm, DBP
68 mmHg, Temp 37◦ C, pO2 85%, biochemical exam revealed mild hepatic dysfunction,
increased creatinine kinase and white blood
cell counts
N/A

N/A

N/A

28 y/o M unconscious at home, previous psychiatric hx and depression, also admitted to
hospital 2 months earlier with loss of consciousness and aspiration pneumonia. During
second admission admitted inhalation of
‘BON’S CRYSTAL’

39 y/o M took picture through bathroom
window screaming ‘a ghost is there’, ran
speaking incomprehensibly. Found covered
in mud in rice field, transported to ED with
hallucinations, delusion, fear, anxiety and
restlessness

32 y/o F found deceased in bed; drug OD
expected

46 y/o M found deceased in hotel room

38 y/o M in fatal motor vehicle crash

α-EAP and
4F-α-PVP

α-PHP

Dibutylone

(85)

(86)

(87)

Drug material confirmation: α-EAP and 4 FαPVP

Serum: 175 (on admission)
64.6 (24 h), 43.6 (48 h), 27.0 (72 h), 15.7
(96 h), 13.4 (120 h), 6.75 (144 h), 2.98
(192 h), 1.79 (216 h)

Femoral blood: 383
Butylone 92.5, THC 2.8, THC-COOH 11
Urine: 3,100
Butylone 69.7
Vitreous: 250
Butylone 108
Liver: +
+Butylone
Femoral blood: <10
Butylone 385, alprazolam 11, BZE 1,600,
hydrocodone 400, oxycodone 12, tramadol
340
Urine: 16,500
Butylone 3,060
Femoral blood: 61.5
Butylone: 6.55, ethanol 190 mg/dL, +4-FA,
methylone 31, +dimethylone, ethylone <10
Urine: 2,140
Butylone 149, ethylone 269

(continued)

(87)

(87)

(84)

Reference

Blood: 32
Urine: 827

Drug results (ng/mL unless specified)
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Palpitations and mild tachycardia (100 bpm). BP,
Temp and chemistries normal on admission.
Tachycardia lasted 2 days until discharge

26 y/o F admitted ED for severe psychomotor
agitation, confusion, disorientation, confabulation, incoherent speech and crying after
sniffing powder purchased on internet

4F-MPH

Clinical symptoms/Autopsy findings

History

Drug
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EPH

29 y/o M with no hx; at electronic dance music
festival
18 y/o F with hx of recreational drug use,
ingested two Molly within 24 h of sample
collection at electronic dance music festival
26 y/o M with unknown hx; at electronic dance
music festival
32 y/o M with unknown hx

Oral fluid: +
+Butylone, +cocaine
Femoral blood: 110
Ritalinic acid 2140, +methadone, +EDDP,
+Morphine, +Fentanyl, +MPH
Urine: 987
Liver: 180 ng/g
Pericardium fluid: 131
Stomach contents: 20.7 (200 mL)

N/A
N/A

N/A

N/A

(87)

Oral fluid: 1,926
Butylone 1,761, +dimethylone, +MDMA,
+MDA
Oral fluid: +
+Butylone
Oral fluid: +
+Butylone

N/A

N/A

37 y/o M with hx of recreational drug use.
MDMA at electronic dance music festival.
Ingested three capsules within 24 h of sample
collection
22 y/o M with hx of recreational drug use
MDMA at electronic dance music festival.
Ingested two capsules within 24 h of sample
collection
Unknown sex, age and hx; at electronic dance
music festival

(87)

N/A
N/A

M unknown age, alleged Molly use
F unknown age, suspected OD

Oral fluid: 138
Butylone 291, +dimethylone, +MDMA,
+MDA

N/A
N/A

M unknown age no hx
M unknown age no hx

(continued)

(72)

(87)

(87)

(87)

(87)

(87)
(87)

(87)
(87)

(87)

N/A

N/A

49 y/o M suspected bath salt use

(87)

Femoral blood: 1,400
Butylone 600
Femoral blood: 10
+4-Chloro-alpha-PVP
Central blood: 10
Femoral blood: 13
Butylone 12
Postmortem Blood: 14
Postmortem Blood: 40
Butylone 15.3, +p-FIBF
Oral fluid: 123
Butylone 206, +dimethylone, +MDMA,
+MDA

N/A

F unknown age suspected OD

Reference

Drug results (ng/mL unless specified)

Clinical symptoms/Autopsy findings

History
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Clinical symptoms/Autopsy findings
N/A

N/A

N/A

N/A

N/A

N/A
N/A

N/A

N/A

N/A

History

38 y/o M with unknown hx

38 y/o M with unknown hx

33 y/o F with unknown hx

31 y/o F with unknown hx

27 y/o M with unknown hx

37 y/o M with unknown hx

31 y/o F with unknown hx

34 y/o M with unknown hx

38 y/o M with unknown hx

20 y/o M with unknown hx

(72)

Femoral blood: 23
Ritalinic acid 943, +pregabalin, +fentanyl,
+norfentanyl
Femoral blood: >2,000
+Tramadol, +acetaminophen, +morphine
and metabolites, +6-AM, +acetone
Femoral blood: 1,900
+Methadone, +procyclidine, +propranolol,
+morphine and metabolites,
+diazepam, +temazepam and metabolites, +THC-COOH, +pregabalin,
+methylthienylpropamine
Femoral blood: 1,200
+Ethanol, +morphine and metabolites,
+diazepam and metabolites
Femoral blood: 760
+Ethanol, +diazepam and metabolite,
+methylthienylpropamine
Femoral blood: 610
+Diazepam and metabolite, +mirtazapine
Femoral blood: 470
+Lignocaine, +methadone, +mirtazapine,
+promethazine
Femoral blood: 410
+Ethanol, +methadone, +diazepam and
metabolites, +THC-COOH
Femoral blood: 350
+α-Methyltryptamine, +etizolam,
+diphenhydramine
Femoral blood: 320
+Fluoxetine and metabolite, +pregabalin,
+zuclopenthixol, +morphine and
metabolites, +etizolam, +pyrazolam,
+2-MeO-diphenidine

(continued)

(72)

(72)

(72)

(72)

(72)

(72)

(72)

(72)

(72)

Reference

Drug results (ng/mL unless specified)
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Clinical symptoms/Autopsy findings
N/A

N/A
N/A

N/A
N/A

N/A
N/A

N/A

N/A

N/A

History

40 y/o M with unknown hx

35 y/o M with unknown hx

33 y/o F with unknown hx

54 y/o M with unknown hx

45 y/o M with unknown hx

44 y/o M with unknown hx

42 y/o M with unknown hx

46 y/o F with unknown hx

25 y/o M with unknown hx

45 y/o M with unknown hx

(72)

Femoral blood: 250
+Methadone, +olanzapine, +diazepam and
metabolites, +THC-COOH
Femoral blood: 140
+Methadone
Antemortem blood: 460
Femoral blood: 130
+Dihydrocodeine, +hydrocodone,
+morphine, +nordiazepam, +ketamine,
+acetaminophen, +alfentanil
Cardiac blood: 41
+Dihydrocodeine
Femoral blood: 40
+Diazepam and metabolites, +methadone,
+morphine and metabolites, +6-AM
Femoral blood: 28
+Methadone, +diazepam and metabolites
Femoral blood: 15
+Ethanol, +dihydrocodeine, +morphine and
metabolites, +diazepam and metabolites
Femoral blood: 10
+β-hydroxybutyrate, +mirtazapine,
+codeine, +morphine, +diazepam and
metabolite, +fluoxetine and metabolite,
+acetaminophen
Femoral blood: 10
+Diazepam and metabolite, acetaminophen,
+codeine and metabolites, +morphine and
metabolites, +6-AM, +mirtazapine
Antemortem blood: 30
Femoral blood: 8
+Ethanol, +morphine and metabolites,
+6-AM, +acetaminophen, +methadone,
+nordiazepam
Serum: 8

(continued)

(72)

(72)

(72)

(72)

(72)

(72)

(72)

(72)

(72)

Reference

Drug results (ng/mL unless specified)
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N/A

N/A
N/A

M with unknown age and unknown hx

M with unknown age and unknown hx

M with unknown age and unknown hx

21 y/o M with hx of drug and alcohol abuse
taken to ED with aggression, disorientation
and loss of consciousness. Sudden cardiac
arrest 5.5 h after admission and unable to
revive. Plastic bag with white powder found
in underwear
25 y/o M driver did not stop at road check.
Stopped after a brief chase and officers noticed
unnatural behavior. Driver appeared stimulated, cheerful with blurred speech. Driver
admitted to taking mephedrone and 2 bags
containing white powder

N/A

M with unknown age and unknown hx

NEH

N/A

M with unknown age and unknown hx

At ED, hyperthermia and wide pupils that
reacted to light. Tachycardia, tachypnea, blood
pressure and anuria present. At autopsy, lung
congestion, mild focal pulmonary edema,
swelling and brain congestion, left ventricular
hypertrophy and focal liver steatosis
Subject exhibited clear speech, steady gait, normal pupils and normal pupillary reaction.
Negative Romberg’s test and finger–nose test

Multiple injection sites. Pulmonary and pericerebral edema and multivisceral congestion

N/A
N/A

M with unknown age and unknown hx
M with unknown age and unknown hx

39 y/o M with hx of drug addiction, found
deceased in caravan

Clinical symptoms/Autopsy findings

History

(72)
(72)

Femoral blood: 2,180
Femoral blood: 1,370
+BZE, +sertraline, +diphenhydramine
Femoral blood: 870
+Dothiepin, +methiopropamine, +ethanol
Femoral blood: 110
+Methadone, +EDDP, +zopiclone,
+sertraline, +aripiprazole,
+dehydroaripiprazole, +2-aminoindane,
+ethanol
Femoral blood: 140
+Morphine, +codeine, + ketamine,
+cocaine, +BZE, +venlafaxine, +Odesmethylvenlafaxine
Femoral blood: 30
+Methiopropamine, +5-APB/6-APB
Femoral blood: 110
+Diazepam, +nordiazepam, +temazepam,
+oxazepam, +morphine, +codeine

(continued)

(90)

(89)

Femoral blood: 145
Amphetamine 12, THC-COOH <5

Blood: 34

(88)

Femoral blood: 47/1.6
THC 1.4, THC-COOH 6.6
Cardiac blood: 97/3.5 ethanol 50 mg/dL
Urine: 2380/49,700

(72)

(72)

(72)

(72)

(72)

Reference

Drug results (ng/mL unless specified)
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NEP

Dissociative effects, auditory hallucinations and
paranoia for 5 days
Delusional disorder and pharmacopsychosis for
2 days

Delusional disorder

At autopsy, facial swelling, cyanosis of extremities and yellow liquid coming from mouth
and nostrils. Internal exam revealed generalized hemorrhage of pulmonary alveoli and
abnormal liver size
Tachycardia, mydriatic pupils, oscillation between psychomotor agitation and
neurological depression

38 y/o M with hx of cathinone use last 3 years
and HIV, IV injected 2 g drug

33 y/o M no hx of substance abuse and under
pre-exposure prophylaxis with emtricitabinetenofovir, insufflated drug with GHB

44 y/o M with hx of NPS use and HIV, oral
ingestion

32 y/o M attending rave party displayed psychomotor agitation and aggressiveness before
fainting. Decedent died en route to hospital

18 y/o M admitted to ED from rave party.
Agitated and signs of several injuries

Paranoia and auditory hallucinations for 4 days

39.6◦ C Temp, delirium and agitation. Multiple
organ failure
Tachycardia 100 bpm, nonspecific ST interval
alteration on ECG. Laboratory evaluation
showed neutrophil leukocytosis and mild
rhabdomyolysis
Subject experienced bad trip and asthenia for
4 days

Elevated temp, tachycardia, rhabdomyolysis and
acute kidney and liver injuries

36 y/o M with hx of cathinone use for 2 years,
IV 0.2 g twice

31 y/o M with hx of cathinone use for 3 years
and HIV, IV 0.2 g twice

22 y/o M brought to ED with agitation and
acute psychosis after ingesting instant coffee
packet
22 y/o M admitted after ingesting instant coffee
packet
29 y/o M with hx of depression, admitted to ER
agitated with visual hallucinations, delirium,
mydriasis and nausea

N/A

27 y/o M involved in road crash resulting in
death
18 y/o M DUID
N/A

Clinical symptoms/Autopsy findings

History

Serum: 7
Urine: +

Blood: +
Urine: +
Powder: +
Blood: +
Urine: +
Powder: +
Blood: +
Urine: +
Powder: +
Blood: +
Urine: +
+cocaine, +amphetamines
Powder: +
Blood: +
Urine: +
Powder: +
Postmortem Blood: 170

Urine:
+N-ethylnorpentylone
Urine: +
*Urine positive 4 days postadmission

Blood: 37
3-fluorophenmetrazine 9
Blood: 8
THC 1.6, THC-COOH 8.7
Urine:
+N-ethylnorpentylone

Drug results (ng/mL unless specified)
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(continued)

(94)

(94)

(93)

(93)

(93)

(93)

(93)

(92)

(91)

(91)

(90)

(90)

Reference

e134
Mohr et al.

26 y/o M with hx of mental disorders admitted
to psychiatry for differential diagnosis of drug
misuse

At ED, subject confused, sleepy with tongue
injuries from intentional biting, disconnected
speech and visual hallucinations. Anterograde
amnesia at discharge. Creatine kinase elevated
Subject conscious and oriented but agitated
with palpitations and tachycardia (180 bpm).
Creatine kinase elevated

26 y/o F arrived at ED after report to poison
control center. Found unconscious with sphincter release. Consumed ecstasy and cannabis at
a party the night prior
19 y/o attended rave and consumed alcohol
and various drugs including 5 ecstasy tablets,
1 LSD blotter, 2 packs cigarettes and drank
unknown amount of Catuaba
35 y/o M with hx of alcohol and drugs over
2 days, found unconscious
Neurological depression GCS 5 and anisocoria.
Elevated creatine kinase and lactase. At 6 h
post admission, neurogenic shock and decerebration. 6 days postadmission vertebral artery
dissection and cerebrovascular hemorrhage of
brain stem. At 35 days, subject discharged in
vegetative state with neurological damage to
third cranial nerve
Subject presented with psychosis, paranoia,
sleeplessness and inconsistent speech. Elevated
creatine kinase

Clinical symptoms/Autopsy findings

History

Serum: 61

Serum: 19
MDMA 54, ethanol 0.8 g/L
Urine: +
+MDMA, +caffeine, +cotinine
Serum: 149
Urine: +

Urine: +
+MDMA

Drug results (ng/mL unless specified)
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(94)

(94)

(94)

(94)

Reference

4F-α-PVP = 4-fluoro-alpha-pyrrolidinovalerophenone, DBP = diastolic blood pressure, EDDP = 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, EMS = emergency medical services, HIV = Human Immunodeficiency Virus, MDA = 3,4-Methylenedioxyamphetamine, pO2 = partial oxygen pressure, SBP = systolic blood pressure, GHB = gamma-hydroxybutyrate, 5-APB = 5-(2-Aminopropyl)benzofuran, 6-APB = 6-(2Aminopropyl)benzofuran, GR = gram.
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Ethylphenidate
EPH first gained attention in 2011 as a legal ethyl acetate
MPH analogue; MPH is Schedule II in the USA (97). EPH
can be formed by transesterification following MPH and
ethanol coingestion, with a significant correlation between the
area under the concentration versus time curve of MPH to
EPH (98). EPH is a potent stimulant with high abuse potential including pleasurable stimulation, euphoria, cognitive
enhancement, indecisiveness and anxiety (99). Physiological
effects of elevated body temperature, increased heart rate and
blood pressure, profuse sweating and muscle tension also
were reported. Other drugs of abuse were frequently found in
EPH fatalities (72) (Table IV). In these fatalities, EPH femoral
blood concentrations were 8–2,180 ng/mL. In two cases, antemortem blood was collect with EPH concentrations of 30 and
460 ng/mL.

Dibutylone
Dibutylone is a substituted beta-keto-methylenedioxyamp
hetamine and one of the analogues in the popular series that
includes methylone, ethylone and butylone. In the previously
published review by Maida et al., dibutylone was a common
finding in cases also positive for NEP, identified in 5 of 12
cases (96). Krotulski et al. reported 15 dibutylone cases, 9
postmortem with blood concentrations of 10–1,400 ng/mL
and 3 recreational use with oral fluid concentrations of 123–
1,926 ng/mL (87). In every dibutylone case, butylone was
also found in blood from <10–600 ng/mL (Table IV). In vitro
metabolism studies identified butylone as an N-demethylated
dibutylone metabolite. Effects related to dibutylone ingestion
were not reported in the case series; however, previous butylone reports included tachycardia, hypertension, rigid muscle
tone, hypersalivation, mydriasis, hyperthermia, arrhythmias
and altered behavior (100, 101). Dibutylone is expected to
produce similar effects based on its structural similarity.
N-Ethylpentylone
NEP, first reported in 2014, became a frequently encountered
NPS cathinone in the USA in 2016 (102). In an NEP case
series of 31 reports by Krotulski et al., 26 were death investigations with blood NEP concentrations of 12–50,000 ng/mL
(103). The other five intoxications involved hospitalizations
with coingestion of other cathinones and severe psychiatric
effects with delusion, auditory hallucinations, paranoia and
dissociation persisting in some cases for days (93). Similarly,
NEP was confirmed in subjects’ blood, serum and/or urine in
a series of acute drug intoxications in Brazil—noting palpitations; tachycardia; agitation; aggression; coma and in one
case, death—with blood concentrations of 7–170 ng/mL (94).
N-Ethylhexylone
NEH was the most frequently seized cathinone in 2017 and
among the top three in 2018, according to the 2019 European
Drug Markets Report (104). NEH is sold via the internet and
reportedly has the strongest effects when snorted, although
it is also administered by rectal, intravenous (IV), oral or
smoked (i.e., e-cigarette) routes (89). Desired effects typically
occur following 10–250 mg doses with an onset of effects for
2–25 min, but effects depend on the route of administration
and drug tolerance. In an NEH fatality, the subject presented
with hyperthermia, dilated pupils, tachycardia and elevated
blood pressure (89). During the autopsy, congestion in the
lungs and swelling and congestion in the brain were noted at a
femoral blood concentration of 145 ng/mL. In three impaired
driving cases, NEH concentrations were 8–34 ng/mL (90).
Other NPS stimulants
Other synthetic stimulants were identified less frequently,
with three case reports from the α-pyrrolidinophenone derivative class. One involved α-PHP in a living individual who
was acting irrationally and presenting with hallucinations,
delusion, fear, anxiety and restlessness. At the ED, the
patient’s Glasgow Coma Score (GCS) was 14, with serum concentrations of 175 ng/mL on admission to 1.8 ng/mL 216 h
later (86). A second case involved an unconscious male
found at home who was previously admitted to the ED
2 months prior because of loss of consciousness and aspira-
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to amphetamine (73). 3,4-Dichloromethylphenidate inhibited NET 10-fold and DAT 2-fold more potently than MPH.
NET (0.04–0.42 µM) and DAT (0.08–0.34 µM) inhibition
potencies for 3,4-dichloroethylphenidate, ethylnaphthidate,
4F-MPH and 4-methylmethylphenidate were similar to those
of MPH (73). Several MPH analogues inhibit NET at submicromolar concentrations, suggesting cardio- and psychostimulant properties.
MPH is almost completely absorbed when ingested orally,
with peak plasma concentrations occurring 1–3 h after a standard oral dose that has a plasma half-life of 1.5–2.5 h (95).
Adverse effects of MPH include pupil dilation, hair loss,
depression, anorexia, headaches, decreases in libido, insomnia, restlessness, anxiety and hypersensitivity; anorexia and
tachyarrhythmia are the most prevalent effects at high concentrations in blood (72). Abuse also produces paranoia,
hallucinations, delusional disorder and euphoria. EPH is commonly insufflated, with an onset of action of 0–5 min and a
duration of effects lasting 15–300 min (72). Adverse effects of
EPH include tachycardia, hypertension, palpitations, endocarditis, fever, mydriasis, insomnia, irritability, paranoia,
anxiety and delusional thoughts.
A comprehensive review during 2017–2020 was recently
published, identifying 31 different synthetic cathinones in
75 reported fatal intoxications (96). NEP was found in 23
fatalities, with blood concentrations of 18.4–50,000 ng/mL
and most commonly coadministered with other cathinones
dibutylone, pentylone or butylone. In NEP-only cases,
concentrations were 150–600 ng/mL. Case reports detailed
aggression, confusion and cardiac arrest in several cases.
4-Chloromethcathinone (4-CMC) was the next most frequently reported cathinone analog associated with nine fatalities. 4-CMC blood concentrations were 0.9–1,870 ng/mL,
but most cases included other drugs, frequently THC.
N-Ethylhexylone (NEH) was confirmed in six fatalities (blood
concentrations 7.2–285 ng/mL), always combined with other
drugs. NEH has a short duration of effects, resulting
in binge dosing. 3-Methylmethcathinone (3-MMC) was
reported in five fatalities, with peripheral blood concentrations of 249–800 ng/mL. In these synthetic cathinone cases,
polydrug consumption frequently included other synthetic
cathinones, synthetic opioids (e.g., U-47700) or other stimulants (e.g., MDMA).

Mohr et al.

NPS Adverse Effects

Discussion
NPS stimulants are among the most sought-after NPS classes
due to the euphoria and altered metal state produced and
the low perception of likelihood of adverse effects. Typical symptoms associated with synthetic stimulant use include
elevated heart rate, increased blood pressure and dilated
pupils (Table III). Individuals under the influence of these
substances often experience hallucinations, paranoia, anxiety and/or aggression with the risk of excited delirium and
life-threatening cardiovascular effects. In these cases, some
effects such as asthenia, paranoia and hallucinations can persist for days after the initial onset of symptoms. Individuals
with cardiac compromise are especially susceptible to toxicity
and death.
Common autopsy findings in synthetic stimulant deaths
included pulmonary edema and in some cases brain congestion (Table III). Scene investigation, paraphernalia recovery
and/or subject self-report of ingested substances provided key
data in these antemortem and postmortem cases that led to
identifying the responsible NPS. Finding additional NPS stimulants along with other therapeutic and illicit substances was
not uncommon in these cases.
Synthetic stimulant users often do not know what they are
ingesting because these substances are often sold as ecstasy
(i.e., MDMA). In one study comparing self-reporting drug
ingestion to toxicological findings, 29.6% of users who
believed they had ingested MDMA had consumed a novel
stimulant (105). Given the persistence and prevalence of
synthetic stimulants, laboratories should remain vigilant in
monitoring these substances and pursue additional analytical testing in suspected cases of stimulant overdoses when
traditional toxicology methods have negative findings. The
continued emergence of novel synthetic stimulant drugs is
expected given the historical popularity of these substances.
Canceling electronic music events and closing dance clubs
during the coronavirus disease 2019 pandemic in 2020 may
have temporarily reduced the availability and popularity of
the synthetic stimulant drug class.

NPS Hallucinogens
Introduction
Hallucinogens are naturally occurring or synthetic drugs that
produce hallucinations, dissociation and out-of-body experiences. Novel hallucinogens are characterized as chemical
derivatives and analogues of classical hallucinogens, such
as the psychedelic lysergic acid diethylamide (LSD) or the
dissociative drugs ketamine and phencyclidine (PCP). Novel

hallucinogens are divided into six subcategories: PCP-like
analogues, ketamine-like analogues, phenethylamine analogues, LSD-like analogues, tryptamine-like analogues and
diarylethylamine analogues. Some novel synthetic drug classes
were derived from legitimate pharmaceutical research, but
others are experiments by illicit drug manufacturers or users
seeking new or different experiences. Novel hallucinogen
preparations include powders, pills, tablets, liquids and blotters (106). PCP-, ketamine- and LSD-like analogues are commonly ingested with the first two generally sold as solid
materials and the last generally as a liquid or on blotters.
Descriptions of these substances’ structures, syntheses and
effects are frequently found in online forums and relevant
popular publications, such as ‘PiHKAL’ (2) and ‘TiHKAL’
(3). The peer-reviewed literature and case reports of intoxications involving novel hallucinogens continue to grow. Table V
(107–146) highlights adverse effects including hospitalization,
death investigation and impaired driving cases—paired with
toxicological findings and/or chemical confirmation from
recent publications.
During 2016–2018, ‘NBOMe’ drugs were the most commonly encountered novel hallucinogens (14); more recently
(2017–2020), PCP- and ketamine-like analogues, including
3-methoxy-PCP (3-MeO-PCP), 2-fluorodeschloroketamine
(2-FDCK) and N-ethyldeschloroketamine (2-Oxo-PCE, eticyclidone) are, in that order, the leading novel hallucinogens
worldwide. Novel hallucinogen prevalence data are lacking for the USA; however, NPS Discovery toxicology testing of samples from across the country identified the most
prevalent novel hallucinogen in 2018 as MeO-PCP and in
2020 as 2-FDCK (70). Among the United States Schedule I
NBOMe(s), there were few 25B-NBOMe and 25C-NBOMe
reports with the market shifting to 25I-NBOMe (147).
Less frequently encountered novel hallucinogens included
phenethylamine
analogs
2C-E,
Bromo-DragonFLY
and DOC (2,5-dimethoxy-4-chloroamphetamine); the LSDlike analogue AL-LAD (6-allyl-6-nor-LSD); tryptamine-like
analogues 5-MeO-MiPT and 5-methoxy-N,N,-diisopro
pyltrptamine (5-MeO-DiPT); diarylethylamine analogues
diphenidine and methoxphenidine (MXP) and the ketaminelike analog methoxpropamine (MXPr).

Pharmacology
MeO-PCP, 2-FDCK and MXP bind to the glutamate Nmethyl-D-aspartate receptor (NMDAR) (148–150). 3-MeOPCP has the highest binding affinity compared to its
2- and 4-MeO-PCP isomers, with similar potency to PCP
at the NMDAR (150). 3-MeO-PCP is metabolized via Odemethylation to 3-hydroxy-PCP (3-HO-PCP), which also is
an emerging novel hallucinogen with even higher NMDAR
affinity (120, 151). The concentration of 3-HO-PCP is thus an
important aspect to consider when interpreting toxicological
data from 3-MeO-PCP and 3-HO-PCP cases (152). 2-MXP,
3-MXP and 4-MXP are relatively selective NMDAR antagonists with IC50 of 56.5 ± 5.8, 30.3 ± 2.6 and 723.8 ± 69.9,
respectively. These NMDAR antagonists exhibit a relatively
similar potency order to MeO-PCP analogues (149). Diphenidine exhibited greater potency than 2-MXP and is thus less
potent than PCP and ketamine (149). Anecdotal reports
claim that 2-FDCK is more potent than ketamine; however,
analytical data are not available.
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tion pneumonia (85). At the first admission, his GCS was 4
with an elevated heart rate; alpha-ethylaminopentiophenone
(α-EAP) and 4-fluoro-alpha-pyrrolidinovalerophenone were
identified as the causative agents. In a third case, a
male with a history of drug addiction had autopsy findings of pulmonary edema and multivisceral congestion
(88). His femoral blood contained 47 ng/mL of 4-methylα-pyrrolidinohexiophenone (MPHP) and 1.6 ng/mL of 4methyl-α-ethylaminopentiophenone (4-MEAP). In a nonfatal
4F-MPH case, a disoriented and confused individual with
severe psychomotor agitation was admitted to the ED and had
mild tachycardia lasting 2 days (84). 4F-MPH blood and urine
concentrations were 32 and 827 ng/mL, respectively.

e137

23 y/o M with hx of ketamine use; Insufflated
what he believed was ketamine

2-FDCK

41 y/o F ingested instant coffee packet;
admitted to ED and psychiatric ward
with drug-induced acute psychosis and
adjustment disorder

18 y/o M ingested instant coffee packet;
admitted to ED and discharged with
consciousness recovery.

6 DUID investigations

Delirium and agitation; BP 111/88, pulse
140 bpm, RR 20, SpO2 100% and Temp
36.3◦ C; acute kidney injury, elevated
creatinine kinase and lactic acidemia
Delirium and suicide attempt by driving car
into tree; BP 157/90, pulse 78 bpm, RR 17,
SpO2 95% and Temp 37.5◦ C

Tactile hallucinations and vomiting; BP 132/79,
pulse 134 bpm, RR 20, SpO2 93% and Temp
36.2◦ C
Delirium and delusion of being monitored; BP
158/94, pulse 120 bpm, RR 20, SpO2 98%
and Temp 38.4◦ C
Delirium, self-harm and agitation; BP 101/77,
pulse 93 bpm, RR 19, SpO2 97% and Temp
36.3◦ C
Impaired consciousness (14), agitation (8),
abnormal behavior (5), hallucination or
delusion (4), loss of consciousness (4), dizziness (3), convulsion (2), hypertension (8),
tachycardia (6), nausea or vomiting (3),
hyperthermia (1), dyspnea (1)
Suspected drug impairment

Delirium and palpitation; BP 121/62, pulse
144 bpm, RR 20, SpO2 98% and Temp
36.3◦ C
Delirium generalized weakness; BP 195/81,
pulse 80 bpm, RR 20, SpO2 100% and Temp
35.6◦ C

Some unconscious and unresponsive; tachycardia, respiratory distress, pain, delusions,
self-harm; some required sedation with
benzodiazepines; all recovered within days

Clinical symptoms/Autopsy findings

(108)

Urine: 104.8
Ketamine 121.9, norketamine 285.5,
mephedrone 991.3
Urine: 918.6
Eutylone 1007.9, mephedrone 991.3

(108)

(108)

Urine: 117.7
4-CEC 1950.2, eutylone 4,131.8, ethylone
1.8, methylone 119.6
Urine: 101.69
NEP 4545.61. mephedrone 91.54

(continued)

(110)

(109)

Urine: +
2-Oxo-PCE (n = 9)
DCK (n = 10) ketamine (n = 17) tiletamine
(n = 2)

Blood: 0.005–0.48 mg/kg
Hair: 0.007–0.034 ng/mg

(108)

Urine: 56.2
Eutylone 54.1, mephedrone 1,345

(108)

(108)

(108)

(107)

Reference

Urine: 21.7
NEP 716

Urine: 213

‘2C-E’
Blood: <0.4
Urine: 1.5–183
‘Bromo-DragonFLY’
Blood: 0.6–2
Urine: 1.6–35

Drug results (ng/mL, unless specified)
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2-Oxo-PCE

29 individuals (15 M, 14 F, 24–56 y/o)
ingested an unknown drug; found lying on
ground, shouting and screaming

2C-E and BromoDragonFLY

39 y/o M ingested instant coffee packet;
admitted to ED and later to psychiatric
ward with drug-induced acute psychosis
and adjustment disorder
40 y/o M ingested instant coffee packet;
admitted to ED and psychotic symptoms
subsided 1 day later
40 y/o M ingested instant coffee packet;
admitted to ED and psychotic symptoms
subsided 1 day later
22 y/o M ingested instant coffee packet;
admitted to ED and discharged with
consciousness recovery
Clinical case series 20 ketamine users (13 F
and 7 M; 18–50 y/o)

History

Drug

Table V. NPS Hallucinogens Case Histories with Clinical Symptoms, Autopsy Findings and Primary Drug and Additional Drug Concentrations
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3-HO-PCP

56 y/o M with hx of myocardial infarction;
admitted regular use of ‘Hexen’ (N-ethyl
hexedrone) and recent 3-HO-PCP use

24 y/o M with no prior clinical hx found
confused and wandering; white powder in
nose

25 y/o M found lying on ground; drowsy but
agitated state; white powder in nose

Hyperthermia (39.9◦ C), sinus tachycardia
(150 bpm), reduced consciousness, ocular
clonus and vertical nystagmus; GCS 6, RR
40, oxygen saturation 99%, HR 144 bpm, BP
145/93; developed rhabdomyolysis

(113)

Serum: +
+3-HO-PCP metabolites,
+N-ethyl hexedrone/metabolites,
+clephedrone/metabolites
Urine: +
+3-HO-PCP metabolites,
+3-MeO-PCP, +N-ethyl hexedrone/metabolites,
+clephedrone/metabolites, +THC-COOH

(continued)

(112)

(112)

(112)

Urine: +

Urine: +

Urine: +

‘25 cases 2-Oxo-PCE only’: impaired consciousness (21), confusion (15), abnormal
behavior (11), agitation (5), aggressive behavior (6), loss of consciousness (5), convulsion
(4), drowsiness (4), unstable emotion (2),
psychotic symptoms (4), dizziness (1), nystagmus (1), unsteady gait (1), hypertension
(20), tachycardia (10), hyperthermia (4) and
rhabdomyolysis (2)
Hyperthermia (39.3◦ C), diabetic ketoacidosis and convulsion; BP 177/117, sinus
tachycardia (116 bpm), GCS 8, UDS negative
Afebrile (37.1◦ C), GCS 9, sinus tachycardia 119 bpm, BP 143/96, UDS positive for
morphine only
Afebrile (36◦ C), GCS 10, sinus rhythm
(85 bpm), BP 146/98, UDS negative

56 clinical case series.

37 y/o M with hx of psoriasis; found
collapsed at home

(111)

Femoral blood: 375
DCK 7, venlafaxine 200,
O-desmethylvenlafaxine 50, Ndesmethylvenlafaxine 40
Heart blood: 2,159
Urine: 3468
Liver: 6,137 ng/g
Bile: 3,290
Gastric contents: 3,086
Urine: +
Cocaine (n = 15), ketamine (n = 14),
methamphetamine (n = 8), cannabis
(n = 1)

Brain swelling (1410 g), moderate lung hyperhydration (420 g), inner organs filled with
blood, urinary bladder moderately opened,
tablets found in stomach and small bowel,
acute respiratory infection, expanded right
ventricle and atrium

52 y/o M found dead in bedroom; found
with head hanging over bucket; drug
paraphernalia at scene

(112)

Reference

Drug results (ng/mL, unless specified)

Clinical symptoms/Autopsy findings

History
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Petechial hemorrhage of oral mucosa, brain
edema, pulmonary congestion and edema,
discrete coronary atherosclerosis and enlarged
liver
Fresh myocardial injury, congestion of internal
organs and mucous membranes, pulmonary
edema, brain and heart edema; incipient
pneumonia and aspirated stomach content
after vomiting

32 y/o M with hx of drug use; found dead in
residence; drug materials and paraphernalia
at scene

Brain edema, pulmonary edema, a patent
foramen ovale and discrete coronary
atherosclerosis
Congestion of lungs and liver

29 y/o M with hx of bipolar disorder and
drug use; found hanged in residence after
leaving good-bye message; pills and drug
paraphernalia at scene

27 y/o M with psychiatric problems; found
on chair in residence

27 y/o M; found dead at home in bathtub; hx
of drug use; regularly ordered hallucinogens
online
21 y/o M with suicidal intentions found
unresponsive in room; hx of drug use

19 y/o M with hx of drug use and depression;
found awake at home; white powder and
drug paraphernalia recovered

(117)

Blood: 180 ng/g
Buprenorphine 2.2 ng/g,
5-MeO-MiPT 130 ng/g
Blood: 230 ng/g
Methadone 440 ng/g, diazepam 530
ng/g, methamphetamine 40 ng/g,
buprenorphine 0.2 ng/g
Blood: 120 ng/g
Flubromazolam 10 ng/g,
+AB-FUBINACA, +THJ-018, buprenorphine 2 ng/g, methylphenidate 20
ng/g
Blood: 60 ng/g
Oxycodone 100 ng/g, amphetamine 130
ng/g, flubromazolam 9 ng/g, MT-45 110
ng/g, 4-MeO-PCP 30 ng/g, THJ-018,
THC 1.1 ng/g

(continued)

(117)

(117)

(117)

(117)

(117)

(116)

(115)

(114)

(114)

Reference

Blood: 380 ng/g

N/A

Tachycardic, hypertensive, tachypneic and
catatonic; developed fever and lactic acidosis
concomitant with psychomotor agitation and
hallucinations; sinus rhythm, respiratory rate
22 bpm, pulse 130 bpm, BP 147/104, oxygen
saturation 96%, GCS 11, pupils dilated
Brain swelling, pulmonary edema and urine
retention; burns on body from hot water

Blood: 63 and 498
Urine: 94 and 16,700
Hair: +
Blood: 400 ng/g

Delusions, vital signs normal, borderline
tachycardia

27 y/o M with hx of schizophrenia; found
unconscious in car by police; reported feeling sedated and ‘loopy’; unable to remember
events, denied drug use
2 fatal cases: 30 y/o F found murdered; 41 y/o
F found dead at home

21 y/o M hospitalized; nasal fracture;
ingestion of unknown pills

Blood: 350
Ethanol 2 g/L
Urine: 6109.2
Blood: 180.1
Ethanol 1.7 g/L
Urine: 3,003.5
Urine: +(PCP screen)

Altered state, delirious and euphoric; respiratory acidosis, right anisocoria, mydriatic
pupils and hypothermia
Altered state; respiratory acidosis, right
anisocoria, mydriatic pupils and hypothermia

19 y/o M hospitalized; ingestion of unknown
pills

Drug results (ng/mL, unless specified)

Clinical symptoms/Autopsy findings

History
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Confusion, aggressiveness, logorrhea, hypertonia, myosis, hypersalivation; BP 151/90, HR
100 bpm and Temp 37.3◦ C
BP 137/87, HR 83 bpm and Temp 36◦ C

36 y/o M found agitated on street

32 y/o M with hx of cannabis use; presented
to ED for abdominal pain but painkillers
inactive at high doses

Temp 23.1◦ C, face, neck and eyes stowed;
foam on mouth; small injuries on hands and
legs

(120, 121)
Blood: 63
Urine: 94
Bile: 64
Hair: 731–893 pg/mg
Ethanol 1.37 g/L, diazepam 157, cocaine
25
Blood: 498
Urine: 16,700
Blood: 152
Ethanol 1.2%
Serum: 123
Amphetamine 85
Drug product: +
Urine: +
Ethanol 0.185 g/dL, +buprenorphine,
+tramadol
Urine: +

∼ 35 y/o M with hx of cannabis and
amphetamine use; found dead near lake
with face in water; ingested ant poison drug
prior to death

41 y/o M found dead at home

(119)

Blood: 17.1
Urine: 706.9

(continued)

(123)

(123)

(122)

(120)

(118)

(117)

BP 158/131, tachycardia (100 bpm), neurological manifestations; confusion, hypertonia,
nystagmus and agitation; symptoms similar
but less severe during second overdose
Parched horizontal ligature encircling neck;
broad red area from intense subcutaneous
hemorrhage; clear ligature abrasion; fractures
with hemorrhage of superior horn of thyroid
cartilage and right greater horns of hyoid
bone; intense multi viscera congestion
Needle marks noted

Pulmonary and cerebral edema and internal
organ congestion
RR 18, oxygen saturation 96%, sinus
tachycardia 115 bpm and Temp 37.9◦ C

20 y/o F found dead in bed; reportedly taking
tramadol and benzodiazepines
40 y/o M with HIV admitted to hospital;
went to bathroom to use drugs (0.2 mg IV);
found lying on ground unconscious; patient
survived; drug sample recovered for testing
17 y/o M purchased 3-MeO-PCP on internet;
took 200 mg oral dose and admitted to ED;
7 days later returned to ED after insufflating
50 mg
39 y/o F with hx of drug use; found dead at
home after assault by partner

(117)

Blood: 50 ng/g
Tramadol 60 ng/g, alprazolam 20 ng/g,
fentanyl 25 ng/g, amphetamine 90 ng/g
Blood: 80 ng/g
Tramadol 13,000 ng/g
Drug product: +

Internal organ congestion, pulmonary edema,
petechiae on heart surface

27 y/o M with hx of drug use; found
unresponsive in bed

Reference

Drug results (ng/mL, unless specified)

Clinical symptoms/Autopsy findings

History
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29 y/o M injected solution of
5-MeO-DiPT into the anus
4 M suspected of using 5-MeO-DiPT
32 y/o M ingested LSD-like substance; found
standing naked and without orientation in
street; drugs recovered from residence

17 y/o M with hx of NPS use; ingested
25B-NBOMe tablets sublingually; friends
monitored state for hours; found unresponsive by EMS and pronounced
dead
23 y/o M ingested substances labeled 25BNBOMe 1 GR and 4-CMC 1 GR; found in
residence and died in route to ED
23 y/o M ingested substances labeled 25BNBOMe 1 GR and 4-CMC 1 GR; jumped
out window of fifth floor and found dead

25B-NBOMe

21 y/o M with hx of drug use; found naked
and unresponsive; recently discharged from
drug treatment; empty pill bottles recovered
from person
58 y/o M with hx of opiates and methamphetamine; significant health problems;
found unresponsive in drug treatment
facility

(125)

Blood: 3,200
Ethanol 47 mg/dL, bupropion 1800,
+delorazepam, +mitragynine,
+paroxetine
Blood: 630
+PCP (screen), methamphetamine 110
Urine: +
+Amphetamine (screen)

(129)

Blood: 66.5
4-CMC 2.14, +THC, THC-COOH 11,
+ethanol
Blood: 661
4-CMC 0.887, +THC, +THC-COOH,
+ethanol

Aggressive, agitated, moving anxiously,
shouting, convulsions, heavy breathing and
salivations
N/A

(continued)

(129)

(128)

(126)
(127)

Urine: 0.3–0.8
Blood: 160
Methylphenidate 1.36, ritalinic acid 64.1,
BZE 305
Urine: 3,380
+ 5-MeO-MiPT metabolites,
methylphenidate 671, ritalinic acid 2,230
Drug powder: +
Blood: 3.14

(126)

Dried urine spot: 2.3

(125)

(124)

(124)

Serum: 49
Methamphetamine 121, amphetamine 10

Serum: 66
Ethanol 1.02 g/L

Reference

Drug results (ng/mL, unless specified)

Hallucinogenic effects, convulsive episodes,
various arrhythmias, led to cardiac arrest and
death

No abnormal signs/symptoms when presented
to ED days later
N/A
Agitated and aggressive; several abrasions on
body and in bad state

MOD: accident; COD: acute intoxication due
to polydrug consumption

Hypertensive (170/100), tachycardic (120),
signs of psychosis and altered neurological
status GCS 10–12; increased muscle tone
with spastic leg postures; fluctuating state of
consciousness
Hypertensive (172/113), tachycardic (126),
breathing spontaneously and normoglycemic;
altered state of consciousness 12 GCS; did
not obey commands; pupils isocoric and
miotic
MOD: accident; COD: acute intoxication due
to polydrug consumption

37 y/o M admitted to ED after drug ingestion

40 y/o M with no hx drug use; referred to
ED for cramps and deteriorating state of
consciousness

Clinical symptoms/Autopsy findings

History
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Seizures, muscle swelling, diminished
motor function; severe clinical toxicity and developed exceptionally massive
rhabdomyolysis

‘Upon presentation’: vital signs unremarkable,
excessively dilated pupils, strong sweating,
disorientation and agitation.
‘30 min later’: severe agitation, screaming,
coenesthesia, hallucinations; BP 127/97, HR
100; symptoms resolved in 6 h
Impairment, altered behavior and visual
hallucinations
Forensic clinical evaluation of brain dysfunctions after cardiorespiratory arrest
Hypertonia, tremors, partial seizure, mydriasis,
tachycardia, hypertension, hyperthermia, profuse sweating, serotonin syndrome; persistent
cognitive and psychiatric abnormalities
2 tonic-clonic seizures, became unresponsive and apneic; BP 106/53, HR 140, Temp
38.9◦ C and oxygen saturation 98%

Serum: 0.9
Urine: +
+ 25C-NBOMe metabolites
Pink liquid: +
Serum: 3
2C-I 55
Urine: 10
2C-I 225
Blood: 0.24

Plasma: 37 and 72
Powder: +
Hair: 1.0–4.9 pg/mg

Serum: 4.2–34
25I-NBOH, 2C-I 2.1–12
Urine:
25I-NBOH 1.2, 2C-I 3.5–8.2

(continued)

(137)

(136)

(135)

(134)

(133)

(132)

(131)

Peripheral blood: 2.8
25H-NBOMe 0.29, THC 15.5, THCCOOH 56
Central blood: 1.43
25H-NBOMe 0.13, THC 9.9, THCCOOH 8.5
Urine: 0.94
25H-NBOMe 0.14, THC-COOH 43

Death occurred by drowning
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20 y/o with no medical hx ingested small dose
of Alice in Wonderland had seizure episode
during a party

17 y/o M ingested two lines of acid; found
having multiple seizures and transported by
EMS to ED

29 y/o M unconscious after instilling pink
liquid in nose thought to be NBOMe(s)

Two individuals insufflated white creamy
powder
Drug consumption

42 y/o M with no medical hx; severe
headache ingested pediatric analgesic syrup replaced with ethanolic
25I-NBOMe ∼ 320 µg/mL developed
restlessness

25I-NBOMe

(130)

(129)

Blood: 38.4
+4-CMC, +THC, THC-COOH 13,
+ethanol
Blood: +

Reference

Drug results (ng/mL, unless specified)

‘First admission’: aggressive, confrontational
but alert; BP 139/90, HR 146, RR 28, Temp
36.6◦ C, oxygen saturation 98%; no evidence
of trauma; tachycardia and agitated
‘Second admission’: agitated; BP 153/119,
HR 120, RR 22, Temp 36.8◦ C and oxygen
saturation 98%

Aggressive, agitated, moving anxiously,
shouting

24 y/o M ingested substances labeled 25BNBOMe 1 GR and
4-CMC 1 GR; found in residence, transported to ED and lived

27 y/o M with re-admission to ED after
ingestion of drugs
‘First admission’: found acting erratically,
resisted arrest, was physically restrained and
transported to ED
‘Second admission’: ∼ 3 weeks later; ingested
tablets of 25I-NBOMe and transported to
ED
Teenage M attended party, drugs for sale;
seen smoking cannabis; altered state of
mind; taken home by friends; jumped in
waterway and body later found downstream; plant material and blotters found
on decedent

Clinical symptoms/Autopsy findings

History

25C-NBOMe

Drug
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26 y/o M with hx of drug use admitted to
ED; drug recovered for analysis

MXPr

Urine: +
Drug product: + (95%)

Urine: +
+ AMT
Pills: +
+ AMT

Profuse sedation, hyperthermia, tachycardia
(HR 140) and mydriasis; GCS 10; serotonin
syndrome suspected
Asymptomatic

Powder: +

Plasma: <18
Urine: 300–1,300
Liver: 99 ng/g
Spleen: 28 ng/g
Bone: 14 ng/g
Lung: 15 ng/g
Hair: 32 pg/g

Agitation, aggressiveness, reported dissociative
effects; Withdrawal after 7 days in hospital

No traumatic injury

Severe clinical symptoms

(139)

Plasma: 308
Diclazepam 3.5, methylphenidate 3.0
Urine: 631
+methylphenidate,
THC-COOH 120
Hair: 4,400 pg/mg
Alpha-PVP 1,040 pg/mg, MDPV 120
pg/mg, methoxetamine 27 pg/mg,
4-FA 55 pg/mg, methylone
Powder: +
Blood: 73
7-aminoflunitrazepam 86,
7-aminonimetazepam 27, chlorpheniramine 66
Blood: 12 ± 2.6
+ Diphenidine metabolites, 5F-ADB
0.19 ± 0.04 and metabolites

(146)

(145)

(144)

(143)

(142)

(141)

(140)

(138)

Reference

Serum: +
+ lysergic acid
Urine: +

Drug results (ng/mL, unless specified)
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5-MeO-DiPT = 5-methoxy-N,N,-diisopropyltrptamine, AMT = alpha-methyltryptamine, DCK = deschloroketamine, MOD = manner of death, UDS = urine drug screen.

21 y/o M with hx of bipolar disorder and
drug use; patient reported use of 125–
150 mg MXP purchased online; presented
to ED; powder collected for testing
33 y/o M with hx of autism and treatment
with methadone, loxapine and lorazepam;
found agitated and presented to ED; small
yellow pills collected from residence

MXP

No apparent specific injuries or internal
findings

53 y/o M found dead in residence; ‘Heart
Shot BLACK’ package with herbal material
recovered and confirmed as 5F-ADB

Five nonfatal cases 18–23 y/o believed to
ingest LSD
Two found dead after insufflating powder
believed to be LSD; 4 years later, bodies
exhumed for additional testing

Slight abrasions on hands; no signs of natural
disease; slight brain edema, pulmonary edema
and organ congestion

∼ 25 y/o F; found dead in bed; NPS packages
recovered

DOC

Tachycardia (HR 160), tachypnea and miotic
nonreactive pupils; agitation, disorientation
and altered consciousness with GCS 9; Temp
38.0◦ C

30 y/o M with hx of drug use found confused, agitated and unable to communicate;
white powder labeled diphenidine 1 g
recovered

Diphenidine

BP 73–123/54–90, HR 57–122, Temp 35.7–
36.9◦ C, SpO2 98–100%, GCS 3, pupils 3 mm

51 y/o M with hx of hyperlipidemia and vertebral artery stenosis; shot two teenagers
and ignited a building; police placed individual in patrol car and he became pulseless;
transported to ED in cardiac arrest

AL-LAD

Clinical symptoms/Autopsy findings

History

Drug
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NPS Adverse Effects

PCP-like analogs
3-MeO-PCP and 3-HO-PCP are methoxy- and hydroxysubstituted chemical derivatives of the traditional hallucinogen PCP, respectively, which can exist as positional isomers
(e.g., 4-MeO-PCP and 4-HO-PCP). MeO-PCP derivatives
were first synthesized in the 1960s and 1970s (159), but
the first fatalities were reported in 2014 from Sweden (160).
3-MeO-PCP and 4-MeO-PCP are not explicitly controlled in
the USA (147) but could be considered PCP analogs, federally
controlled under Schedule II by the DEA.
During 2017–2020, nonfatal and fatal 3-MeO-PCP cases
reported hospitalized individuals as delirious, confused and
aggressive. Clinical signs and symptoms included hypertension, tachycardia, hypothermia, tachypnea, mydriasis and
excessive sweating, with most individuals recovering from
their overdose. Decedents were commonly found unresponsive with edema and lung, brain and heart congestion at
autopsy. There was no distinction between quantitative toxicology concentrations for antemortem and postmortem cases.
A nonfatal intoxication following 3-HO-PCP and NEH ingestion led to reduced consciousness, hyperthermia and tachycardia; a patient who was eventually discharged from the hospital
also had rhabdomyolysis (113).
Ketamine-like analogues
Modified or substituted chemical derivatives of the traditional
hallucinogen ketamine include 2-FDCK, which replaces the
chlorine atom with fluorine, and 2-Oxo-PCE, which removes
the chlorine atom and elongates the methyl chain to an ethyl
chain on the secondary amine. 2-FDCK was first synthesized in 2009, but both ketamine-like analogues emerged
on the world recreational drug market in 2016 (161), with
2-FDCK first identified in the USA in 2018 (162). In that
same year, a cluster of 2-Oxo-PCE poisonings were reported
(112). 2-FDCK and 2-Oxo-PCE are not explicitly controlled
in the USA (147), although both were implicated in fatal
and/or nonfatal overdoses. Individuals hospitalized following
2-FDCK intake experienced impaired consciousness, agitation, abnormal behavior, hallucinations and/or delusions,
loss of consciousness, dizziness, convulsion, nausea and/or
vomiting (109). Clinical signs and symptoms included hypertension, tachycardia, hyperthermia and dyspnea with individuals recovering and released from the hospital. 2-FDCK
also was involved in six DUID investigations; however, lim-

ited information was available (110). No fatal cases involving
2-FDCK were reported.
Individuals hospitalized following 2-Oxo-PCE ingestion
experienced impaired consciousness, confusion, abnormal
behavior, agitation, aggressive behavior, loss of consciousness, convulsions, drowsiness, unstable emotion, psychotic
symptoms, dizziness, nystagmus and unsteady gait (112).
Clinical signs and symptoms included hypertension, tachycardia, hyperthermia and rhabdomyolysis, with a single reported
fatal outcome (111). The decedent was found in his bedroom with his head hanging over a bucket. At autopsy, brain
swelling and lung hyperhydration were noted, and tablets
were found in the stomach and small bowel.
MXPr is a ketamine-like analogue with structural similarity to 2-Oxo-PCE but is structurally dissimilar from MXP and
diphenidine. MXPr contains a 3-methoxy moiety and a propyl
group on the amine. MXPr was reported in one nonfatal case
in which the individual was reported to be asymptomatic after
presentation to the hospital (146). Toxicology testing and
chemical analysis confirmed MXPr ingestion.
Phenethylamine analogues
25I-NBOMe was the most commonly encountered
phenethylamine-like novel hallucinogen during the period
of review, with observed behaviors including agitation,
aggression, seizures, euphoria, hallucinations and sweating
(14). Hospital personnel reported tachycardia, hypertension,
hyperthermia and mydriasis in patients. Similar case scenarios and clinical findings were reported for 25B-NBOMe and
25C-NBOMe.
A mass poisoning occurred when multiple individuals at
a seminar ingested the same drug product containing 2C-E
and Bromo-DragonFLY, yet there was considerable variability
in the outcomes (107). Some individuals were found unconscious and unresponsive, with clinical signs and symptoms of
tachycardia and respiratory distress. Some required sedation
with benzodiazepines, but all recovered within days without
any fatalities.
DOC intoxications and adverse effects were well characterized in ‘PiHKAL’ in 1991 (2, 14). Since 2017, five nonfatal
and two fatal DOC intoxications were confirmed following
ingestion of what was thought to be LSD (142). Also, DOC
ingestion was confirmed in two exhumed bodies after their
unexplained deaths followed insufflation of an ‘LSD’ powder
(132).
LSD-like analogues
AL-LAD first emerged in Europe in 2015, and only one
nonfatal LSD-like analogue intoxication was reported during 2017–2020 (138); however, comprehensive international
data for this drug are not available (163). The individual
acted erratically, shooting two teenagers and setting fire to
a building. Police responded and apprehended the individual,
who became unresponsive while in the patrol car and later
had a cardiac arrest. Clinical signs and symptoms included
tachycardia, hypotension, hypothermia and mydriasis.
Tryptamine-like analogs
5-MeO-MiPT and 5-MeO-DiPT share structural similarity
with tryptamine but with the addition of a methoxy group
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NBOMe(s), like the classical hallucinogen LSD, are agonists of the serotonergic system (153–155). 25I-NBOMe
is a potent full 5-HT2A receptor agonist, with a Ki of
0.044 ± 0.006 nM and an EC50 of 0.44 ± 0.07 nM (153);
25B-NBOMe and 25C-NBOMe are partial agonists, with Ki
of 0.19 ± 0.01 nM (154) and 0.9 nM (155), respectively. The
onset of effects of oral 25I-NBOMe in humans is 15–120 min,
with a duration of action of 6–10 h (similar duration for 25Band 25C-NBOMe).
Tryptamine-like analogues are also agonists at the SERT
5-HT2A receptors; however, these hallucinogens have lower
binding affinity compared to LSD (156). 5-MeO-MiPT
has moderate 5-HT2A receptor activity with a Ki of
0.163 ± 0.03 nM (156); 5-MeO-DiPT has a Ki of 0.560 nM
and induced hallucinogenic effects in rodents (157, 158).
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Table VI. Summary of Toxicity Profile of NPS Hallucinogen Drug Subclasses

PCP-like analogues

Ketamine analogues

Phenethylamine analogues

CNS

Delusions, confusion, aggression,
psychomotor agitation, altered or
fluctuating consciousness

Agitation, aggression, seizures,
euphoria, hallucinations and loss
of consciousness

Cardiovascular

Tachycardia and hypertension

Pulmonary

Tachypnea, respiratory acidosis

Agitation, aggression, abnormal behavior, hallucination, delusions, impaired
consciousness, loss of consciousness, unstable emotions, psychotic
symptoms and unsteady gait
Tachycardia, hypertension and
palpitations
Dyspnea

Other

Hypothermia, mydriasis, excessive
sweating and vertical nystagmus

Postmortem findings

Edema and congestion of lungs,
brain and heart

Hyperthermia, rhabdomyolysis,
nystagmus, drowsiness, dizziness,
convulsion, nausea, vomiting and
self-harm
Brain swelling and lung hyperhydration

on the indole and alkyl groups on the amine. 5-MeO-DiPT
is a Schedule I substance in the USA, while 5-MeO-MiPT
is not explicitly scheduled (147, 164). 5-MeO-DiPT intoxications are described in the literature, but details on case
scenarios and clinical findings are lacking. In one case, no
abnormal clinical signs or symptoms were reported (126).
A naked individual was disoriented, agitated and aggressive
with several abrasions after ingesting an LSD-like substance
in another nonfatal intoxication (127). The biological samples and recovered drug material confirmed the presence
of 5-MeO-MiPT intoxication. Positional isomers of these
tryptamine-like analogues are also available; 4-MeO-MiPT
was first documented in Europe in 2019 (16).
Diarylethylamine analogues
MXP is structurally related to diphenidine. Two nonfatal
MXP cases since 2017 documented agitation, aggressiveness,
dissociative effects and sedation in the patients (14). Clinical signs and symptoms for both included hyperthermia,
tachycardia and mydriasis. In one case, serotonin syndrome
was suspected, similar to findings that involved other novel
hallucinogens and novel stimulants. Tachycardia, tachypnea
and miosis were observed in two nonfatal and one fatal
diphenidine intoxications; one individual experienced agitation, disorientation, altered consciousness and an inability to
communicate (139). In the fatal case, abrasions were noted at
autopsy, along with pulmonary and brain edema and organ
congestion (140).

Discussion
Recently reported novel hallucinogens, documented adverse
effects and toxicological confirmation of the responsible
drug include PCP-like analogues (e.g., 3-MeO-PCP and
3-HO-PCP), ketamine-like analogues (e.g., 2-FDCK, 2-OxoPCE and MXPr), phenethylamine analogues (e.g., 25INBOMe, 25B-NBOMe, 25C-NBOMe, DOC, 2C-E and
Bromo-DragonFLY), LSD-like analogues (e.g., AL-LAD),
tryptamine-like analogues (e.g., 5-MeO-DiPT and 5-MeOMiPT) and diarylethylamine analogs (e.g., MXP and diphenidine). Although these drugs are classified under one NPS
class, adverse effects may be similar or can differ based
on the specific novel hallucinogen ingested (Table VI). For

Tachycardia, hypertension and
cardiac arrest
Respiratory distress, heavy breathing
and apnea
Hyperthermia, mydriasis, rhabdomyolysis, sweating, salivation, tremors
and serotonin syndrome
Edema and congestion of lungs and
brain

example, intoxication with most substances resulted in agitation, aggressive behavior and/or delusions. 3-MeO-PCP
was more commonly associated with hypothermia, whereas
other novel hallucinogens produced hyperthermia. The most
common physiological effect reported during hospitalization
was tachycardia, a finding noted for all novel hallucinogens.
Cases of excited delirium and serotonin syndrome were also
reported.
There are no standard laboratory analytical procedures
for the class of novel hallucinogens, and routine testing is
generally lacking in the USA and internationally. This most
likely results in underreporting of the prevalence for this NPS
class. In a 2020 survey of laboratories performing DUID
testing (n = 65), 83% test for PCP in blood (the same percentage as the 2016 survey); however, only 54% test for PCP
in urine (down from 78%) (165, 166). Additionally, 69%
(up from 50%) of laboratories routinely test for ketamine in
blood, but only 40% tested for other ‘hallucinogens’. When
asked what additional drugs should be added to the recommended scope for DUID testing, no laboratory suggested any
novel hallucinogen drugs or subclasses. This could be because
PCP was only the 20th most commonly encountered drug in
DUID casework of survey respondents in 2020 (when ranking
cumulative responses of the top 15 drugs from each respondent); the laboratories did not list any other hallucinogens,
including ketamine, LSD or novel analogues. Survey results of
the scope of analytical confirmation during death and DUID
investigations are not currently available; however, PCP and
ketamine are included in draft standards documents produced
by the Academy Standards Board: ‘Standard for the Analytical Scope and Sensitivity of Forensic Toxicological Testing
of Blood in Medicolegal Death Investigations’ and ‘Standard
for the Analytical Scope and Sensitivity of Forensic Toxicological Testing of Blood in Impaired Driving Investigations’.
As expected, no novel hallucinogens are included (167, 168).
Although hallucinogens are not among the top drugs detected
in DUID investigations, the above draft standards strongly
suggest the need to test for novel hallucinogens in nonfatal intoxications, fatalities and DUID investigations based on
case circumstances and investigative information.
With the current state of novel drug markets, laboratory
personnel need to consider the challenges and limitations of
testing for novel hallucinogens. Some immunoassay screening assays for traditional hallucinogens do cross-react with

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

Organ system

NPS Adverse Effects

e147

NPS Benzodiazepines
Introduction
The NPS market grew rapidly during 2008–2018, but new
analogues in some subclasses such as SC slowed, while
novel benzodiazepine analogues increased. Currently, the
EMCDDA monitors 30 novel benzodiazepines, with 21
detected in 2015 or later (67, 171). In 2020, the EMCDDA
reported 1.4 million tablets, 1.3 L of liquid and about 8 kg
of powder of new benzodiazepine seizures. Novel benzodiazepines are typically distributed by pressing into tablet molds
that appear similar to pharmaceutical alprazolam (Xanax® )
or diazepam (Valium® ) (172–176). This poses an additional
health concern as individuals believe they are taking traditional benzodiazepines of known potency, dose and quality. Novel benzodiazepines are readily available online and
marketed as ‘legal’ versions of authorized medications (67).

Pharmacology
As previously reported (14), the pharmacology of designer
benzodiazepines is similar to that of traditional benzodiazepines. Benzodiazepines bind to gamma-aminobutyric acid
A (GABAA ) receptors that are ligand-gated chloride-selective
ion channels activated by the inhibitory GABA neurotransmitter (177). Traditional benzodiazepines are classified as short(1–12 h), intermediate- (12–40 h) or long (40–250 h)-acting
drugs based on their half-lives (178). They are prescribed
as anxiolytics, sedatives or anticonvulsants. Common side
effects include drowsiness, lethargy, fatigue, dizziness, vertigo
and loss of motor control. Long-term use of benzodiazepines
can lead to tolerance, dependence and withdrawal (178).
Novel benzodiazepines also are agonists at GABAA receptors, producing adverse effects such as amnesia, drowsiness
and incoordination. Table VII provides a summary of the
toxicological profile of novel benzodiazepines.

Table VII. Summary of Toxicity Profile of NPS Benzodiazepines

Organ system

Symptoms and signs

CNS

Amnesia, sedation, drowsiness, lethargy,
slurred speech, incoordination, delayed
comprehension and reaction time,
dizziness, vertigo and coma
Bradycardia and hypotension
Mild respiratory depression
Bloodshot eyes

Cardiovascular
Pulmonary
Other

Table VIII (179–187) provides, when available, detailed
case histories, clinical symptoms, toxic effects, field sobriety testing, autopsy findings and biological data for cases
involving NPS benzodiazepines.
Flualprazolam
Flualprazolam (Figure 2) is a triazolo-benzodiazepine
patented in 1976 by Upjohn (188). Flualprazolam is a fluorinated analogue of alprazolam, but there is little information
in the literature regarding its specific pharmacological effects
because it was never legitimately marketed. Based on its structural similarity to traditional benzodiazepines, alprazolam
and triazolam, and user reports, flualprazolam most likely
has similar CNS depressant effects (189, 190). Flualprazolam was reported to be in circulation by the EMCDDA and
DEA in 2018; as of the third quarter in 2020, flualprazolam
was the most reported novel benzodiazepine in the USA. The
first cases were identified in March 2018 by retrospective data
mining of two biological specimens collected in Pennsylvania
and Indiana (191). The rapid increase in positive cases worldwide led the World Health Organization (WHO), DEA and
NPS Discovery to release reports and drug information sheets
to inform clinicians and first responders about this new drug
(183, 192–194).
In June 2019, six adolescents (five males and one female;
14–16 years old) in Oregon were admitted to the ED after
ingesting what they believed were Xanax or alprazolam
tablets (179). All displayed lethargy and slurred speech on
admission. One developed mild respiratory depression, with
a respiratory rate of 10 breaths per minute. All recovered
within 6 h of displaying symptoms and were discharged. Urine
samples from three adolescents contained 3–72.1 ng/mL flualprazolam, and one blood sample from another adolescent
contained 14.6 ng/mL flualprazolam. A piece of a counterfeit tablet was also analyzed and contained about 2.75–3 mg
flualprazolam but no alprazolam or other substances.
A collaborative effort reported flualprazolam concentrations in 23 postmortem cases from Sweden and 10 from Finland (180). The deaths (27 males and 6 females; 16–70 years
old) occurred during February 2018–January 2019 in Sweden
and June 2018–July 2019 in Finland. The median concentration and range were 18.0 ng/g and 3.0–68 ng/g, respectively,
with no significant differences between countries of origin. In
two cases, fatal poisoning from flualprazolam was listed as
the COD and the only substance detected in femoral blood at
19 ng/g and 21 ng/g. In the other 20 cases, the most common additional substances detected were opioids, alcohol,
pregabalin and antidepressants.
A 2020 study compiled quantitative flualprazolam concentrations for 197 cases (171 medicolegal death investigations, 22 DUID cases and 4 unclassified cases) submitted
to NMS Labs (Willow Grove, PA) during August 2019–
February 2020 (181). Demographic data were provided for
151 (113 males and 38 females) postmortem cases with a
mean ± standard deviation of 35 ± 12, median of 34 and
age range of 18–69 years. The cases occurred in 28 states
in the USA and a single Canadian province. The most
common other drug coadministrations were opioids including methadone, buprenorphine, oxycodone/oxymorphone,
heroin (6-acetylmorphine [6-AM] and morphine), fentanyl
(n = 106), carfentanil, tianeptine, mitragynine and isotonitazene. In addition to flualprazolam, etizolam was detected in
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novel hallucinogens (e.g., specifically MeO-PCP derivatives
with PCP kits) (169, 170). However, data for other subclasses
regarding cross-reactivity are lacking, and laboratories should
be aware that immunoassay screening will not detect most
novel hallucinogens. Comprehensive toxicological screening
by high-resolution mass spectrometry (HRMS) is a far superior approach for identifying novel hallucinogens when testing
is requested. Novel hallucinogens and their metabolites identified in this review should be incorporated into screening
applications, especially 3-MeO-PCP and 2-FDCK. Laboratories should also consider adding novel hallucinogens as they
emerge. It is important for toxicologists to understand evolving NPS drug markets and to remain current with literature
on novel hallucinogen intoxications and fatalities.

N/A

*Standard Field Sobriety Test was uncoordinated, had delayed comprehension and
reaction times and lethargic behavior

COD attributed to mixed drug toxicity

N/A

167 US/Canadian postmortem cases

22 US DUID cases*
*24 y/o M in MVC with bus

30 y/o M IV drug user with suspected OD

44 y/o M with hx of depression and possible heroin use discovered dead at home
with drug paraphernalia: packet Xanax
(alprazolam) tablets, empty pill dispenser,
prescription medications and empty syringes
40 y/o F with hx of mamba use (presumed
SCRA), found deceased on floor of home

(180)

Femoral blood:
Mean: 17.2 ng/g
Median: 17 ng/g
Range: 3–45 ng/g
Femoral blood:
Mean: 25.0 ng/g
Median: 22.5 ng/g
Range: 6.6–68.0 ng/g
Blood:
Mean: 20 ± 63
Median: 8.2
Range: 2–620
Blood:
Mean: 22 (± 18)
Median: 14
Range: 4.4–68
*13
NaF/KOx preserved blood: 2.8
Unpreserved blood: 3.0 pregabalin
12,000, +morphine, +codeine, +6-AM,
+noscapine, +papaverine, +diazepam,
+mirtazapine, +THC
NaF/KOx preserved blood: 30.3
Unpreserved blood: 35.1
+methadone, +MDMA, +MDA,
+pregabalin, +mirtazapine, +BZE,
+diazepam, +morphine, +gabapentin
Unpreserved blood: 14.5
+methadone, +EDDP, +pregabalin,
+mirtazapine, +4F MDMB-BINACA
metabolites, +MDMB-4en-PINACA and
metabolites

(continued)

(182)

(182)

(182)

(181)

(181)

(180)

(179)

(179)

(179)

Reference

Urine: 3.0

Urine: 72.1
+cannabinoids
Blood: 14.6
Urine: 19.4

Drug results (ng/mL unless specified)

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

N/A

N/A

10 Finnish postmortem cases

CNS depression, slurred speech and mild respiratory depression; unresponsive to 0.4 mg
IV naloxone
Lethargy and slurred speech

Lethargy and slurred speech

N/A

16 y/o M presented to ED after ingesting
counterfeit Xanax tablet
16 y/o M presented to ED after ingesting
counterfeit Xanax tablet

Flualprazolam

Clinical symptoms/Field Sobriety Testing/
Autopsy findings

16 y/o F presented to ED after ingesting
counterfeit Xanax tablet
23 Swedish postmortem cases

History

Drug

Table VIII. NPS Benzodiazepine Case Histories with Clinical Symptoms, Autopsy Findings and Primary Drug and Additional Drug Concentrations
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Diclazepam

N/A

N/A

37 y/o M found face down in mud

40 y/o M with hx of alprazolam use, IV drug
use and anxiety and depression, found lying
on river embankment with rigor mortis.
Bottle of methadone on him, 30 mL bottle
nystatin in river and green herbal material
and white pills in wallet
51 y/o M with hx of depression and heroin
use found deceased in his bathroom.
Hepatitis C positive and in methadone
program

N/A

42 y/o F with hx of heroin abuse found
unresponsive at home
42 y/o M with hx of IV drug use and selfharm found unconscious on pathway, CT
scan: severe hypoxic brain injury

N/A

N/A

Ten antemortem cases

334 antemortem cases

N/A

123 DUID investigations, Sacramento
County, CA

N/A

N/A

57 y/o M with hx of chronic obstructive
pulmonary disease, chest infections, heart
problems and crack cocaine and heroin use

N/A

Clinical symptoms/Field Sobriety Testing/
Autopsy findings

History

Blood:
Range: 1.6–250
Median: 9.6

NaF/KOx preserved blood: 3.1
+morphine, +codeine, +methadone,
+EDDP, +alprazolam, +diazepam,
+nordiazepam, +temazepam, +oxazepam,
+sertraline, +pregabalin, +risperidone,
+BZE
NaF/KOx preserved blood: 4.7
Unpreserved blood: 5.7
+cocaine,
+BZE, +citalopram
NaF/KOx preserved blood: 15.1
+morphine, +codeine, +pregabalin
Antemortem citrate preserved blood: 8.5
+cocaine, +BZE, +mirtazapine,
+nitrazepam, +alprazolam, +diazepam,
+nordiazepam, +morphine,
+codeine, +clonazepam, +pregabalin,
+buprenorphine
Serum: 4.9
Blood:
Mean: 25
Median: 18
Range: 5–154
Blood:
Range: 3.3–56
Median: 8.0

(182)

NaF/KOx preserved blood: 3.5
Unpreserved blood: 14.1
+methadone, +pregabalin, +etizolam,
+MMB-PINACA metabolites,
+carbamazepine, +THC-COOH
Unpreserved blood: 26.5
+diazepam, +nordiazepam, +methadone,
+EDDP, +pregabalin

(continued)

(184)

(184)

(183)

(182)

(182)

(182)

(182)

(182)

Reference

Drug results (ng/mL unless specified)
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Cardiomegaly and moderate pulmonary congestion/edema. No pill or pill fragments
found in stomach

Pulmonary anthracosis and drug material in
stomach

Mild macrovesicular steatosis in liver, left
ventricular hypertrophy and hepatoduodenal lymph adenopathy

27 y/o F with hx of mental health issues
found with suicide note and other medications on scene. Last known alive 1 week
prior

34 y/o M with hx of illicit drug use found
unresponsive on street, paramedics unable
to revive. Syringe, spoon, tourniquet and
alcohol located near decedent

(186)

(186)

(187)

Blood: 88 (∼1.75 h post incident)
THC 11 ng/mL
Blood: 330 (∼3.5 h post incident)
+methamphetamine, +amphetamine
Cardiac blood: 29 ethanol 0.02,
+methadone, +EDDP, +oxycodone,
+oxymorphone, +norfentanyl,
+mirtazapine
Urine: 2
Vitreous humor: +
Cardiac blood: 45 fentanyl 6, ethanol
0.23, alprazolam 228, +alphahydroxyalprazolam, +chlordiazepoxide,
+nordiazepam, +norfentanyl
Urine: 13
Vitreous humor: +
Peripheral blood: 237 fentanyl 21, ethanol
0.12, alprazolam 282, cocaine 302, +BZE,
+cocaethylene, +diphenhydramine,
+methamphetamine, +nordiazepam,
+norfentanyl
Cardiac blood: 813
Vitreous humor: 2,921
Peripheral blood: 9 ethanol 0.23, 6-AM 11,
morphine 185, +citalopram, +codeine,
+diphenhydramine, +desalkylflurazepam,
+nordiazepam
Cardiac blood: <5

(continued)

(187)

(187)

(187)

(186)

(185)

Blood: diclazepam: 70 flubromazepam: 10
methylamphetamine 290, amphetamine
150, U-47700 330, +lorazepam
Urine: +etizolam
Blood: 40 (∼2 h post incident)
+Amphetamine

Reference

Drug results (ng/mL unless specified)
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29 y/o M with hx of alcohol abuse, hypertension anxiety and gastroesophageal reflux,
found deceased at home, last known alive
3 days prior

51 y/o M found deceased at home after consuming alcohol night prior, hx of alcohol
dependence, chronic opioid use, anxiety,
depression and hypertension

20 y/o F in noninjury 1-car collision after
driving over median. Marijuana roaches in
car
35 y/o M noninjury 1-car MVC
Officer observed: slurred speech, slow
to respond, balance problems, droopy,
bloodshot, glazed and watery eyes
Nose and mouth had dark colored emesis

Observed having trouble maintaining
speed and failing to come to smooth stop
prior to MVC, slurred speech, bloodshot eyes, slow to respond and repeated
questions/comments, failed field sobriety
tests
Officer observations: poor balance, failed
field sobriety tests

38 y/o M driving SUV in MVC

Etizolam

Clinical symptoms/Field Sobriety Testing/
Autopsy findings
N/A

History

Diclazepam/Flubromazepam 28 y/o M with hx of illicit drug use found
deceased at home, believed he was taking
benzos (etizolam)

Drug

Table VIII. NPS Benzodiazepine Case Histories with Clinical Symptoms, Autopsy Findings and Primary Drug and Additional Drug Concentrations
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Flubromazolam

N/A

40 antemortem cases

17 y/o M stopped due to failure to maintain
lane position, driving below speed limit
and almost collided with officer’s vehicle.
Admitted taking Xanax

Officer’s observations: sluggish, slow to
respond to questions, slurred speech, lethargic, balance issues and droopy bloodshot
eyes. Failed sobriety tests

N/A

30 y/o M with hx of cannabis, benzodiazepines and alcohol use, suicide ideations.
Found unresponsive during wellness check,
last known alive 1 day prior. Small bag
with blue substance and scale with white
powdery substance found on scene

49 y/o M found prone in bed

Cardiomegaly, moderate pulmonary
congestion/edema and cerebral swelling

Blood: 17 (∼1.5 h post incident)
THC 6.1

(187)

Peripheral blood: 15 alprazolam 179,
+fentanyl, +7-aminoclonazepam,
+acetaminophen, +alphahydroxyalprazolam, +chlorpheniramine,
+diazepam, +methamphetamine,
+nordiazepam
Cardiac blood: 20
Urine: 20
Peripheral blood: 6 fentanyl 5, cocaine 43,
methamphetamine 246, +alprazolam,
+amphetamine, +BZE, +cocaethylene,
+carboxy-THC, +THC, +norfentanyl
Urine: <5
Cardiac blood: 22 fentanyl 13, +THCCOOH, +gabapentin, +morphine,
+norfentanyl
Urine: 26
Vitreous humor: <5
Peripheral: 187 fentanyl 17, ethanol 0.02,
flubromazolam 619, +alprazolam,
+amphetamine, +delorazepam,
+flualprazolam, +lorazepam,
+methamphetamine, +norfentanyl
Cardiac blood: 214
Urine: 64
Vitreous humor: 33
Blood:
Range: 15–300
Median: 54
Femoral blood: 770
Cardiac blood: 2,820

Pulmonary edema and congestion

61 y/o M found unresponsive during wellness check. Syringe and other prescription
medications found at scene

(187)

Peripheral blood: 25 codeine 17, morphine 219, +6-AM, +alprazolam,
+THC-COOH, +THC-OH, THC,
+diphenhydramine
Urine: 13

Pulmonary edema and congestion and
cerebral edema

(continued)

(186)

(174)

(184)

(187)

(187)

(187)

(187)

Peripheral blood: 10 fentanyl 31, alprazolam 27, methamphetamine 1,212,
+amphetamine, +EDDP, +methadone,
+norfentanyl
Urine: 8

Pulmonary edema and cerebral edema

Cardiomegaly, moderate pulmonary
congestion/edema, and cerebral swelling

Reference

Drug results (ng/mL unless specified)

Clinical symptoms/Field Sobriety Testing/
Autopsy findings

30 y/o M found unresponsive in his room by
housemate. Small bag with white substance,
glass pipe, charred aluminum foil, lighter
and plastic straw found at scene

36 y/o M with hx of benzodiazepine and
heroin abuse found lying in front of building, EMS unable to revive, pronounced dead
at scene. Drug paraphernalia found on individual included white pills, syringe plunger,
tourniquet and a cooker
30 y/o M with hx of heroin abuse found
by girlfriend in hotel room snoring, EMS
unable to revive. Small amount of green vegetable material, lighter, needle, cooker and
bundles of possible illicit substances found
at scene
28 y/o M found deceased in car. Attended
party a day prior and left by friend in car
to ‘sleep it off’. No paraphernalia at scene.
Family reported seeing him with pills of
unknown content

History
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N/A

Blood:
Range: 1.8–850
Median: 22
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(184)

(184)

(184)

(184)

DRE = drug recognition expert, MVC = motor vehicle collision, PBT = preliminary breath test, SCRA = synthetic cannabinoid receptor agonist, SUV = sport utility vehicle, THC-OH = hydroxytetrahydrocannabinol.

138 antemortem cases

Phenazepam

N/A

5 antemortem cases

Blood:
Range: 1.7–53
Median: 4.1

Blood:
Range: 4–36
Median: 5.6
Blood:
Range: 7–700
Median: 37

N/A

N/A

(186)

Blood: 8.2 (∼2.25 h post incident)
BZE 356, THC 1

Officer’s observations: slurred speech, slow to
respond to questions and balance issues

22 antemortem cases

(186)

(186)

(186)

Blood: 31 (∼1.5 h post incident)
THC 4.1

(186)

Blood: 21 (∼2.5 h post incident)
BZE 749, THC 11, +cocaine
Blood: 7 (∼1.75 h post incident)
Clonazepam 17, 7-aminoclonazepam 26,
THC 27, +oxycodone

Officer’s observations: cannabis odor and
individual impaired, failed field sobriety
tests

(186)

Blood: 14 (∼2.75 h post incident)
PBT (22 min post incident) 0.014 g%

Blood: 12 (∼1.5 h post incident)
THC 2.9

(186)

(186)

Blood: 18 (∼1.75 h post incident)
THC 2.2

Blood: 19 (∼1 h post incident)
BZE 348, THC 1.5

Reference

Drug results (ng/mL unless specified)

Officer observations: cannabis odor

Officer’s observations: slow to respond,
repeated questions/comments, balance
issues, slurred speech and bloodshot eyes.
field sobriety tests could not be conducted
due to injury
Officer’s observations: failed to maintain lane
position and speed, improper lane changes,
difficulty with motor control and inconsistent story. Failed field sobriety tests; DRE
evaluation under the influence of cannabis
Officer’s observations: faint odor of alcohol, slurred speech, slow to respond to
questions, failed field sobriety tests
Officer’s observations: slurred speech, slow to
response to questions and balance issues
Officer observations: slurred speech, dexterity
issues and poor balance

Clinical symptoms/Field Sobriety Testing/
Autopsy findings

17 y/o F stopped by officer for failure to
maintain lane position and driving in
opposing lane
19 y/o F in noninjury MVC when she struck a
legally parked vehicle
19 y/o M stopped by officer for failure to
maintain lane position, found with drug
paraphernalia, lit cannabis cigarette and
counterfeit Xanax tablet
22 y/o F driver in 2-car MVC, drove off roadway and overcorrected striking another
vehicle
35 y/o F stopped for failure to maintain lane
position, almost driving into oncoming traffic, admitted smoking cannabis ∼30 min
prior and cannabis in vehicle
21 y/o M in 2-car MVC stated he consumed
two bars of Xanax 3.5 h prior to collision
and 1 g cocaine and acid/LSD
20 antemortem cases

21 y/o M reported to highway patrol for
erratic driving. Individual fell asleep in chair
at hospital while waiting for blood draw

18 y/o M driving sedan involved in MVC

History

Clonazolam

Drug
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Multiple Designer Benzodiazepines—clonazolam,
diclazepam, etizolam, flualprazolam, flubromazepam,
flubromazolam and phenazepam
In 2020, 33,700 cases that occurred in Norway during June
2016–September 2019 were evaluated for the presence of
seven designer benzodiazepines: clonazolam, diclazepam, etizolam, flualprazolam (added to scope in December 2018),
flubromazepam, flubromazolam and phenazepam (184). A
novel benzodiazepine was identified in 575 cases or 1.7%; in
554 of these cases, subjects were living and were apprehended
drivers or those arrested for other drug offenses. The most
common age group was 30–34 years old, with 87% males.
In 25 living subjects, the only impairing substance identified was one of the seven designer benzodiazepines, enabling
comparison of biological sample benzodiazepine drug concentration to clinical tests of impairment (CTI) performed
by physicians around the time of the incident. In 19 of the
25 single-drug cases, the CTI results showed mild, moderate or considerable impairment; no impairment was identified
in the other six cases. Amphetamine, THC, clonazepam and
methamphetamine were the most frequently detected drugs in
conjunction with these novel benzodiazepines.
Diclazepam and flubromazepam
In January 2016, a 28 y/o male from Australia with a history
of illicit drug use was found deceased at home after indicating to a friend that he was taking a ‘benzo’ he believed to be
etizolam (185). Initial drug screening revealed only methamphetamine, amphetamine and trace levels of lorazepam. After
an update to the library of the screening platform and a
retrospective analysis of the data file months later, it was
revealed that the sample also contained U-47700, diclazepam,
flubromazepam and DOC.

There were also nine flubromazolam postmortem cases
from the UK during April–December 2019 (182). All cases
had additional toxicological findings including pregabalin,
heroin, etizolam and SC (4F MDMB-BINACA and MDMB4en-PINACA).
Etizolam
The concomitant intake of etizolam and an opioid in 10
decedents (9 males and 1 female; 27–61 years old) during
2017–2019 was investigated (187). Etizolam was quantified,
where available, in peripheral and central blood, urine, vitreous humor and gastric fluid. The mean and median ages
were 35.6 and 30 years, respectively. In general, the COD in
these cases was listed as drug toxicity, but etizolam was never
explicitly mentioned; in fact, only one case even referenced
benzodiazepines being a contributing factor to death.
A 49 y/o German male was found dead with two plastic bags filled with a large number of white tablets stamped
with XANAX (174). These tablets were identified as etizolam,
which was also identified in the decedent’s stomach contents.
Etizolam and flubromazolam
In Wichita, KS, 12 DUID cases involved use of a designer
benzodiazepine etizolam in three cases and flubromazolam in
nine (186). Apart from one case, etizolam and/or flubromazolam were the only benzodiazepines, routine or novel, detected
in blood samples. The most prevalent additional toxicology
finding was THC. In all cases, arresting officers’ observations
mentioned slurred speech, loss of balance and slow response
to questions.
Clonazolam, delorazepam, diclazepam, flualprazolam and
flubromazolam
In 2019, 33 NY samples collected during 2016–2018 were
reanalyzed for the presence of the following novel benzodiazepines: 3-hydroxyphenazepam, clobazam, clonazolam,
delorazepam, deschloroetizolam, diclazepam, flualprazolam,
flubromazepam, flubromazolam, meclonazepam, nifoxipam
and pyrazolam (195). It should be noted that there is a
metabolic relation between diclazepam, lorazepam and delorazepam; however, it is not always possible to determine the
parent drugs. Five of the aforementioned cases were positive for an additional novel benzodiazepine. The biological
specimen for Case 1 was heart blood and Cases 2–5 were
femoral blood. Case 1 was originally positive for lorazepam
and etizolam, and the subsequent analysis also identified
delorazepam (68 ng/mL), diclazepam (<1 ng/mL) and flubromazolam (40 ng/mL). Case 2 was positive for etizolam, and
reanalysis identified delorazepam at 1.1 ng/mL. Case 3 initially tested positive for diazepam, nordiazepam, etizolam,
lorazepam, oxazepam and temazepam, with delorazepam
later identified at 68 ng/mL. Case 4 was positive for 7aminoclonazepam and etizolam, with 1.1 ng/mL clonazepam
later added. The initial analysis of Case 5 showed alprazolam, alpha-hydroxyalprazolam and lorazepam, but expanded
testing identified 5.3 ng/mL delorazepam and 1.9 ng/mL flualprazolam.

Discussion
Novel benzodiazepines are a growing class of NPS that
requires monitoring in forensic casework, especially DUID
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12 cases. There were 22 (20 males and 2 females) DUID cases
submitted from Pennsylvania, Texas, Oregon, and Mississippi
with a mean age of 27 years (17–51 years old) (181). Only
flualprazolam at 13 ng/mL was identified in the blood of a 24year-old male involved in a motor vehicle crash with a bus. He
was uncoordinated, showed delayed comprehension and reaction times and demonstrated lethargic behavior during field
sobriety testing. The most common substance found in addition to the flualprazolam in DUID cases was THC (n = 8),
followed by ethanol (n = 4).
Flualprazolam was detected in 124 cases in Sacramento
County, CA, during May 2018–August 2019, more than the
traditional benzodiazepine alprazolam (183). Almost all flualprazolam cases were DUID investigations (n = 123). The
flualprazolam concentrations ranged from 5 to 154 ng/mL,
with a mean and median concentration of 18 ng/mL and
25 ng/mL, respectively.
Flualprazolam was reported at a low prevalence rate of
only nine positive cases of 2,911 reported in the UK during April–December 2019 (182). The range of flualprazolam
concentrations in the postmortem cases (n = 8) was 2.8–
35.1 ng/mL in femoral blood. One of the previously mentioned positive cases had an antemortem serum concentration
of 4.9 ng/mL and an antemortem citrate preserved blood
concentration of 8.5 ng/mL. Flualprazolam concentrations in
preserved and unpreserved blood were compared in four cases
with all but one case having comparable concentrations.

e153
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NPS Opioids
Introduction
Novel synthetic opioids (NSO) are agonists at opioid receptors and produce analgesia, euphoria, sedation and respiratory depression. In recent years, NSO have dominated the
NPS market in the USA, leading to numerous hospitalizations,
human performance cases and deaths (198–201). The rise and
proliferation of NSO are an extension of the opioid epidemic,
largely fueled in the USA by the increased use of illicit opioids (e.g., heroin and fentanyl) in response to pharmaceutical
opioids (e.g., oxycodone) prescription (202–204).
The current wave of the US opioid epidemic began around
2013, with illicit fentanyl followed by the appearance of many
fentanyl analogs (e.g., acetylfentanyl, butyrylfentanyl and
2-furanylfentanyl) and other novel opioids (e.g., AH-7921,
MT-45 and U-47700) (205, 206). However, in response
to core-structure scheduling actions enacted in 2018 by the
US DEA to curb the spread of fentanyl analogues, there
has been a shift toward novel and varied chemical subclasses of drugs with opioid activity. At present, NSO are
commonly represented in six primary categories: fentanyl
analogues, cyclohexylbenzamides, 2-benzylbenzimidazoles,
benzimidazolones, cinnamylpiperazines and atypical opioid
agonists (e.g., tianeptine); however, other NSO have emerged
with varying degrees of prevalence including piperidylthiambutene, 2F-viminol and diphenpipenol (207–209). NSO
have dominated the NPS market since the mid- to late2010s, so there are multiple recent scientific reviews
(64, 210–221). Hence, this review includes toxicologically
confirmed case reports and/or those with chemical confirmations paired with reported adverse effects not described in
other reviews (Table IX [222–246]).
NSO can be sold on the internet or the recreational drug
market as powders, tablets or nasal sprays. These dosage
formulations frequently contain multiple drugs (opioids and
other drug classes), including new substances that can appear
and disappear over a few months. NSO are also frequently
found in preparations of other major drug classes, appearing
in counterfeit pharmaceuticals, heroin and fentanyl packaged for street sale (215, 247–252). Further complicating

the illicit opioid market is the presence of residual unreacted
NSO precursor materials from illicit fentanyl manufacturing
(205, 253, 254). Many recreational opioid users are unknowingly exposed to NSO, leading to an increased risk of adverse
events including overdoses and deaths contributing to the
public health crisis (255–258).

Pharmacology
Biomedical literature and pharmaceutical patents that result
from research and transform into potential therapeutic analgesics have proven to be a source for pirating and repurposing
research chemicals, especially opioids. The NSO subclass
includes fentanyl analogs and chemically distinct nonfentanyl
drugs, based on diverse drug scaffolds. These drugs may
often retain µ-opioid receptor (MOR) agonism, conferring
similar opioid effects. MOR activation results in a typical
constellation of effects including sedation, analgesia, miosis,
cough suppression, altered mental status, euphoria, decreased
gastrointestinal motility and respiratory depression; the latter is the most significant concern for lethality in overdoses
(259). Naloxone, a competitive MOR antagonist, successfully reverses overdose-related respiratory depressant effects
for many NSO, but this has not been studied universally
or systematically (260). Enhanced potency and/or prolonged
duration of action may require multiple and/or higher naloxone doses and respiratory support over a sustained period to
effect opioid symptom reversal (261).
Pharmacological studies can assist in determining an NSO’s
potency, the potential public health threat it presents and the
need for control and/or scheduling. In vitro studies can quantify the potency and efficacy of NSO in cells expressing opioid
receptors, but in vivo studies are needed to investigate the
analgesic and reinforcing effects of NSO in animal models
(262). Potency and efficacy in animal models however do not
necessarily reflect true potency or toxicity in humans. Caution must be used in estimating abuse potential or lethality in
humans based on experimental values alone. More accurate
estimates may be obtained by examining NSO concentrations in drug fatalities, especially when NSO are the only
drugs present. However, practitioners should exercise caution when interpreting drug concentrations alone due to the
unknowns surrounding tolerance. NSO analgesic potencies
compared to fentanyl and heroin can vary widely, but in vitro
binding affinity does not necessarily predict in vivo potency
(259). Two of the most potent and dangerous fentanyl analogues, carfentanil and cis-3-methylfentanyl, have estimated
relative analgesic potencies 10,000 and 6,000 times higher
than morphine, respectively (31, 64). However, this does not
mean that these two analogues are toxic by the same factors.
For prior NSO, 2-furanylfentanyl has a higher affinity than
fentanyl at the MOR, and acrylfentanyl, isobutyrylfentanyl
and cyclopropylfentanyl have similar affinities (79). Structural similarity to a known opioid does not necessarily mean
the NSO has sufficient pharmacological activity. For example, two supposed NSO, W-18 and benzylfentanyl, reached
the illicit market in 2018, but they lacked significant pharmacological activity and did not gain any traction in the USA
(263, 264).
Identifying the expanding number of NSO is challenging for many reasons including variability in location, dates
of appearance, national and international proliferation and
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cases. Due to the mechanism of action of benzodiazepines,
CNS depressant effects can be severe even when ingested
alone, but coma and death occur rarely. Of all flualprazolam cases, only two listed toxicity associated with the drug
with the manners of death being ‘unclear’ and accident (180).
The greatest concern is when individuals co-ingest these drugs
with other CNS depressants, causing synergistic effects that
lead to unconsciousness, coma or death. In many of the cases
discussed, a novel benzodiazepine was not the only impairing
substance detected; individuals may have taken novel benzodiazepines to combat the effects of opioid withdrawal or the
after effects of stimulant use or to increase the effects of other
illicit substances (178, 196). Prescription and novel benzodiazepines do not generally result in death when taken alone and
may not be emergency scheduled, but WHO recommended
in December 2019 that flualprazolam and etizolam be classified as Schedule IV (197). The NPS market may be slowing,
but the diversity of novel benzodiazepines in recent years is
increasing, and novel benzodiazepines should be monitored
in forensic toxicology analyses.

Mohr et al.

(223)

Blood: (±)-cis-3-MF 0.18, (±)-trans-3MF <0.10; ethanol 30 mg/dL, BZE 1100,
+naloxone, THC 1.8

Pulmonary and cerebral edema

(continued)

(223)

(223)

(223)

Blood: (±)-cis-3-MF 0.84, (±)-trans-3-MF
0.37
Oxycodone 62, oxymorphone (free) 1.1, 7AMC 120, +naloxone

N/A

33 y/o M with hx of seizures, bipolar disorder and heroin abuse found dead with four
stamp bags in pants
22 y/o M found in girlfriend’s apartment
hallway, transported by EMS to hospital,
pronounced dead. Subject recently released
from prison for driving without license and
drug possession. Girlfriend stated he took
two clonazepam and one oxycodone that
night
22 y/o M unresponsive after insufflating what
he believed was cocaine. Unmarked blue
plastic baggies found by decedent’s feet
consistent with heroin
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Pulmonary and cerebral edema and urine
retention. Injection sites observed

Pulmonary and cerebral edema

50 y/o M with remote hx of drug and alcohol
abuse gurgling in sleep, stopped breathing.
EMS unable to revive

(223)

(223)

(223)

Blood: (±)-cis-3-MF 1.2, (±)-trans-3-MF 0.7
Morphine (free) 8.3, fentanyl 1.8, norfentanyl
0.2
Vitreous: 6-AM (free) 1.0
Blood: (±)-cis-3-MF 0.78, (±)-trans-3-MF
0.39
Fentanyl 0.54, norfentanyl 0.63, oxymorphone (free) 1.7, diazepam 850, nordiazepam 800, oxazepam 23, temazepam
27, alprazolam 55
Blood: (±)-cis-3-MF 0.34, (±)-trans-3MF 0.23 ethanol 188 mg/dL, +naloxone,
diazepam 22, nordiazepam 69, chlordiazepoxide 110, morphine (free) 12, THC
0.7
Urine: +6-AM
Blood: (±)-cis-3-MF 1.34, (±)-trans-3-MF
0.69
Oxycodone (free) 6.2, BZE 56, 7-AMC 22,
lamotrigine 4.6, quetiapine 710
Urine: +6-AM
Blood: (±)-cis-3-MF 1.6, (±)-trans-3-MF
0.71

Severe pulmonary and cerebral edema and
urine retention. No injection sites observed

N/A

(222)

Reference

Antemortem blood: 1.1

Drug results (ng/mL unless specified)

N/A

Autopsy findings included pulmonary edema

80 y/o M died at hospital after 3methylfentanyl OD
30 y/o M found supine in bed with drug paraphernalia (blue wax baggies and capped
syringe) nearby. Last known alive ∼24 h
prior
54 y/o M with hx of depression, anxiety and
alcohol abuse

3-Methylfentanyl

Clinical symptoms/Autopsy findings

36 y/o M found dead in residence with needle
in arm

History

Drug
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Pulmonary and cerebral edema

Pulmonary edema, moderate cerebral edema
and urine retention

(continued)

(223)

(223)

(223)

(223)

Blood: (±)-cis-3-MF 0.71, (±)-trans-3-MF
0.38
Morphine (free) 14, fentanyl 1.5, norfentanyl
0.27
Urine: +6-AM
Blood: (±)-cis-3-MF 0.74, (±)-trans-3-MF
0.69
p-FIBF 1.4, 4-ANPP 0.53, alprazolam 14,
morphine (free) 14, quetiapine 370, zolpidem 17, THC 5, fentanyl 1.2, norfentanyl
0.2
Urine: +6-AM
Blood: (±)-cis-3-MF 1.4, (±)-trans-3-MF
0.77; alprazolam 16, morphine (free) 25,
dextro/levomethorphan 38, fentanyl 0.7
Urine: +6-AM
Blood: (±)-cis-3-MF 0.38, (±)-trans-3-MF
0.19

Pulmonary edema and IV injection site in
antecubital fossa

Pulmonary edema, moderate cerebral edema
and IV injection sites observed

(223)

Blood: (±)-cis-3-MF 0.35, (±)-trans-3-MF
0.19

Pulmonary edema

(223)

(223)

Blood: (±)-cis-3-MF 3.28, (±)-trans-3-MF
1.9
Cocaine 140, BZE 420, amitriptyline 420,
nortriptyline 890, clonazepam 8.1, 7-AMC
180, +naloxone, ethanol 13 mg/dL
Blood: (±)-cis-3-MF 0.33, (±)-trans-3-MF
0.25 Citalopram/escitalopram 370

Mild pulmonary edema

Visceral congestion and mild pulmonary
edema

(223)

Blood: (±)-cis-3-MF 0.51, (±)-trans-3-MF
0.26 6-AM 33, morphine (free) 40, cocaine
100, cocaethylene 32, BZE 1600, oxycodone (free) 81, oxymorphone (free) 1.2,
quetiapine 230

Pulmonary and cerebral edema

46 y/o M with hx of heroin abuse, recently
released from prison, found unresponsive
in brother’s basement. EMS administered
three doses of epinephrine, naloxone and
intubated decedent. Two empty bags heroin
found at scene
55 y/o M with MVC, hx of chronic pain led
to heroin and prescription opioids use.
Found unresponsive at another residence.
EMS administered 0.4 mg naloxone and
started OD protocol. Unable to revive
26 y/o F with hx of opioid abuse and rehab.
Witnessed insufflating white substance
she believed was fentanyl. Boyfriend
administered naloxone and second dose
administered by police
31 y/o M with hx of opioid addiction found
unresponsive in bedroom with vomit around
nose and mouth. Decedent insufflated drugs.
3 orange glassine baggies and straw found
on desk
32 y/o M with hx of heroin abuse and outpatient rehab found unresponsive in kitchen
with syringe in hand and three blue wax
baggies and one clear baggie in shorts.
Decedent’s spouse stated he relapsed
32 y/o F with hx of heroin abuse currently
in rehab found unresponsive after recently
released from jail. Decedent found with
zolpidem, quetiapine and lansoprazole, with
syringe in package and plastic straw. Clear
plastic bag with white powder found in bra
at autopsy
28 y/o M with hx of heroin abuse and rehab
found dead in bathroom. Blue wax paper
substance found on toilet seat and half
straw near decedent
36 y/o M with hx of asthma, heroin abuse
and suicidal tendencies, recently released
from prison, found unresponsive

Reference

Drug results (ng/mL unless specified)

Clinical symptoms/Autopsy findings

History
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Carfentanil

48 y/o F with hx of depression and drug use,
found unconscious at home after use of
fentanyl purchased over internet. Empty
boxes pregabalin and buprenorphine on
scene. EMS medical care included sufentanil
delivery. Admitted to hospital comatose

41 y/o M insufflated white powder purported
to be cocaine at private party. Comatose
within minutes

33 y/o M with hx of ethanol, cannabis and
cocaine use found bradypneic by EMS following insufflating white powder, admitted
to hospital

Patient miotic and naloxone administered
without success. Hospitalized, intubated,
ventilated and treated with lidocaine, etomidate and propofol. Recovery completed
after 8 days in ICU and 12 days in internal
medicine ward

RR 9 breaths/min, EMS 2 mg IV naloxone, assisted ventilation. At ED, another
2 mg IV naloxone without improvement.
Subject comatose with pupillary miosis
fixed at 2 mm, diaphoretic and warm. HR
113 bpm, BP 165/84 mmHg. Awoke 31 h
post admission and discharged 3 days after
admission
Patient presented with myosis and bradypnea and subsequently hospitalized in ICU.
Patient recovered and returned home after
few days

N/A

29 y/o M DUID

(225)

Plasma: <0.01
Norcarfentanil <0.05
Urine (+1 h): 2.88
Norcarfentanil 8.8, cocaine 570, BZE 1,230,
EME 367
Plasma: 32.4
Norcarfentanil 15.8, <0.04 fentanyl,
sufentanil <0.05, buprenorphine 0.48,
norbuprenorphine <0.5
Urine: 1,430
Norcarfentanil 1,820, fentanyl 1.7,
sufentanil <0.05, buprenorphine 6.0,
norbuprenorphine 19.4

(continued)

(225)

(224)

Venous blood: 22.4 (at admission), 1.0
(25.5 h post admission), 0.52 (31 h post
admission; interpolated)
Ethanol 99 mg/dL, norcarfentanil 3.95 (at
admission), 0.93 (25.5 h post admission)
Urine:
+THC-COOH, +cocaine

(223)

(223)

(223)

Blood: (±)-cis-3-MF 0.35, (±)-trans-3-MF
0.19
Clonazepam 7.7, 7-AMC 100, cocaine 160,
BZE 1,100, morphine (free) 20, lamotrigine
0.21, dextro/levomethorphan 44
Blood: (±)-cis-3-MF 0.21, (±)-trans-3-MF
0.13
+Caffeine
Blood: (±)-cis-3-MF 0.79, (±)-trans-3-MF
0.19
Clonazepam 48, 7-AMC 64, cocaine 60, BZE
1700, fentanyl 1.0, norfentanyl 0.53

Pulmonary edema. Injection sites observed on
antecubital fossa, right hand and& neck

N/A

(223)

Blood: (±)-cis-3-MF 0.79, (±)-trans-3-MF
0.54
Alprazolam 6.5, morphine (free) 10, fentanyl
0.79, THC 1.0

Pulmonary edema, moderate cerebral edema
and IV injection sites observed

22 y/o M with hx of heroin abuse and rehab
found unresponsive in bedroom. Unmarked
baggie and syringe and empty blue paper
wrapper from jean pocket found on scene.
Decedent revived with naloxone twice
previously
30 y/o F with hx of drug abuse recently
released from prison on drug charges, found
unresponsive in room littered with syringes
and empty blue and clear baggies. One
baggie imprinted with word ‘OWL’
Unknown gender and age DUID

Reference

Drug results (ng/mL unless specified)

Clinical symptoms/Autopsy findings

History
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23 y/o M with hx of heroin use, found
deceased slumped in bathroom with syringe
in hand. Syringe analysis indicated heroin,
fentanyl and methamphetamine
43 y/o M with hx of opiate dependence from
chronic pain, found deceased with syringe in
antecubital fossa. Family denied hx of drug
abuse; syringes reportedly for testosterone

34 y/o F with hx of drug use, including
heroin, found deceased in shed with syringes
nearby

43 y/o F with hx of recent drug OD, found
deceased with tourniquet on arm, drug
paraphernalia and white powder present

Acute and chronic needle punctures; pulmonary edema with microscopy consistent
with IV drug use; cardiomegaly and left
ventricular hypertrophy. COD mixed
carfentanil and mitragynine toxicity

Pulmonary edema, urinary retention, acute
needle puncture marks, no significant natural disease. COD ruled carfentanil and
ethanol toxicity
Pulmonary edema and airway foam, urinary
retention. No significant natural disease.
COD ruled acute carfentanil and ethanol
toxicity
Foam in airway, no significant natural
disease. COD ruled carfentanil, methamphetamine, alprazolam and diazepam
toxicity
Pulmonary edema, obesity, focally severe
atherosclerosis of left circumflex artery.
COD carfentanil, methamphetamine,
alprazolam and opiate
Drug bindle in axilla, track marks, pulmonary edema with foam, no significant
natural disease. COD mixed drug toxicity
(carfentanil, opiate and methamphetamine)
Pulmonary edema, acute needle puncture
mark. COD ruled acute carfentanil toxicity

EMS found in respiratory depression (2
breaths/min), GCS 3. EMS administered
three doses 0.4 mg naloxone. At ED subject
lost consciousness again, given two more
0.4 mg naloxone and admitted to ICU with
naloxone infusion
Patient hypotensive (71/58 mmHg), tachycardic (128 bpm), hypopneic and cyanotic
(pO2 saturation 70%). Temp normal and
normal pupils responded to light

41 y/o M with hx of opioids and benzodiazepines use found unconscious by family.
When conscious, subject stated he took
0.025 mg (nasally) and 0.025 mg (IV)
carfentanil with 0.5 g heroin 5 h prior

16 y/o M found unconscious after taking
unknown substance. Intubated, airlifted
to hospital, regained consciousness after
IV naloxone and flumazenil. White powder discovered in patient’s belongings was
carfentanil. Patient was also prescribed
atomoxetine
31 y/o M with hx of heroin use. Last seen
asking for money to buy drugs. Found
deceased with drug paraphernalia, white
powder and rock-like substance
33 y/o F with hx of heroin use, last seen
highly intoxicated while mixing heroin and
fentanyl. Found deceased on mattress on her
floor with drug paraphernalia nearby
26 y/o F with hx of drug use found unresponsive after reportedly insufflating heroin.
Drug paraphernalia on scene

Clinical symptoms/Autopsy findings

History

(continued)

(228)

(228)

Blood: 0.44
Morphine 60, methamphetamine 180, BZE
150, clonazepam 2.7, 7-AMC 160

Blood: 0.26
Alprazolam 27, mitragynine 160, citalopram
400

(228)

Blood: 0.27
Morphine 30, methamphetamine 20,
alprazolam 15

(228)

(228)

Blood: 0.12
Methamphetamine 90, alprazolam 14,
diazepam 57, nordiazepam 100

Blood: 0.14
Urine: 6-AM 6

(228)

(228)

Blood: 0.64
Ethanol 177 mg/dL, quinine 430

Blood: 0.13
Ethanol 226 mg/dL

(227)

(226)

Urine: 457
+Norcarfentanil, +morphine-3-glucuronide,
+codeine-6-glucuronide, +buprenorphine,
+methadone, +benzodiazepines, +ethyl
glucuronide, +ethyl sulfate
Serum (1 h after use): 0.6
Norcarfentanil 0.2
Urine: 1.3
Norcarfentanil 0.5

Reference

Drug results (ng/mL unless specified)
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Cyclopropylfentanyl

COD mixed drug intoxication

Coma, miosis, RR 14/min. BP 127/70 mmHg
and HR 65 bpm. Given 0.8 mg naloxone and breathing stabilized. Patient had
decreased pO2 for 12 h, discharged after
1 day

27 y/o M with hx of recreational drug use
found deceased at home with 18 rectangular
white pills marked ‘XANAX’ but identified
as cyclopropylfentanyl

25 y/o M developed nausea, profuse sweating
and dyspnea 10 min after using a ‘fentanyl
research chemical’ nasal spray from a local
drug trafficker. He also used cannabis the
same day. Symptoms progressed to coma,
respiratory depression and admitted to
hospital
25 y/o M with hx of oxycodone drug abuse
after sports injury 5 years prior, found
unresponsive in bed at home

Dry white foam purge on decedent’s mouth.
COD alcohol, cocaine, oxycodone and
cyclopropylfentanyl

Autopsy findings included weak brain edema
and blood congested lungs. Frothy fluid
found in larynx and respiratory tract

Pulmonary edema with mucus plugging.
COD carfentanil and trazodone toxicity

39 y/o M with hx of chronic pain treated
with insufflated ground oxycodone. Discovered on couch in crouched position with
small plastic bag with an unknown white
powder

63 y/o M with hx of heroin use, reportedly
insufflating heroin with someone else and
both found unresponsive. Other person
revived with naloxone

Pulmonary edema, anoxic brain injury. COD
anoxic brain injury after resuscitated cardiopulmonary arrest due to carfentanil and
cocaine toxicity
Acute needle puncture, no significant natural
disease. COD acute carfentanil toxicity

39 y/o M with hx of heroin dependence on
methadone, found in alley and initially
responded to naloxone. Pronounced dead
at hospital
23 y/o M with hx of heroin use, reportedly insufflated cocaine, found slumped in
bathroom with spoon and a syringe in pants
32 y/o M with hx of heroin dependence,
found dead prone with drug paraphernalia
present
Pulmonary edema, no significant natural disease. COD mixed carfentanil, fentanyl and
methamphetamine toxicity

Clinical symptoms/Autopsy findings

History

Heart blood: 14
Oxycodone (free) 60, oxymorphone (free) 30,
BZE 100 ng/mL, cocaethylene 70, ethanol
26 mg/dL

Heart blood (at autopsy): 52.4
Femoral blood (collected 11 h post death):
15.7
Femoral blood (collected 29 h post death at
autopsy): 19.8
Ethanol 127 mg/dL, codeine 480, diphenhydramine 1000, morphine 14, oxycodone 6,
zolmitriptan 4.5
Blood: 29
Pregabalin 10 mcg/mL, morphine 49,
amphetamine 365, MDMA 460, MDA 48,
BZE 5.2, 7-AMC 250, buprenorphine 0.89,
norbuprenorphine 6.2, THC 4.7
Urine: 610
Urine: 7
Cyclopropylnorfentanyl 220, THC-COOH
9.2, BZE 23, EME 9.2

(228)

Blood: 0.12
Methamphetamine 410, amphetamine 80,
7-AMC 13
Liver: fentanyl 7.4 mcg/kg
Urine: 6-AM 7
Serum: 0.10
BZE 30, trazodone 0.21 mcg/mL

(continued)

(232)

(231)

(230)

(229)

(228)

(228)

(228)

Reference

Blood: 0.16

Blood: 0.19
Cocaine 30, BZE 580

Drug results (ng/mL unless specified)
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Furanylfentanyl

30 y/o M with hx of drug and alcohol
addiction found in father’s kitchen in cardiorespiratory arrest. Unable to revive.
Recently released from jail and oxycodone
dependent. Decedent had prescription
for pregabalin, methylphenidate and
clonazepam

46 y/o F with hx of alcoholism, found dead in
unsanitary apartment. Decomposition noted

(236)

(237)

Serum: 3.6
Urine: 17.6

Cardiac blood: 14
U-47700 54, 4-ANPP 33, methadone
154, EDDP 27, methamphetamine 664,
amphetamine 103, cocaine 12, BZE 840
Femoral blood: 0.89
U-47700 26, 4-ANPP 18, clonazepam 94,
methylphenidate 15, pregabalin 5,571,
THC 18, THC-COOH 32, THC-OH 3.3,
naproxen 2,118, nortriptyline 14, diazepam
11
Cardiac blood: 2.4
U-47700 45

In ED, lethargic, minimally responsive,
cyanotic and coughing, acute respiratory distress and aspiration. Hypertensive
149/112 mmHg, tachycardic 143 bpm and
hypoxic 80% pulse oximeter. Pupils 2 mm
and reactive to light. Normal muscle tone,
but acute lung injury due to aspiration.
Extubated after 30 h and symptoms resolved
No traumatic or preexisting lesions
considered as COD

(continued)

(237)

(235)

Blood: 1.6
MMMP 6.7, THC 10, THC-COOH 23, mirtazapine 200, paliperidone 30 quetiapine
200

Coarse white froth in distal trachea and
main bronchi and pulmonary edema and
congestion

Coronary artery presented moderate to severe
atherosclerosis

(234)

(233)

Blood: 20.4
+Heroin, +cocaine, +amphetamine (other
stimulants), +therapeutic drugs
Femoral blood: 2.7
Cardiac blood: 11.8
Urine: 71.3
Bile: 7.7
Cerebrospinal fluid: 2.6
Gastric content: 40.1 ng/g

Reference

Drug results (ng/mL unless specified)

Multivisceral congestion, pulmonary and
cerebral edema, with no evidence of disease
or physical injury. Petechia on lower limb
surface. Recent needle punctures on back of
hands and track marks on forearms

Lung congestion with fluid and dark blood.
Suspected COD polydrug intoxication

24 y/o M found dead at home

53 y/o M with hx of heroin and other
drugs use and depression found unresponsive at home, sitting on chair with
head and chest collapsed on desk and butterfly needle inserted into left-hand vein.
EMS noted rigor mortis and decedent was
declared dead. White powder on scene was
furanylfentanyl
44 y/o M with hx of IV drug use found
unresponsive at home. Attempted revival
unsuccessful. Drug paraphernalia on scene,
plastic bag containing white powder and
two small plastic tubes containing colored
liquid. White powder was furanylfentanyl
and other crystalline powders contained
MMMP. Two liquids for vaping contained
glycerin, nicotine and furanylfentanyl
19 y/o F insufflated a fentanyl powder called
‘China White’ and developed apnea. Found
unresponsive, normotensive and bradypneic. Treated with supplemental oxygen
and 3 mg IV naloxone, some mental status improvement. Powder identified as
furanylfentanyl

Clinical symptoms/Autopsy findings

History
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History

22 y/o touched tongue to powdered ‘fentanyl’
to treat migraine headache, unresponsive
and apneic. EMS gave 2 mg IM naloxone
on arrival. Powder chemically verified as
beta-hydroxyfentanyl

35 y/o M found dead in bathroom. Glass pipe
with brown color contamination found at
scene
29 y/o M with hx of drug use and rehab
found dead with syringe in hand and empty
bottles of steroids nearby. Decomposition
noted

41 y/o M with hx of cocaine and heroin use
collapsed in hotel room bathroom. Decedent
vomited all day and injected four bags of
heroin. Stamp bags labeled ‘Stranger Danger’ with blue skull wearing hat and needle
recovered at scene
46 y/o F found in supine position on bedroom
floor with livor mortis. 13 stamped bags of
‘Stranger Danger’ with blue skull wearing
hat recovered at scene
58 y/o M with hx of IV heroin for past 5 days
collapsed in front of mother. EMS transferred decedent to hospital, resuscitation
efforts were unsuccessful
39 y/o F with hx of drug abuse recently
released from prison for drug charge. Text
messages about illicit substances to ‘celebrate’. Drug paraphernalia found on scene
included clean baggies with brown-white
powder, spoon and loaded syringe

beta-Hydroxyfentanyl

p-FIBF

U-48800

No traumatic or preexisting lesions noted
during autopsy

COD circulatory failure associated with NPS

At ED, patient conscious, alert with
tachycardia (141 bpm), hypertension
(149/95 mmHg) and pO2 saturation 100%.
Observed for 4 h

Clinical symptoms/Autopsy findings

(238)

Blood: 74
Despropionyl p-fluorofentanyl 6.5, alphaPiHP 5.6, THC-COOH 16
Femoral blood: 27
Methoxyacetylfentanyl 14, cyclopropylfentanyl 0.10, 4-ANPP 9.7, alprazolam 12,
quetiapine 58, gabapentin 15, +duloxetine,
+U-47700, +acetylfentanyl, +despropionyl
fluorofentanyl
Cardiac blood: 31
Methoxyacetylfentanyl 70, cyclopropylfentanyl 0.15, 4-ANPP 3.1, +U-47700,
+acetylfentanyl, +despropionyl fluorofentanyl, +N-methyl U-47931E

(239)

Peripheral blood: 5.3
4-ANPP 7, p-FIBF 0.13, cocaine 530, BZE
960, morphine 12, fentanyl 58, norfentanyl
8.3, acetylfentanyl 0.93
Peripheral blood: 2.8
Ethanol 203 mg/dL, 7-AMC 9, codeine
14, morphine 210, 6-AM 12, THC 0.62,
+naloxone, +caffeine
Peripheral blood: 6.2
4-ANPP 0.66, cocaine 140, BZE 3,300, morphine (free) 24, hydroxyzine 24, fentanyl
9.7, norfentanyl 1.7, acetylfentanyl 0.64,
+caffeine, +cotinine, +levamisole

(continued)

(239)

(239)

(239)

Peripheral blood: 0.27
4-ANPP 0.4, cocaine 95, BZE 120, fentanyl
7.2, norfentanyl 11.3

(237)

(236)

Reference

Serum: 6.5
+Alprazolam

Drug results (ng/mL unless specified)

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

Drug

Table IX. NPS Opioids Case Histories with Clinical Symptoms, Autopsy Findings and Primary Drug and Additional Drug Concentrations

NPS Adverse Effects
e161

Isotonitazene

Needle marks in antecubital fosse. Hypertensive cardiovascular disease

42 y/o M with hx of drug abuse last seen
alive with withdrawal symptoms, including
seizures and vomiting
45 y/o M suspected OD

N/A

Multiple track marks noted on body

Heart weighed 483 g with signs of stenosis.
Right lung 832 g, left lung 667 g. Pulmonary
edema, hypertensive, cardiovascular disease

N/A

27 y/o M with hx of heroin use found
unresponsive at home with needles and
substance believed to be heroin

66 y/o M with hx of heroin use, hypertension and seizures found deceased in bed by
family

41 y/o F with hx of heroin use found unresponsive. 1.5 days prior visited ED at
hospital for suspected drug OD and 5 days
prior released from drug rehabilitation
program. White powder found in pocket

N/A

36 y/o F unknown circumstances

27 y/o F with hx of heroin use found
deceased in car with head in a bucket of
water

N/A

33 y/o F with hx of heroin abuse, suspected
OD

N/A

Clinical symptoms/Autopsy findings

History

Blood: 1.0
Fentanyl 5.7, norfentanyl 2.4, 4-ANPP 1.4,
etizolam 6.2, diazepam 120, nordiazepam
210, oxazepam 22, THC 1.3, THC-COOH
64, +caffeine, +cotinine, +naloxone,
+diphenhydramine, +quinine
Cardiac blood: 1.9
Etizolam 15, +caffeine, +acetaminophen,
+diphenhydramine
Vitreous: 0.1
Urine: 2.6
Peripheral blood: 1.5
Fentanyl 2.9, norfentanyl 1.0, etizolam 13,
levetiracetam 14 µg/mL, diphenhydramine
200, +cotinine, +quinine
Urine: +morphine
Subclavian blood: 0.9
Fentanyl 5.8, norfentanyl 0.61, acetylfentanyl 0.69, 4-ANPP 1.6, morphine (free)
12, cocaine 89, BZE 800, +naloxone,
+tramadol, +O-desmethyltramadol,
+acetaminophen, +cotinine, +caffeine,
+levamisole, +quinine
Urine: 3.5
+Xylazine

(239)

Peripheral blood: 1.9
Amphetamine 33, methamphetamine 61,
+naloxone
Femoral blood: 0.8
Cyclopropylfentanyl 2.5, ethanol 144 mg/dL,
+cotinine
Iliac blood: 1.0
Cocaine 69, BZE 530, morphine 14, THC
7.3, dextromethorphan 26, fentanyl 7.5,
norfentanyl 2.1, acetylfentanyl 0.18,
4-ANPP 0.13,
U-47700 1.8, morphine 10, 6-AM 1.1,
+caffeine, +levamisole, +naloxone
Cardiac blood: 1.8
Methoxyacetylfentanyl 32, +4-ANPP,
+caffeine

(continued)

(9)

(9)

(9)

(9)

(239)

(239)

(239)

Reference

Drug results (ng/mL unless specified)
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Clinical symptoms/Autopsy findings
Pulmonary and cerebral edema, moderate
atherosclerosis of left descending artery

Linear puncture marks on right and left
thighs. Pulmonary edema; right lung
weighed 976 g and left 992 g. Kidneys
red-brown and slightly granular

Mild cardiomegaly (470 g) with focal
histologic changes from hypertension.
Pulmonary edema: right lung 930 g and
left 800 g. Vascular congestion and kidney
glomerulosclerosis and arteriolosclerosis
Red purge extruding from oral and nasal
cavities. No foam cone noted. Distended
bladder and organs congested
Blood organ congestion, gastric material in
upper and lower respiratory tract, heavy
lungs (lung weights 840 and 640 g)

Blood organ congestion, gastric material in
upper and lower respiratory tract, heavy
lungs 1,260 and 900 g

History

53 y/o M found unresponsive on back on
floor of friend’s apartment. Showed friend
white powdery substance night before

27 y/o M found lifeless in cemetery

56 y/o F with hx of opiate use disorder, pain
symptoms and previous suicide attempt
by drug OD, found deceased slumped over
toilet. Known suboxone user

41 y/o M with hx of heroin use and prior
OD found deceased by hotel staff. White
powdery substance found on scene
Hx of depression and drug abuse, including
fentanyl. White powder at scene chemically
verified as isotonitazene

M with hx of isotonitazene use, including
hospitalization for isotonitazene detoxication 2 months prior to death. White powder
and pipe discovered at scene. Night of death
decedent took lorazepam too

Femoral blood: 2.28
Diazepam 29, nordiazepam 71, oxazepam
4.8, mefenamic acid <5.0 µg/mL, domperidone 6.0, acetaminophen 4.8 µg/mL
Cardiac blood: 1.70
Urine: 1.88
Vitreous humor: 0.36
Liver: <0.05 ng/g
Heart: 7.74 ng/g
Brain: 18.6 ng/g
Femoral blood: 0.59
Lorazepam 12, THC 56, THC-OH 1.8,
THC-COOH 6.5, CBN 2.9
Cardiac blood: 1.13
Urine: 3.37
Vitreous humor: 0.12
Liver: <0.05 ng/g
Heart: 2.17 ng/g
Brain: 2.72 ng/g

(9)

Peripheral blood: 2.7
+4-ANPP, BZE 370, U-47700
0.34, +phenacetin, +levamisole,
+diphenhydramine
Urine: 4.0
Peripheral blood: 1.8
Etizolam 30, THC-COOH 7.7, THC
1.2, diphenhydramine 190, +caffeine,
+cotinine, +quinine +piperidylthiambutene
Urine: 2.8
+piperidylthiambutene
Iliac blood: 0.4
Flualprazolam 4.0, +naloxone,
+hydroxyzine, +etizolam, +cotinine,
+caffeine, +O-desmethylvenlafaxine,
venlafaxine, norfluoxetine, +fluoxetine,
+quetiapine
Subclavian blood: 1.7
Flualprazolam 6.4, +caffeine, +cotinine

(continued)

(240)

(240)

(9)

(9)

(9)

Reference

Drug results (ng/mL unless specified)
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Brorphine

N/A

N/A

N/A

45 y/o M suspected drug OD

57 y/o F suspected drug OD with drug
paraphernalia at scene

42 y/o M suspected drug OD

(continued)

(10)

(10)

(10)

(10)

(10)

Femoral blood: 10
Flualprazolam 50, +4-ANPP, +caffeine,
+cotinine, +quinine, codeine 6.6, morphine
66, 6-AM 1.5, citalopram/escitalopram 76,
fentanyl 3.4, norfentanyl, +isotonitazene
Urine: 23
Femoral blood: 0.9
+4-ANPP, +caffeine, methadone 160, EDDP
45, morphine 42, bupropion 18, hydroxybupropion 380, duloxetine 520, lamotrigine
6.8 µg/mL, gabapentin 15 µg/mL, fentanyl
14, norfentanyl 11, +flualprazolam
Urine: 0.4
Femoral blood: 1.0
Flualprazolam 2.5, +4-ANPP, +caffeine,
+cotinine, tramadol 33, THC 0.62, fentanyl
5.0
Urine: 1.9
Peripheral blood: +
+4-ANPP, +caffeine, +cotinine, +naloxone,
cocaine 110, BZE 1,300, THC 0.88, diphenhydramine 61, fentanyl 31, norfentanyl 5.5,
acetyl fentanyl 0.13
Peripheral blood: 1.1
+4-ANPP, +caffeine, +cotinine, +naloxone,
diphenhydramine 620, fentanyl 36, norfentanyl 1.4, morphine 110, 6-AM 7.3,
+flualprazolam
Urine: 3.3

N/A

N/A

(241)

Serum: 69.4
+sertraline, +mirtazapine, +risperidone
Serum (+60 h): 7.9
+trazodone, +nordiazepam

Normal BP with tachycardia 114 bpm, O2
saturation 98% and Temp 37.3◦ C. Clammy
and sweaty. Treatment with trazodone and
nordiazepam

60 y/o M with unknown hx

24 y/o M with hx of opioid use, withdrawal
symptoms in ED. Generalized pain in chest,
abdomen and muscles, weakness, cramping,
confusion and bradyphrenia. 1–2 months
prior, started brorphine orally 4×/day and
etizolam and prescribed sertraline and
mirtazapine
53 y/o M with hx of opioid use, suspected
drug OD. ‘Heroin’ recovered at scene

Reference
(240)

Blood organ congestion, gastric material in
upper and lower respiratory tract, heavy
lungs 610 and 580 g

Hx of depression

Drug results (ng/mL unless specified)
Femoral blood: 0.74
Ethanol 57 mg/dL
Cardiac blood: 0.70
Urine: 0.19
Vitreous humor: 0.65
Liver: <0.05 ng/g
Brain: 4.45 ng/g

Clinical symptoms/Autopsy findings

History
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Clinical symptoms/Autopsy findings
N/A

N/A

N/A

N/A

Puncture marks

N/A

N/A

History

60 y/o M suspected drug OD

47 y/o M experienced sudden suspected drug
OD death. Counterfeit pills identified as
brorphine

39 y/o M suspected drug OD

37 y/o F suspected drug OD

48 y/o M suspected drug OD

47 y/o F suspected heroin OD

30 y/o F suspected drug OD. Died at hospital

(10)

Peripheral blood: 8.1
+Cotinine, sertraline 26, desmethylsertraline 110, verapamil 42, diphenhydramine
960, fentanyl 3.1, morphine 79, 6-AM 2.5,
+flualprazolam
Urine: 21
Femoral blood: 2.5
+4-ANPP, +naloxone, oxycodone 22, sildenafil 35, n-desmethylsildenafil 10, fentanyl
16, norfentanyl 1.1
Peripheral blood: 6.7
+4-ANPP, +caffeine, +cotinine, +nicotine,
alprazolam 14, tramadol 70, gabapentin
10 µg/mL, diphenhydramine 1,200, fentanyl
45, norfentanyl 2.1, codeine 6.5, morphine
290, hydromorphone 4.7, +flualprazolam
Urine: 7.3
Peripheral blood: 0.7
Ethanol 138 mg/dL, +4-ANPP, +cotinine,
+naloxone, THC-COOH 85, THC
18, diphenhydramine 110, fentanyl 22,
+flualprazolam
Iliac blood: 0.1
Flualprazolam 5.4, +4-ANPP, +caffeine,
+naloxone, morphine 8.0, diphenhydramine 190, fentanyl 4.7, norfentanyl 1.6,
acetyl fentanyl 1.2, +clonazolam
Hospital blood: 0.6
Urine: 0.2
Femoral blood: 6.7
Flualprazolam 13, +4-ANPP, +cotinine,
+naloxone, codeine 7.0, morphine 85,
6-AM 12, xylazine 170, amphetamine
55, methamphetamine 580, fentanyl 190,
norfentanyl 5.4, acetyl fentanyl 0.15
Urine: 2.1
Hospital blood: 0.3
+Caffeine, +naloxone, midazolam 20,
amphetamine 110, methamphetamine
1900, MDA 9.8, MDMA 75, fentanyl 0.37,
norfentanyl 0.97
Urine: 1.4

(continued)

(10)

(10)

(10)

(10)

(10)

(10)

Reference

Drug results (ng/mL unless specified)
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Clinical symptoms/Autopsy findings
N/A

Pulmonary and cerebral edema noted at
autopsy

N/A

N/A

N/A

N/A

N/A

History

53 y/o M suspected drug OD

54 y/o F suspected drug OD

M unknown age suspected drug OD

51 y/o M suspected drug OD

49 y/o F suspected drug OD

29 y/o M with hx of drug use, suspected drug
OD. Illicit drugs found at scene

61 y/o F suspected drug OD

(10)

Hospital blood: Negative
Flualprazolam 20, +4-ANPP, +caffeine,
+naloxone, morphine 15, xylazine 30,
fentanyl 19, norfentanyl 4.2
Iliac blood: 0.1
EtOH 19 mg/dL, codeine 21, morphine
290, 6-AM 34, lamotrigine 0.60 µg/mL,
topiramate 9,400, cyclobenzaprine 38,
amphetamine 140, methamphetamine 730,
fentanyl 17
Peripheral blood: 0.7
Ethanol 100 mg/dL, +4-ANPP, +caffeine,
+cotinine, +naloxone, +nicotine, nordiazepam 130, chlordiazepoxide 66,
lorazepam 9.4, THC 0.70, diphenhydramine
53, fentanyl 32, +flualprazolam
Peripheral blood: 1.1
Ethanol 60 mg/dL, +4-ANPP, +caffeine,
+cotinine, +naloxone, +nicotine, cocaine
71, BZE 1,600, diphenhydramine 98, fentanyl 9.3, norfentanyl 5.6, morphine 19,
+flualprazolam
Urine: 0.4
Peripheral blood: 3.8
+4-ANPP, +caffeine, +naloxone, diphenhydramine 260, fentanyl 21, norfentanyl
12, acetyl fentanyl 2.0, morphine 70,
+flualprazolam
Urine: 1.8
Peripheral blood: 1.1
Flualprazolam 3.6, +4-ANPP, +caffeine,
+cotinine, +naloxone, +nicotine,
+quinine, acetaminophen 16 µg/mL, 7AMC 5.2, tramadol 70, diphenhydramine
490, amphetamine 10, methamphetamine
42, fentanyl 37, norfentanyl 1.3
Urine: 0.8
Peripheral blood: 0.4
Ethanol 57 mg/dL, +4-ANPP, +cotinine,
+naloxone, +nicotine, alprazolam 65, BZE
330, morphine 33, 6-AM 2.3, gabapentin
9.9, fentanyl 21, norfentanyl 1.9
Urine: 0.2

(continued)

(10)

(10)

(10)

(10)

(10)

(10)

Reference

Drug results (ng/mL unless specified)
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28 y/o M with hx of alcohol, tobacco and
illicit drug use, depression and anxiety,
found lying on floor of home. Capsules
and powders on scene, foil pouch labeled
‘Powder City Tianeptine 12.5 mg’
30 y/o M with hx of remote head injury
found deceased in residence. Prescribed
alprazolam for adjustment disorder, generalized anxiety disorder and paranoia. Drug
paraphernalia at scene, included tianeptine
powder ordered from internet

38 y/o M with hx of drug abuse suddenly
fainted and died in kitchen of his workplace. Syringes discovered in refrigerator.
Tianeptine tablets located in pocket

Recent puncture mark on right antecubital
fossa. Hypertensive cardiovascular disease, pulmonary edema and pulmonary
congestion

Cerebral and pulmonary edema, tracheal
lumen edema, unilateral inguinal lesion to
facilitate IV drug injection. Granulomatous
inflammation foci and focal necrotic foci in
lungs. Chronic liver inflammation and mild
perivascular fibrosis of heart
Cerebral and pulmonary edema, tracheal
lumen edema. Bilateral inguinal lesions for
IV drug injections. Diffuse granulomatous
inflammation loci as foreign body in lungs
and chronic liver inflammation
Pulmonary edema, urinary retention, modest cardiomegaly and evidence of remote
surgical closure of ductus arteriosus

Patient comatose with intact brainstem
reflexes, intubated due to low respiratory
rate. 2 days after admission, brain MRI
indicated diffuse white matter damage
characteristic of toxic leukoencephalopathy
Upon arrival at ED, excessive pupil
constriction, sedation and RR 6/min noted

COD toxic effects of multiple substances,
including brorphine and fentanyl

61 y/o F with hx of obesity, tobacco
use, hypertension, chronic obstructive
pulmonary disease, schizophrenia, hyperlipidemia, found deceased at home following
OD. Last seen alive 5 days prior, advanced
decomposition

24 y/o M with 2-year hx of tianeptine and
phenibut misuse, lethargic, slurred speech
and found unresponsive. Transported to
ED where he died 19 days after initial
submission
36 y/o M IV tianeptine powder to ‘help him
see into the future’. Became unresponsive,
EMS called, naloxone administered and
patient discharged 13 h after admission
51 y/o M found deceased in hotel room with
syringes beside bed

Clinical symptoms/Autopsy findings

History

(243)

Serum: 3,000
+Clonazepam, +7-AMC, +midazolam,
+alpha-hydroxymidazolam, +THC,
+THC-OH, +methylphenidate

(245)

(246)

(246)

Postmortem blood: 2,000
+ 8-aminoclonazolam (presumptive)

Postmortem blood: 8,400
Ethanol 12 mg/dL, alprazolam 33

(245)

Femoral blood: 538
+Nordiazepam

Femoral blood: 4,401
Citalopram 288, +7-AMC

(244)

(242)

Cardiac blood: 2.0
Fentanyl 0.32, ethanol 27 mg/dL, chlorpromazine 82, gabapentin 6.8 mcg/mL

Urine: 2
Serum: Ethanol 133 mg/dL

Reference

Drug results (ng/mL unless specified)

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

3-MF = 3-methyl fentanyl, 4-ANPP = N-phenethyl-4-piperidinone, 7-AMC = 7-aminoclonazolam, CBN = cannabinol, IM, intramuscular, MMMP = 2-methyl-4′ (methylthio)-2-morpholinopropiophenone,
MRI = magnetic resonance imaging, THC-OH = 11-Hydroxy-delta-9-tetrahydrocannabinol.

Tianeptine

Drug
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Fentanyl analogues
A variety of sites on the fentanyl core-structure backbone
can be substituted to create numerous new fentanyl analogues. Common structural modifications include substitution to or on the phenethyl group, the piperidine ring, the
aniline ring and/or the N-propionyl group. This can also
result in drug manufacturers creating closely related structural
isomers with similar chemical behaviors (e.g., butyrylfentanyl/isobutyrylfentanyl,
cis-/trans-3-methylfentanyl and
cyclopropylfentanyl/crotonylfentanyl), which then requires
development of specialized analytical methods to separate and
distinguish these isomers (223, 268–278).
Of the fentanyl analogues, acetylfentanyl was first to
emerge on the recreational market in 2014. This analogue is less potent than fentanyl and did not last long
in US markets on its own (279). Although acetylfentanyl is a known impurity in the pharmaceutical manufacturing of fentanyl (222), its continued presence at
low levels in death cases is almost certainly an indication of fentanyl synthesis through the Janssen method or
a similar process (280–282). Following the initial appearance of acetylfentanyl in 2014, additional analogues were
encountered over the next 5 years including butyrylfentanyl;
beta-hydroxythiofentanyl; 2-furanylfentanyl; carfentanil;
ocfentanil; para-fluorobutyrylfentanyl; para-fluoroisobuty
rylfentanyl; 4-methoxybutyrylfentanyl; 3-methylfentanyl;
para-fluorofentanyl; ortho-fluorofentanyl; acrylfentanyl;
tetrahydrofuranylfentanyl; cyclopropylfentanyl; methoxy
acetylfentanyl; valerylfentanyl; 2,2-difluorofentanyl; 4-chloro
isobutyrylfentanyl; para-hydroxy-butyrylfentanyl; benzoyl
fentanyl; 4-fluorofuranylfentanyl; cyclopentanoylfentanyl;
beta-hydroxyfentanyl; chlorofentanyl and bromofentanyl
(199, 235, 236, 253, 272, 283–306). Fentanyl analogues
have been associated with adverse events in the USA and other
countries (222, 232–234, 307–329).
The widespread availability of illicitly manufactured fentanyl and the spread of fentanyl analogs are responsible for the
majority of opioid-related deaths through 2020 (330, 331).
In particular, major spikes in mortality were attributed to
the introduction of carfentanil into the illicit drug supply in
Wayne County, MI, and Summit County, OH, during 2016–
2017 (318, 328), as well as smaller outbreaks in other states
including FL, PA and KY (326). The subsequent decline in
US deaths in 2018 was postulated to carfentanil’s decreased
availability, although the DEA’s core-structure scheduling

ban of fentanyl analogues was most likely also a significant
contributing factor for the overall decline in fentanyl analogue
deaths after April 2018 (332, 333).
During 2015–2020, laboratories gradually developed and
implemented new analytical methods to detect fentanyl analogues in toxicological casework, resulting in increased
identification and reporting in peer-reviewed case reports,
case series and epidemiological studies. During October
2016–April 2017, 2-furanylfentanyl (n = 1,228), carfentanil (n = 697), para-fluoroisobutyrylfentanyl/para-fluorobut
yrylfentanyl (n = 563), U-47700 (n = 543) and acrylfentanyl
(n = 266) were the most frequently reported NSO; average concentrations for 2-furanylfeantanyl, carfentanil and
acrylfentanyl were less than 8 ng/mL, but concentrations
ranged up to 760 ng/mL (272). Blood carfentanil concentrations were 0.2–9.3 ng/mL in nine postmortem cases from
Lithuania (329). In 17 postmortem investigations from
Michigan, the average blood carfentanil concentration was
<1.2 ng/mL, but additional substances were detected in all
cases (323). Postmortem femoral blood carfentanil concentrations were 0.01–0.54 ng/mL in 10 OH cases (222). During
October 2016–April 2017, carfentanil concentrations were
0.10–14 ng/mL in 355 cases, with a mean of 0.57 ng/mL
(334). In 29 postmortem femoral blood samples with only carfentanil detected, concentrations were 0.02–1.3 ng/mL; carfentanil concentrations in paired vitreous fluid samples were
typically lower (335). Chesser et al. noted that NSO were
more detectable in the brain than blood and the vitreous
humor (336). Cyclopropylfentanyl femoral blood concentrations in four overdose deaths were 16.6–28.9 ng/mL, with
a median of 23.7 ng/mL (271). Busardò et al. reported the
average postmortem NSO blood concentrations for cyclopropylfentanyl (n = 8) at 7.8 ± 7.2 ng/mL, methoxyacetylfentanyl (n = 4) at 4.1 ± 2.3 ng/mL and furanylfentanyl (n = 1) at
3.6 ng/mL (269). Identifying multiple NSO in a single case is
not uncommon; in fact, one case report mentioned that 17
different NSO had been detected (237). Findings in overdose
cases related to fentanyl analogues include miosis, respiratory depression and coma, which is a common occurrence.
At autopsy, common findings include pulmonary edema and
congestion, cerebral edema and frothy fluid in the larynx and
respiratory tract.
Cyclohexylbenzamides
U-47700
(trans-3,4-dichloro-N-[2-(dimethylamino)cyclo
hexyl]-N-methylbenzamide), emerged in 2015–2016 as the
first and most popular substance in the ‘U series’ and was
placed under international control in 2017 (337). U-47700
is one of the first nonfentanyl NSO and was associated with
numerous intoxications and fatalities. U-47700 is an Nsubstituted cyclohexylbenzamide investigated by Upjohn in
the 1970s and 1980s as a potential therapeutic agent, but
this NSO never advanced to human clinical trials (338, 339).
Baumann et al. evaluated the medicinal chemistry, preclinical
pharmacology, clandestine availability, methods for detection
and forensic toxicology pharmacology of U-47700 and its
analogs and postulated that the reason U-47700 was the only
drug to gain traction in US illicit markets was because of its
higher potency compared to other drugs in the series (340).
A subsequent case series involving U-48800 was published
(239).
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longevity among recreational markets. Some NSO, such as 2furanylfentanyl, carfentanil and U-47700, are widely reported
in a number of US states and other countries, but NSO
are concentrated in one geographical area; for example, 3methylfentanyl was popular only in PA and surrounding states
(223, 265, 266). The popularity and life cycle of a drug on
the recreational market are generally influenced by a number of factors; these factors include availability, distribution,
potency, toxicity and information including anecdotal reports
about adverse effects, shared among users by word of mouth
or on internet forums and social media (267). Scheduling
actions at the state or federal level also influence changes
in supply, accompanied by a rapid market shift, which is
demonstrated by the replacement of 2-furanylfentanyl with
cyclopropylfentanyl and methoxyacetylfentanyl (268).
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Benzimidazolones
Brorphine is a piperidine benzimidazolone, with slight structural similarities to fentanyl but outside the scope of fentanyl
core-structure scheduling. Janssen Pharmaceuticals first developed this synthetic opioid subclass as a CNS depressant with
morphine-like analgesic activity, but this is another example
of a failed pharmaceutical candidate repurposed for recreational use (354). Brorphine was reported in Europe in early
2020 and emerged in the USA in June 2020 after the DEA
enacted temporary scheduling of isotonitazene (241, 355).
In vitro studies determined brorphine is a full MOR agonist
with a higher potency than morphine (241, 356). Brorphine
was confirmed in several deaths at concentrations <5 ng/mL
in postmortem blood (10, 242) and was ultimately listed for
temporary scheduling in the USA in December 2020 (357). In
one case that did not result in death, the subject presented
with a normal blood pressure but was tachycardic; observations indicated that the individual was also clammy and
sweaty (241).
Cinnamylpiperazines
AP-237, 2-methyl-AP-237, AP-238 and para-methyl-AP-237
are cinnamylpiperazines that are structurally distinct from
other synthetic opioid subclasses. AP-237 (bucinnazine) was
developed in the 1960s for pain management among Chinese cancer patients, and 2-methyl-AP-237 was patented in
the 1980s (202, 358–360). 2-Methyl-AP-237 has 68–156
times lower potency than fentanyl, which may account for the
lack of popularity on the drug market (361). AP-237 is estimated to be 3.5–13 times less potent than 2-methyl-AP-237
(361, 362). para-Methyl-AP-237 was recently reported in the
USA (363), but the low potencies of the cinnamylpiperazines
may indicate a lack of interest within the NSO community.

Table X. Summary of Toxicity Profile of NPS Opioids

Organ system

Symptoms and signs

CNS
Cardiovascular
Pulmonary

Analgesia, somnolence and sedation
Hypercarbia, acidosis and hypoxemia
Hypoventilation that can progress to
respiratory arrest
Miosis; constipation; rapid onset of rigidity of muscles in the jaw, neck, chest wall
and abdomen
Organ edema and congestion; urine
retention; frothy watery fluid in airways

Other

Postmortem
findings

Atypical opioid agonists
Substances that typically combine opioid and nonopioid
mechanisms are considered atypical opioid agonists. Mitragynine was addressed in our previous NPS review and is
still detected in toxicological casework; however, its role in
adverse events continues to be debated. Tianeptine is another
atypical opioid agonist with increasing popularity in the USA.
Tianeptine is legally prescribed in Europe, Asia and Latin
America, but not in the USA. Tianeptine is pharmacologically
classified as a modified tricyclic antidepressant and anxiolytic,
but it is also a full agonist at MOR and the δ opioid receptor
(364, 365). Therapeutic doses of tianeptine were investigated
for major depression, depressed bipolar disorder, dysthymia
and adjustment disorder (366). In the USA, tianeptine is
sold online as a nootropic or cognitive enhancer. At high
doses, tianeptine can produce euphoria. Other adverse effects
include dependence, withdrawal and psychosis (367–370).
Over the past 10–20 years, the CDC has reported an increase
in National Poison Data System calls related to tianeptine
because individuals have been self-administering it with little
to no medical guidance and are unaware of the drug’s health
risks (371–373).

Discussion
The infiltration of NSO into the drug market has exacerbated
the ongoing opioid epidemic, posing significant risks to public
health and safety. Individuals may be unintentionally exposed
to NSO, which, depending on the drug, may have significantly
higher potency compared to routinely encountered opioids.
NSO are predominantly encountered with fentanyl and/or
heroin, either in the drug material or in toxicology samples.
This results in at least additive effects of CNS depression but
complicates correlation and interpretation of drug use with
those effects. Table X presents a summary of adverse effects
by organ system.
Laboratories lack standardization for toxicological testing, and some laboratories may struggle to keep pace with
the rapid emergence and changes related to NPS. Additionally, due to the potency of some NSO they may be detected
in sub-nanogram concentrations and require higher analytical sensitivity. NSO pose a significant challenge due to their
prevalence and propensity for adverse effects, including overdose and death caused by prolonged respiratory depression.
NSO are commonly encountered with other traditional opioids; therefore, reporting of the commonly known drug (e.g.,
fentanyl) might be sufficient. Unless a toxicology laboratory maintains current testing methods and libraries, NSO
are likely to be missed; these new drugs are typically tested
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2-Benzyl benzimidazole ‘Nitazenes’
Isotonitazene is structurally related to etonitazene, an opioid
investigated for its analgesic properties but ultimately internationally controlled because of health threats (341, 342).
Isotonitazene was first developed in 1957 and later emerged
on the illicit opioid market in 2019, likely in response to
fentanyl analogue core-structure scheduling (343). Isotonitazene’s potency and efficacy are comparable to fentanyl
(344). Isotonitazene was first reported in Europe, Canada
and the USA in 2019, followed by proliferation into 2020
(9, 240, 344–346). In the USA, the majority of cases centered around Midwestern states—including Illinois, Indiana, Michigan, Minnesota and Wisconsin (347). In June
2020, the DEA announced temporary scheduling of isotonitazene in Schedule 1 of the Controlled Substances Act (348).
Reported postmortem blood concentrations of isotonitazene
(0.4–9.5 ng/mL) are comparable to the potent fentanyl analogues carfentanil and 3-methylfentanyl. Pulmonary and cerebral edemas along with blood organ congestion were reported
in autopsied cases.
Additional 2-benzyl benzimidazole opioid agonists include
etonitazene, metonitazene, protonitazene, butonitazene,
etodesnitazene and clonitazene (349–352). Lutz published a
review of benzimidazole opioid agonists in 2012 and suggested that the abuse liability of etonitazene made it likely
for other members of this class also to be used recreationally
(353).
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Limitations and Summary
This updated review reflects the fact that NPS markets have
continued to evolve rapidly in the past 4 years since our initial 4-year review that ended in 2016. Data presented in this
review consolidates reports of adverse events associated with
the most prevalent NPS categories published between January 2017 and December 2020 and contained case-specific
syndromic information, along with qualitative or quantitative toxicological confirmation. This information can assist
forensic and clinical toxicologists in their assessment and
interpretation of future cases involving these substances, as
well as provide references to literature that may include analytical methods used for confirmation and typical concentrations of the drugs encountered in these cases. Reviews of
the chemistry, pharmacology, selected adverse events and
recommendations for testing for novel SC, stimulants, hallucinogens, benzodiazepines and opioids are provided. This
includes case history, clinical symptoms and autopsy findings,
where available. Each topic heading also includes the citation
to the published case report.
Limitations of this approach in terms of assessing true
prevalence or prevalence trends of NPS involvement in toxic
emergencies resulting in death or hospitalization are severalfold. These include the testing capabilities of hospital and
medical examiner/coroner toxicology laboratories performing the testing, since laboratory scopes will frequently lag
behind the dates of emergence of the latest drugs. Intoxications from some NPS categories, notably the SC, are likely
underdiagnosed and reported due to the low concentrations
of the drugs, the fact that they are not detected in typical routine drug tests, lack of available immunoassay screening tests
and lack of available standard reference materials (SRMs)
for confirmatory analysis of the drugs and their metabolites.
In addition, many hospitalized patients in toxic emergencies
are treated symptomatically and released without even basic
testing and with little follow-up as to the causative agent.
This is particularly true for opioids, which represent the class
of drugs responsible for the largest number of emergency
room admissions. In these cases, after the subject has been
treated with naloxone, responds and is released, there is no
further toxicological investigation of the specific substances
ingested. This is true also for benzodiazepines and other
depressants where the subject is typically allowed to sleep
off the effects of the drug. In addition, NPS benzodiazepines
have highly variable cross-reactivity in immunoassays typically used in hospital emergency room (ER) toxicology panels

and many likely go undetected (374, 375). In the stimulant
category, many cathinone or phenethylamine NPS stimulants
also do not cross-react on amphetamine or methamphetamine
immunoassays. Furthermore, there can be additional factors,
including available research funding for testing, geographic
differences in drug trends, cases in teaching hospitals versus EDs and availability of medical toxicology consultants,
among other reasons, that will influence whether cases are
written up and submitted for publication. Many cases of
intoxication were excluded from our review because of lack
of appropriate toxicological confirmation or lack of case histories or were previously included in other review articles. In
addition, not all case reports are indexed with search terms
that would come up in our search, including spellings of
chemical names, mentions of the drug class or category of
NPS.
In short, the frequency of reports of intoxications indicted
in our review should be used cautiously with a respect to estimation of comparative prevalence or public health impact of
the various drug classes involved. In every case, these reports
should be considered the tip of the iceberg in terms of the
actual number of intoxications. The rates of identification of
new substances, however, are important, and in aggregate,
a good indicator of changes in drug markets over the review
period. There is also some utility in evaluating the frequency
of published reports between this period (2017–2020) and the
previous reporting period covering 2013–2016. The greatest
contribution of this survey of literature is in its spotlighting of
symptomology, drug concentrations and diversity of members
within specific drug classes.
Considering this review covering the period 2017–2020,
together with our prior review covering 2013–2016, this work
represents a collection of 8 years of published reports covering 600 citations cataloging adverse toxicological details
for over 80 individual substances. In the present review,
there were over 60 substances in the most prevalent classes
including NPS benzodiazepines, SC, opioids, hallucinogens and stimulants. Again, the relevant prevalence of
reporting may not reflect the prevalence of use and will
be influenced by the testing capabilities of laboratories
reporting.
Between 2017 and 2020, 63 substances were mentioned
in qualifying reports. The types of case reports included
overdose fatalities (378 cases), clinical treatment and hospitalization (771 cases) and DUID (170 cases). Figure 3 shows
the overall number of cases by NPS class during these two
4-year periods and combined over the entire 8-year period
covered by the two review cycles. Note that the NPS benzodiazepine category, which has the largest number of cases,
is influenced by a few reviews with very large numbers of
cases. Figure 4 depicts the overall frequency of NPS substances by drug class, reflecting the larger number of SC
drugs, followed by hallucinogens, opioids, benzodiazepines
and stimulants. This trend also reflects the general experience
in terms of activity within drug classes in Europe reported by
the EMCDDA. Generally, the most current 4-year period saw
a 70% increase in new NPS over the prior 4-year period of
2013–2016. During 2017–2020, 50 new NPS not reported in
the previous review article were identified in this assessment
of the literature, representing cannabinoids (n = 19), hallucinogens (n = 11), stimulants (n = 10), opioids (n = 9) and
benzodiazepines (n = 1).
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for only when routine toxicology reporting is insufficient to
explain scene/autopsy findings. Ultimately, the prevalence of
NSO is certainly underestimated.
There have been successful efforts to stem the flow of NSO.
For example, fentanyl core-structure scheduling reduced
the spread of fentanyl analogues and overall cases involving fentanyl-related NSO. However, this also resulted in
a shift toward more varied subclasses, further straining
laboratories’ efforts and resources. Experience with NSO
and NPS shows that an overall reduction in the emergence
and use of these drugs is unlikely as long as there is user
demand and a market or manner by which the drugs can be
sold.
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Figure 4. Overall frequency of NPS substances by drug class.

Synthetic cannabinoids
The introduction of new SC to illicit markets continues and
while this NPS class has demonstrated far fewer unique substances compared to a decade ago, more new substances
appeared in adverse event reports in 2017–2020 (n = 22) versus the period 2013–2016 (n = 11). SC are generally named
using chemical structure conventions, such as the modified
Uchiyama system, and are often based on names adopted by
the vendors of analytical SRMs (23, 24). The pharmacokinetics and pharmacodynamics of SC vary compared to THC
and each other and can yield contradictory effects (i.e., tachycardia versus bradycardia and agitation versus somnolence).
Toxidromes and clinical effects of SC can be nonspecific
and inconsistent; however, with unique sequelae, such as
tonic-clonic seizures, respiratory depression and heightened

agitation or sedation not resolved with naloxone observed in
the context of drug use history, SC should be considered when
opioid testing for legacy and NPS opioids is negative. SC are
not routinely tested for and require special methods to detect
them in biological samples. Testing of drug paraphernalia
or drug products found with the patient can assist toxicologists in performing the appropriate toxicological testing to
properly identify SC that may be involved.
Generally, the newer indole- and indazole-carboxamides
(e.g., 5F-MDMB-PICA) are more potent than older SC, such
as JWH-018 and XLR-11. During 2017–2020, the adverse
events of 22 unique SC were reported in 60 cases: 43 clinical, 15 postmortem and 2 DUID. There were 19 instances
of an additional SC confirmed (31.7%) with the reported SC,
and another 19 instances of another drug identified (31.7%).
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Figure 3. Total cases reported in the literature by NPS class.
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Evidence of polydrug use in SC was substantially higher than
in our previous review (2013–2016: 2 cases and 2017–2020:
44 cases). During 2013–2016 and 2017–2019, five SC were
identified—AB-CHMINACA, AMB-FUBINACA (FUB-AMB)
AB-PINACA, MDMB-CHMICA and UR-144 in both reviews.

NPS stimulants

NPS hallucinogens
In this literature review, NPS hallucinogens represented the
second largest number of novel substances in a class, after
SC. It is likely, however, that due to limited testing for these
diverse drug types, these reports may mask or underrepresent
their true prevalence while their potential for severe psychiatric side effects may increase the likelihood of the cases
being published. In addition, in many cases, these individuals
were using multiple novel substances at the same time. NPS
hallucinogens are largely analogues of traditional hallucinogens: PCP-like (e.g., 3-MeO-PCP and 3-HO-PCP); ketaminelike (e.g., 2-FDCK, 2-Oxo-PCE and MXPr); LSD-like (e.g.,
AL-LAD); tryptamine-like (e.g., 5-MeO-DiPT and 5-MeOMiPT) and diarylethylamine-like (e.g., MXP and diphenidine). Although these drugs are analogues of traditional hallucinogens, immunoassay screening tests may not cross-react
and confirmation tests must have the drugs indicated for
proper identification. Common signs and symptoms of NPS
hallucinogenic intoxication included agitation, aggressive
behavior, delusions and tachycardia. Hypo- or hyperthermia,
excited delirium, and serotonin syndrome were less frequently
reported. In total, 14 NPS hallucinogens were reported in
151 cases during 2017–2020. In our prior review, three
substances—25B-NBOMe, 25C-NBOMe and 25I-NBOMe—
were previously mentioned and 11 novel hallucinogens were
newly identified: 2-FDCK, 2-Oxo-PCE, 2C-E, 3-HO-PCP, 5MeO-DiPT, AL-LAD, Bromo-DragonFLY, diphenidine, DOC,
MXP and MXPr. Adverse events for NPS hallucinogens

were detailed in 6 DUID, 123 clinical and 22 fatal cases.
Moreover, novel multidrug use in individuals who use NPS
hallucinogens was high and represented a diverse use profile—
as noted in the top three drug classes (in order of highest
concomitant use): other hallucinogens (64 cases showing at
least 14 substances) were greater than stimulants (48 cases
showing at least 12 substances), followed by cannabinoids
(eight cases showing at least four substances). NPS hallucinogens were also confirmed in the presence of opioids,
benzodiazepines, chlorpheniramine, antidepressants and
ethanol.

NPS opioids
Opioid misuse in the USA reached epidemic proportions and
continued to rise over three distinct phases beginning with
pharmaceutical opioids (e.g., oxycodone and methadone)
prescription in the early 1990s, followed by an increased
use of illicit opioids (e.g., heroin and fentanyl) in the early
2010s and most recently the current phase of NSO, beginning in 2013 with the introduction of illicitly manufactured
fentanyl (376). Illicit fentanyl is the major contributor to
opioid death in the USA today. In response to the 2018 corestructure scheduling actions to address the proliferation of
fentanyl analogues, divergent chemical subclasses of NSO
have begun to emerge. During 2017–2020, there were 93
published case reports identified in our literature search of
NSO: 9 clinical, 82 postmortem and 2 DUID. The number of NSO fatalities involving polydrug use also increased.
Ninety percentage of the published cases (n = 84) had another
drug confirmed in addition to the reported NSO. Nine new
NSO were reported during 2017–2020 that had not been
reported in our previous review—3-methylfentanyl, betahydroxyfentanyl, brorphine, carfentanil, cyclopropylfentanyl, isotonitazene, para-fluoroisobutyrylfentanyl (p-FIBF),
tianeptine and U-48800.

NPS benzodiazepines
While NPS benzodiazepines have far fewer and less severe
adverse effects than other NPS when ingested alone, coingestion with other CNS depressants or opioids results in synergistic effects that may lead to unconsciousness, coma or death.
Toxidromes of NPS benzodiazepines are mostly CNS depressants in nature and indistinct from intoxication with medically prescribed benzodiazepines. The toxidrome includes
amnesia, drowsiness, lethargy, slurred speech, incoordination, delayed comprehension and reaction time, dizziness,
vertigo, sedation and coma. NPS benzodiazepines were the
most frequently reported NPS class during 2013–2016 and
2017–2020, largely due to case series with large numbers of
cases included from DUID or clinical populations. Often, the
literature does not indicate if other drugs were identified as
most of the cases were clinical, and comprehensive testing
is generally not performed in a hospital setting. Flualprazolam was the only newly reported NPS benzodiazepine in
published case reports during 2017 through 2020. Six NPS
benzodiazepines that were reported during 2013–2016 and
continued to be reported during 2017–2020 included clonazolam, diclazepam, etizolam, flubromazepam, flubromazolam
and phenazepam.
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The toxic profile of NPS stimulants includes CNS effects
such as agitation, psychosis, delusions, aggression, irritability,
paranoia, delirium, hallucinations, sedation, coma, abnormal
behavior and altered fluctuating consciousness; cardiorespiratory effects such as tachycardia, hypertension, palpitations
and increased respiration rate; and other symptomology such
as hypothermia, mydriasis, rhabdomyolysis, compartment
syndrome and sweating (most of these physiological findings
are similar to traditional stimulants). Organ edema and congestion are often present in autopsy findings, as they are with
traditional stimulants. During 2017–2020, a total of 10 NPS
stimulants were reported; in DUID, clinical and fatal cases,
this was an increase of six from only four new substances
during the previous 4-year period. All 10 synthetic stimulants
in the literature we reviewed were newly identified: 4-MEAP,
4F-MPH, α-EAP, 4F-αPVP, α-PHP, dibutylone, EPH, MPHP,
NEH and NEP. Polydrug use for synthetic stimulants representing instances of subjects co-ingesting more than one
synthetic stimulant appeared higher in recent reports than in
the prior review (24 cases reported compared to 1). An even
greater increase in the number of reported cases of synthetic
stimulants combined with other drugs were reported during
this same time. Opioid use with synthetic stimulants has also
increased.
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Conclusions

are ingested in combination. NSO are often found along with
fentanyl and/or each other, which will lead to a greater risk
of overdose and death.

Recommendations
To better understand the public health and public safety
threats from NPS, the USA needs to continue to support and
expand ongoing efforts to develop a national rapid surveillance monitoring program that will provide real-time clinical
and forensic toxicology data about emerging drugs and their
known toxidromes and side effect profiles. Medical, forensic and treatment communities, policy makers, regulators
and other stakeholders would benefit from more rapid access
to this information. Today, new tools such as the CFSRE’s
NPS Discovery program, the DEA’s Emerging Threat Reports,
NFLIS and the UNODC EWA on NPS including the EWA
Tox-Portal (377) are innovative approaches for collecting,
analyzing and sharing data and real-time insights on toxicology and harm related to the use of NPS in the USA and
worldwide. Such systems need to be monitored, managed and
curated to ensure that the data are evidence-based, comprehensive and reported consistently, that the substances have
been confirmed analytically and that there is a focus on rapid
targeted dissemination of information to stakeholders within
a timeframe that makes the information actionable in terms
of epidemiological surveillance,
As noted in our prior review, toxicological testing of samples from individuals reporting to EDs and hospitals following
NPS adverse events and ingestion would add greatly to our
knowledge about the progression of toxicity in individuals
harmed by these substances and the efficacy of treatments or
countermeasures. The American College of Medical Toxicology has for a number of years run a program called the Toxic
Investigators Consortium is now adding toxicological testing
data to some of the cases where syndromic data are also collected, which will provide a great insight into the nuances
and toxic profile of NPS (378). Similarly, as evidenced by the
increased reporting during this review period of toxic effects,
increased rates of testing by clinical and forensic laboratories are leading to more reports of adverse effects for more
substances, improving our insight into this problem area.
The use of multiple substances by people who use drugs
continues to rise. Polydrug-related deaths and case reports
are increasing, and increased combined use of NPS opioids
and NPS benzodiazepines as well as NPS stimulants and opioids is also evident from the reports reviewed herein. The
more widespread use of a drug use evaluation system such as
the TSS developed by Elliot et al. can further assist decisionmakers in the inclusion of drug findings into death certificate data, making it easier to aggregate in national death
statistics (65).
Finally, although toxicology laboratories have made significant progress with the increased availability of nontargeted
HRMS screening, this approach needs to be applied more
comprehensively to improve the detectability of NPS in clinical and forensic toxicology, a research need identified by
the Organization of Scientific Area Committees for Forensic Science (379). Best practices for maintaining awareness of
new and emerging substances and adding them to the scope
of testing include maintaining a dialog with local/regional
forensic chemistry laboratories to improve awareness about

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

The impact of emergent NPS continues to be a significant
international public health threat, especially with respect to
overdose fatalities. Opioid deaths continue to be the most
impactful in relation to adverse events with 90% of the published case reports involving opioids resulting in fatalities,
as opposed to clinical intoxications or DUID. Surveillance
systems, such as NPS Discovery and NFLIS, indicate NPS
classes for seized drugs are highest for stimulants, opioids and
cannabinoids. Widespread awareness of a new substance in
NPS markets typically happens after a mass poisoning or a
series of deaths in a specific location. Lower frequency occurrences or events with less serious health outcomes are more
likely to be overlooked. Routine approaches to analytical toxicology based on a tiered approach of immunoassay, coupled
with targeted gas or liquid chromatography mass spectrometry screening are now more likely to fail to find the causative
agent because the defined scope often does not include the
most recently emerged NPS. With some drug classes, such as
the typically neutral SC, widely used routine basic extraction
chemistries are not capable of detecting these drugs.
For all these reasons, identifying the chemical cause of toxic
incidents or deaths via traditional analytical approaches targeting common therapeutic or abused agents is not adequate
for comprehensive detection in NPS markets. This realization
is driving laboratories toward HRMS techniques such as timeof-flight mass spectrometry and more nontargeted analytical
approaches, which while effective, add cost and complexity
to analyses for detecting high-risk, low-frequency intoxication
events. While this technology is increasingly available to some
forensic toxicology laboratories, it creates an additional burden in terms of research and development, method validation
and additional confirmations. It is less common for comprehensive testing to be performed to identify the causative agent
in clinical intoxications because treatment is generally supportive and based on symptomology. In addition, drug testing
results for nontraditional drugs (i.e., beyond traditional opiates, cocaine, amphetamines and benzodiazepines) are not
directly used in patient care, so insurance companies typically
will not reimburse for the cost of testing. Delays in identifying
the presence of these NPS and making stakeholder communities in clinical medicine, medicolegal death investigation,
harm reduction, rehabilitation and safety-sensitive drug testing programs aware of their presence have significant negative
consequences for public health and public safety.
Challenges arise for forensic toxicologists in interpreting
NPS results in general and even more so when multiple NPS
and therapeutic or legacy drugs of abuse are present. Coingestion of NPS with other NPS or common drugs of abuse is
common, but the interaction of the drugs is largely unstudied, leading to difficulties in formulating opinions based on
polydrug toxicity and effects. Conclusions should generally
be based on basic knowledge of general pharmacological
effect, scene and circumstances, observation, autopsy findings or clinical assessments, field sobriety tests and other tools.
Animal-based dose/response studies (EC50 ) or in vitro receptor efficacy or binding affinity profiles which are often lacking
for NPS should be extrapolated with caution to humans. Polydrug combinations involving benzodiazepines and opioids are
commonly encountered in forensic toxicology and are understood to be at least additive in nature. NPS or novel versions
of these drugs are likely to cause increased toxicity when they
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111. Theofel, N., Möller, P., Vejmelka, E., Kastner, K.,
Roscher, S., Scholtis, S., et al. (2019) A fatal case involving Nethyldeschloroketamine (2-Oxo-PCE) and venlafaxine. Journal
of Analytical Toxicology, 43, e2–e6.
112. Tang, M.H.Y., Chong, Y.K., Chan, C.Y., Ching, C.K., Lai, C.K.,
Li, Y.K., et al. (2018) Cluster of acute poisonings associated with
an emerging ketamine analogue, 2-oxo-PCE. Forensic Science
International, 290, 238–243.
113. Dunlop, L.C., Wood, D., Archer, J., Hudson, S., Dargan,
P. (2020) Severe toxicity to the new psychoactive substances
3-hydroxyphencyclidine and N-ethylhexedrone: an analytically
confirmed case report. Journal of Medical Toxicology, 16,
67–70.

e177

e178

148. Roth, B.L., Gibbons, S., Arunotayanun, W., Huang, X.-P.,
Setola, V., Treble, R., et al. (2013) The ketamine analogue
methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate
NMDA receptor. PLoS One, 8, e59334.
149. Wallach, J., Kang, H., Colestock, T., Morris, H.,
Bortolotto, Z.A., Collingridge, G.L., et al. (2016) Pharmacological investigations of the dissociative ‘legal highs’ diphenidine,
methoxphenidine and analogues. PLoS One, 11, e0157021.
150. Morris, H., Wallach, J. (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to
MXE. Drug Testing and Analysis, 6, 614–632.
151. Davidsen, A.B., Mardal, M., Johansen, S.S., Dalsgaard, P.W.,
Linnet, K. (2020) In vitro and in vivo metabolism and detection of 3-HO-PCP, a synthetic phencyclidine, in human samples and pooled human hepatocytes using high resolution mass
spectrometry. Drug Testing and Analysis, 12, 987–993.
152. Kamenka, J.M., Chiche, B., Goudal, R., Geneste, P., Vignon, J.,
Vincent, J.P., et al. (1982) Chemical synthesis and molecular
pharmacology of hydroxylated 1-(1-phenylcyclohexyl)piperidine
derivatives. Journal of Medicinal Chemistry, 25, 431–435.
153. World Health Organization: Expert Committee on Drug Dependence. (2014) 25I-NBOMe: Critical Review Report. http://www.
who.int/medicines/areas/quality_safety/4_19_review.pdf (Nov
12, 2016).
154. World Health Organization: Expert Committee on Drug Dependence. (2014) 25B-NBOMe: Critical Review Report. http://
www.who.int/medicines/areas/quality_safety/4_17_review.pdf
(Nov 12, 2016).
155. World Health Organization: Expert Committee on Drug
Dependence. (2014) 25C-NBOMe: Critical Review Report.
https://legal-high-inhaltsstoffe.de/sites/default/files/uploads/25cnbome.pdf (Nov 12, 2016).
156. Rickli, A., Moning, O.D., Hoener, M.C., Liechti, M.E. (2016)
Receptor interaction profiles of novel psychoactive tryptamines
compared with classic hallucinogens. European Neuropsychopharmacology, 26, 1327–1337.
157. Sogawa, C., Sogawa, N., Tagawa, J., Fujino, A.,
Ohyama, K., Asanuma, M., et al. (2007) 5-Methoxy-N,Ndiisopropyltryptamine (Foxy), a selective and high affinity
inhibitor of serotonin transporter. Toxicology Letters, 170,
75–82.
158. Fantegrossi, W.E., Harrington, A.W., Kiessel, C.L., Eckler, J.R.,
Rabin, R.A., Winter, J.C., et al. (2006) Hallucinogen-like actions
of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacology, Biochemistry, and Behavior, 83, 122–129.
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Cingöz, G., et al. (2018) death due to tianeptine injection
through inguinal incision: two case reports. The Bulletin of Legal
Medicine, 23, 123–128.
Bakota, E.L., Samms, W.C., Gray, T.R., Oleske, D.A.,
Hines, M.O. (2018) Case reports of fatalities involving tianeptine in the United States. Journal of Analytical Toxicology, 42,
503–509.
Ciccarone, D., Ondocsin, J., Mars, S.G. (2017) Heroin uncertainties: exploring users’ perceptions of fentanyl-adulterated and
-substituted ‘heroin’. The International Journal on Drug Policy,
46, 146–155.
Klar, S.A., Brodkin, E., Gibson, E., Padhi, S., Predy, C.,
Green, C., et al. (2016) Furanyl-fentanyl overdose events caused
by smoking contaminated crack cocaine — British Columbia,
Canada, July 15–18, 2016. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 36,
200–201.
Fogger, S.A. (2019) Methamphetamine use: a new wave in the
opioid crisis? Journal of Addictions Nursing, 30, 219–223.
Han, Y., Yan, W., Zheng, Y., Khan, M.Z., Yuan, K., Lu, L.
(2019) The rising crisis of illicit fentanyl use, overdose, and
potential therapeutic strategies. Translational Psychiatry, 9, 282.
LaRue, L., Twillman, R.K., Dawson, E., Whitley, P.,
Frasco, M.A., Huskey, A., et al. (2019) Rate of fentanyl positivity among urine drug test results positive for cocaine or
methamphetamine. JAMA Network Open, 2, e192851.
DiSalvo, P., Cooper, G., Tsao, J., Romeo, M., Laskowski, L.K.,
Chesney, G., et al. (2021) Fentanyl-contaminated cocaine outbreak with laboratory confirmation in New York City in 2019.
The American Journal of Emergency Medicine, 40, 103–105.

e181

e182

284. Krotulski, A.J., Logan, B.K. (2019) FluoroFuranylfentanyl. Center for Forensic Science Research & Education.
https://www.npsdiscovery.org/wp-content/uploads/2019/05/Flu
oroFuranylfentanyl_012319_ToxicologyAnalyticalReport.pdf
(Feb 13, 2021).
285. Brandt, S.D. (2018) Critical Review Report: p-Fluorobutyrylfentanyl. World Health Organisation. http://www.who.
int/medicines/access/controlled-substances/Parafluorobutyrfenta
nyl.pdf (Dec 5, 2020).
286. WHO (2019) Expert Committee on Drug Dependence: forty-first
report. Geneva: World Health Organization; (WHO Technical
Report Series, No. 1018). Licence: CC BY-NC-SA 3.0 IGO.
https://apps.who.int/iris/bitstream/handle/10665/325073/97892
41210270-eng.pdf?ua=1 (Mar 6, 2022).
287. Expert Committee on Drug Dependence. (2017) Critical
Review Report: Acrylolyfentanyl. World Health Organization.
https://www.who.int/medicines/access/controlled-substances/Cri
ticalReview_Acrylolyfentanyl.pdf?ua=1 (Dec 6, 2020).
288. Expert Committee on Drug Dependence. (2017) Critical Review
Report: Tetrahydrofuranylfentanyl (THF-F). World Health
Organization. https://www.who.int/medicines/access/controlledsubstances/CriticalReview_THFF.pdf (Dec 6, 2020).
289. Expert Committee on Drug Dependence. (2017) Critical_Review Report: Carfentanil. World Health Organization.
https://www.who.int/medicines/access/controlled-substances/Cri
tical_Review_Carfentanil.pdf (Dec 6, 2020).
290. Expert Committee on Drug Dependence. (2017) Critical
Review Report: Furanyl Fentanyl. World Health Organization.
https://www.who.int/medicines/access/controlled-substances/Cri
ticalReview_FuranylFentanyl.pdf?ua=1 (Dec 6, 2020).
291. Breindahl, T., Kimergård, A., Andreasen, M.F., Pedersen,
D.S. (2017) Identification of a new psychoactive substance
in seized material: the synthetic opioid N-phenyl-N-[1-(2phenethyl)piperidin-4-yl]prop-2-enamide (Acrylfentanyl). Drug
Testing and Analysis, 9, 415–422.
292. Degreef, M., Blanckaert, P., Berry, E.M., van Nuijs, A.L.N.,
Maudens, K.E. (2019) Determination of ocfentanil and W-18 in
a suspicious heroin-like powder in Belgium. Forensic Toxicology,
37, 474–479.
293. Liu, C., Li, T., Han, Y., Hua, Z., Jia, W., Qian, Z.
(2018) The identification and analytical characterization of 2,2′ difluorofentanyl. Drug Testing and Analysis, 10, 774–780.
294. Oldenhof, S., Ten Pierick, A., Bruinsma, J., Eustace, S., Hulshof, J., van den Berg, J., et al. (2020) Identification of a novel
fentanyl analogue: p-Hydroxy-butyrylfentanyl. Drug Testing and
Analysis, 12, 152–155.
295. Richeval, C., Baillieux, M., Pawlak, G., Phanithavong, M.,
Wiart, J., Humbert, L., et al. (2019) Benzoylfentanyl and
parafluorobutyrfentanyl: some analytical and metabolism data.
Toxicologie Analytique Et Clinique, 31, 258–267.
296. Vincenti, F., Pagano, F., Montesano, C., Sciubba, F., Di Cocco,
M.E., Gregori, A., et al. (2020) Multi-analytical characterization of 4-fluoro-furanyl fentanyl in a drug seizure. Forensic
Chemistry, 21, 100283.
297. Rab, E., Flanagan, R.J., Hudson, S. (2019) Detection of fentanyl and fentanyl analogues in biological samples using liquid chromatography-high resolution mass spectrometry. Forensic
Science International, 300, 13–18.
298. Gampfer, T.M., Wagmann, L., Richter, M.J., Fischmann, S.,
Westphal, F., Meyer, M.R. (2020) Toxicokinetic studies and analytical toxicology of the new synthetic opioids cyclopentanoylfentanyl and tetrahydrofuranoyl-fentanyl. Journal of Analytical
Toxicology, 44, 449–460.
299. Krotulski, A.J., Papsun, D.M., Friscia, M., Swartz, J.L., Holsey,
B.D., Logan, B.K. (2018) Fatality following ingestion of tetrahydrofuranylfentanyl, U-49900 and methoxy-phencyclidine. Journal of Analytical Toxicology, 42, e27–e32.

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

270. Lee, J., Krotulski, A.J., Fogarty, M.F., Papsun, D.M.,
Logan, B.K. (2019) Chromatographic separation of the isobaric compounds cyclopropylfentanyl,
crotonylfentanyl,
methacrylfentanyl, and para-methylacrylfentanyl for specific
confirmation by LC-MS/MS. Journal of Chromatography. B,
Analytical Technologies in the Biomedical and Life Sciences,
1118–1119, 164–170.
271. Maher, S., Elliott, S.P., George, S. (2018) The analytical challenges of cyclopropylfentanyl and crotonylfentanyl: an approach
for toxicological analysis. Drug Testing and Analysis, 10,
1483–1487.
272. Moody, M.T., Diaz, S., Shah, P., Papsun, D., Logan, B.K. (2018)
Analysis of fentanyl analogs and novel synthetic opioids in blood,
serum/ plasma, and urine in forensic casework. Drug Testing and
Analysis, 10, 1358–1367.
273. Larabi, I.A., Martin, M., Etting, I., Pfau, G., Edel, Y.,
Alvarez, J.C. (2020) Development and validation of liquid
chromatography-tandem mass spectrometry targeted screening
of 16 fentanyl analogs and U-47700 in hair: application to 137
authentic samples. Drug Testing and Analysis, 12, 1298–1308.
274. Mallette, J.R., Casale, J.F., Hays, P.A. (2019) Characterization and differentiation of cyclopropylfentanyl from Ecrotonylfentanyl, Z-crotonylfentanyl, and 3-butenylfentanyl.
Science & Justice, 59, 67–74.
275. Strayer, K.E., Antonides, H.M., Juhascik, M.P., Daniulaityte, R.,
Sizemore, I.E., (2018) LC-MS/MS-based method for the multiplex detection of 24 fentanyl analogues and metabolites in whole
blood at sub ng mL-1 concentrations. ACS Omega, 3, 514–523.
276. Sofalvi, S., Lavins, E.S., Brooker, I.T., Kaspar, C.K., Kucmanic,
J., Mazzola, C.D., et al. (2019) Unique structural/stereo-isomer
and isobar analysis of novel fentanyl analogues in postmortem
and DUID whole blood by UHPLC–MS-MS. Journal of Analytical Toxicology, 43, 673–687.
277. Qin, N., Xiang, P., Shen, B., Zhuo, X., Shi, Y., Song, F.
(2019) Application of a validated UHPLC-MS/MS method for
28 fentanyl-analogue and novel synthetic opioids in whole blood
in authentic forensic cases. Journal of Chromatography B, 1124,
82–99.
278. Zhang, Y., Sheng, Z., Hua, Z., Liang, C., Cai, Z., Wang, R.,
et al. (2020) Simultaneous separation and determination of 32
fentanyl-related substances, including seven sets of isomeric fentanyl analogues, by ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry. Journal of
Separation Science, 43, 3735–3747.
279. Hassanien, S.H., Bassman, J.R., Naccarato, C.M.P.,
Twarozynski, J.J., Traynor, J.R., Iula, D.M., et al. (2020)
In vitro pharmacology of fentanyl analogs at the human mu
opioid receptor and their spectroscopic analysis. Drug Testing
and Analysis, 12, 1212–1221.
280. Dwyer, J.B., Janssen, J., Luckasevic, T.M., Williams, K.E. (2018)
Report of increasing overdose deaths that include acetyl fentanyl
in multiple counties of the southwestern region of the commonwealth of Pennsylvania in 2015–2016. Journal of Forensic
Sciences, 63, 195–200.
281. Moss, D.M., Brown, D.H., Douglas, B.J. (2019) An acetyl fentanyl death in Western Australia. Australian Journal of Forensic
Sciences, 51, 73–77.
282. Vandeputte,
M.M.,
Krotulski,
A.J.,
Hulpia,
F.,
Van Calenbergh, S., Stove, C.P. (2022) Phenethyl-4-ANPP:
a marginally active byproduct suggesting a switch in illicit
fentanyl synthesis routes. Journal of Analytical Toxicology, 46,
350–357.
283. Krotulski, A.J., Walton, S.E., Fogarty, M.F., Mohr, A.L.A.,
Logan, B.K. (2020) Bromofentanyl. NPS Discovery at CFSRE.
https://www.npsdiscovery.org/wp-content/uploads/2020/12/Bro
mofentanyl_121720_CFSRE-Toxicology_Report.pdf (Feb 13,
2021).

Mohr et al.

NPS Adverse Effects

317. Claridge, H., Williams, B.D., Copeland, C.S. (2020) A deadly
trend in fentanyl fatalities (England, 1998–2017). British Journal
of Clinical Pharmacology, 86, 437–444.
318. King, A., Foley, D., Arfken, C., Aaron, C., Sung, L., Hlavaty,
L. (2019) Carfentanil-associated mortality in Wayne County,
Michigan, 2015-2017. American Journal of Public Health, 109,
300–302.
319. Delcher, C., Wang, Y., Vega, R.S., Halpin, J., Gladden, R.M.,
O’Donnell, J.K., et al. (2020) Carfentanil outbreak — Florida,
2016–2017. MMWR. Morbidity and Mortality Weekly Report,
69, 125–129.
320. Massey, J., Kilkenny, M., Batdorf, S., Sanders, S.K., Ellison, D.,
Halpin, J., et al. (2017) Opioid overdose outbreak — West Virginia, August 2016. MMWR. Morbidity and Mortality Weekly
Report, 66, 975–980.
321. Papsun, D., Hawes, A., Mohr, A.L.A., Friscia, M., Logan, B.K.
(2017) Case series of novel illicit opioid-related deaths. Academic
Forensic Pathology, 7, 477–486.
322. Vohra, V., Hodgman, M., Marraffa, J., Barba, K., Stoppacher, R.
(2020) Fentanyl- and fentanyl analog-related deaths across five
counties in Central New York between 2013 and 2017. Clinical
Toxicology (Philadelphia, Pa.), 58, 112–116.
323. Corsi, N., Dragovic, L. (2019) Fatal overdoses involving carfentanil: a case series. Journal of Forensic Science and Medicine, 5,
147.
324. Simonsen, K.W., Kriikku, P., Thelander, G., Edvardsen, H.M.E.,
Thordardottir, S., Andersen, C.U., et al. (2020) Fatal poisoning
in drug addicts in the Nordic countries in 2017. Forensic Science
International, 313, 110343.
325. Kahl, J.H., Gonyea, J., Humphrey, S.M., Hime, G.W., Boland,
D.M. (2018) Quantitative analysis of fentanyl and six fentanyl
analogs in postmortem specimens by UHPLC–MS-MS. Journal
of Analytical Toxicology, 42, 570–580.
326. Elliott, S.P., Hernandez Lopez, E. (2018) A series of deaths
involving carfentanil in the UK and associated post-mortem
blood concentrations. Journal of Analytical Toxicology, 42,
e41–e45.
327. Mayer, S., Boyd, J., Collins, A., Kennedy, M.C., Fairbairn,
N., McNeil, R. (2018) Characterizing fentanyl-related overdoses
and implications for overdose response: findings from a rapid
ethnographic study in Vancouver, Canada. Drug and Alcohol
Dependence, 193, 69–74.
328. Waite, K., Deeken, A., Perch, S., Kohler, L.J. (2017) Carfentanil
and current opioid trends in Summit County, Ohio. Academic
Forensic Pathology, 7, 632–639.
329. Fomin, D., Baranauskaite, V., Usaviciene, E., Sumkovskaja, A.,
Laima, S., Jasulaitis, A., et al. (2018) Human deaths from drug
overdoses with carfentanyl involvement—new rising problem in
forensic medicine. Medicine, 97, e13449.
330. Pardo, B., Taylor, J., Caulkins, J.P., Kilmer, B., Reuter, P., Stein,
B.D. (2019) Understanding America’s Surge in Fentanyl and
Other Synthetic Opioids. RAND Corporation, Santa Monica,
CA. https://www.rand.org/pubs/research_briefs/RB10091.html
(Dec 1, 2020).
331. Zoorob, M. (2019) Fentanyl shock: the changing geography
of overdose in the United States. International Journal of Drug
Policy, 70, 40–46.
332. Drug Enforcement Administration. (2018) Schedules of controlled substances: temporary placement of fentanyl-related
substances in Schedule I. Temporary amendment; temporary
scheduling order. Federal Register, 83, 5188–5192.
333. Weedn, V.W., Elizabeth Zaney, M., McCord, B., Lurie, I.,
Baker, A. (2021) Fentanyl-related substance scheduling as an
effective drug control strategy. Journal of Forensic Sciences, 66,
1186–1200.
334. Papsun, D., Isenschmid, D., Logan, B.K. (2017) Observed carfentanil concentrations in 355 blood specimens from forensic
investigations. Journal of Analytical Toxicology, 41, 777–778.

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

300. Shanks, K.G., Behonick, G.S. (2017) Detection of carfentanil
by LC–MS-MS and reports of associated fatalities in the USA.
Journal of Analytical Toxicology, 41, 466–472.
301. Guerrieri, D., Rapp, E., Roman, M., Druid, H., Kronstrand,
R. (2017) Postmortem and toxicological findings in a series of
furanylfentanyl-related deaths. Journal of Analytical Toxicology,
41, 242–249.
302. Guerrieri, D., Rapp, E., Roman, M., Thelander, G., Kronstrand, R. (2017) Acrylfentanyl: another new psychoactive drug
with fatal consequences. Forensic Science International, 277,
e21–e29.
303. Butler, D.C., Shanks, K., Behonick, G.S., Smith, D., Presnell, S.E.,
Tormos, L.M. (2018) Three cases of fatal acrylfentanyl toxicity in
the United States and a review of literature. Journal of Analytical
Toxicology, 42, e6–e11.
304. Helland, A., Brede, W.R., Michelsen, L.S., Gundersen, P.O.M.,
Aarset, H., Skjølås, J.E., et al. (2017) Two hospitalizations
and one death after exposure to ortho-fluorofentanyl. Journal of
Analytical Toxicology, 41, 708–709.
305. Martucci, H.F.H., Ingle, E.A., Hunter, M.D., Rodda, L.N.
(2018) Distribution of furanyl fentanyl and 4-ANPP in an accidental acute death: a case report. Forensic Science International,
283, e13–e17.
306. Park, J.N., Rashidi, E., Foti, K., Zoorob, M., Sherman, S., Alexander, G.C. (2021) Fentanyl and fentanyl
analogs in the illicit stimulant supply: results from U.S. drug
seizure data, 2011–2016. Drug and Alcohol Dependence, 218,
108416.
307. O’Donnell, J.K., Halpin, J., Mattson, C., Goldberger, B., Gladden, R. (2017) Deaths involving fentanyl, fentanyl analogs, and
U-47700 — 10 states, July–December 2016. MMWR. Morbidity
and Mortality Weekly Report, 66, 1197–1202.
308. Colon-Berezin, C., Nolan, M.L., Blachman-Forshay, J., Paone,
D. (2019) Overdose deaths involving fentanyl and fentanyl
analogs — New York City, 2000–2017. MMWR. Morbidity and
Mortality Weekly Report, 68, 37–40.
309. Butler, D.C., Batalis, N.I. (2017) Opioid-associated deaths in
South Carolina, 2013-2016: a retrospective review. Academic
Forensic Pathology, 7, 640–648.
310. Dai, Z., Abate, M.A., Smith, G.S., Kraner, J.C., Mock, A.R.
(2019) Fentanyl and fentanyl-analog involvement in drug-related
deaths. Drug and Alcohol Dependence, 196, 1–8.
311. Daniulaityte, R., Juhascik, M.P., Strayer, K.E., Sizemore, I.E.,
Zatreh, M., Nahhas, R.W., et al. (2019) Trends in fentanyl
and fentanyl analogue-related overdose deaths – Montgomery
County, Ohio, 2015–2017. Drug and Alcohol Dependence, 198,
116–120.
312. Daniulaityte, R., Juhascik, M.P., Strayer, K.E., Sizemore, I.E.,
Harshbarger, K.E., Antonides, H.M., et al. (2017) Overdose
deaths related to fentanyl and its analogs - Ohio, JanuaryFebruary 2017. MMWR. Morbidity and Mortality Weekly
Report, 66, 904–908.
313. Peterson, B.L., Schreiber, S., Fumo, N., Lerner, E.B. (2019)
Opioid deaths in Milwaukee County, Wisconsin 2013-2017: the
primacy of heroin and fentanyl. Journal of Forensic Sciences, 64,
144–148.
314. Serinelli, S., White, S., Arunkumar, P., Wang, D., Gitto, L.
(2019) The outbreak of fentanyl-related deaths in Cook County,
Illinois, between October 2015 and December 2017: a retrospective study and a comparison with previous data. Journal of
Forensic Sciences, 64, 1735–1742.
315. Zibbell, J.E., Aldridge, A., Cauchon, D., DeFiore-Hymer, J.,
Conway, K. (2019) Association of law enforcement seizures of
heroin, fentanyl, and carfentanil with opioid overdose deaths in
Ohio, 2014-2017. JAMA, 2, e1914666.
316. Fagiola, M., Hahn, T., Avella, J. (2019) Five postmortem case
reports with qualitative analysis of cyclopropylfentanyl by LC–
MS-MS. Journal of Analytical Toxicology, 43, e1–e6.

e183

e184

351. Krotulski, A.J., Shuda, S., Fogarty, M.F., Decker, S. (2020)
Metonitazene. NMS Labs. https://www.npsdiscovery.org/wpcontent/uploads/2020/07/Metonitazene_073020_NMSLabs_Re
port.pdf (Feb 13, 2021).
352. Vandeputte, M.M., Uytfanghe, K.V., Layle, N., St. Germaine,
D., Iula, D.M., Stove, C. (2021) Synthesis, chemical characterization, and µ-opioid receptor activity assessment of the emerging group of ‘nitazene’ 2-benzylbenzimidazole synthetic opioids.
ACS Chemical Neuroscience, 12, 1241–1251.
353. Lutz, P. (2012) Benzimidazole and its derivatives—from fungicides to designer drugs. A new occupational and environmental
hazards. Medycyna Pracy, 63, 505–513.
354. Adamson, D.W., Green, A.F. (1950) A new series of analgesics.
Nature, 165, 122.
355. Krotulski, A.J., Papsun, D.M., Noble, C., Kacinko, S.L., Nelson,
L., Logan, B.K. (2020) Public Health Alert: Brorphine. NPS
Discovery. https://www.npsdiscovery.org/wp-content/uploads/
2020/07/Public-Alert_Brorphine_NPS-Discovery_072720.pdf
(Jan 10, 2021).
356. Kennedy, N.M., Schmid, C.L., Ross, N.C., Lovell, K.M., Yue, Z.,
Chen, Y.T., et al. (2018) Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias.
Journal of Medicinal Chemistry, 61, 8895–8907.
357. Drug Enforcement Administration. (2020) Temporary placement of brorphine in Schedule I. Federal Register, 85,
78047–78050.
358. Irikura, T., Nishino, K., Ito, N., Ito, M., Ohkubo, H. (1970)
Studies on analgesic agents. VI. Analgesic effect of 1-butyryl-4cinnamylpiperazine hydrochloride. Japanese Journal of Pharmacology, 20, 287–293.
359. Yu, S.-Y., Wang, J.-J., Huang, Y.-G., Hu, B., Wang, K., Li, P.P.,
et al. (2017) Managing pain in patients with cancer: the Chinese
good pain management experience. Journal of Global Oncology,
3, 583–595.
360. Furlan, D. (1985) US Patent for Methyl-piperazino derivatives with analgesic activity Patent. December 31, 1985.
https://patents.justia.com/patent/4562191 (Jan 10, 2021).
361. Vandeputte, M.M., Cannaert, A., Stove, C.P. (2020) In vitro
functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Archives of Toxicology, 94,
3819–3830.
362. Krotulski, A.J., Fogarty, M.F., Logan, B.K. (2019) AP237. NMS Labs. https://www.npsdiscovery.org/wp-content/
uploads/2019/09/AP-237_091619_NMSLabs_Report.pdf (Feb
2, 2021).
363. Krotulski, A.J., Fogarty, M.F., Logan, B.K. (2020) Para-MethylAP-237. NMS Labs. https://www.npsdiscovery.org/wp-content/
uploads/2020/04/para-Methyl-AP-237_041320_NMSLabs_Re
port.pdf (Feb 2, 2021).
364. Gassaway, M.M., Rives, M.-L., Kruegel, A.C., Javitch, J.A.,
Sames, D. (2014) The atypical antidepressant and neurorestorative agent tianeptine is a µ-opioid receptor agonist. Translational
Psychiatry, 4, e411.
365. Brink, C.B., Harvey, B.H., Brand, L. (2006) Tianeptine: a novel
atypical antidepressant that may provide new insights into the
biomolecular basis of depression. Recent Patents on CNS Drug
Discovery, 1, 29–41.
366. Wagstaff, A.J., Ormrod, D., Spencer, C.M. (2001) Tianeptine:
a review of its use in depressive disorders. CNS Drugs, 15,
231–259.
367. Springer, J., Cubała, W.J. (2018) Tianeptine abuse and dependence in psychiatric patients: a review of 18 case reports in the
literature. Journal of Psychoactive Drugs, 50, 275–280.
368. Nabil, S., Guan, N.C., Rashid, R.A. (2018) Tianeptine dependence: a case report. Malaysian Journal of Psychiatry, 27,
47–51.

Downloaded from https://academic.oup.com/jat/article/46/6/e116/6571677 by Thomas Jefferson University user on 08 August 2022

335. Chatterton, C.N., Handy, R.P., Shoemaker, G.K., Scott-Ham, M.
(2020) The distribution and redistribution of carfentanil in post
mortem samples. Forensic Science International, 309, 110215.
336. Chesser, R. (2018) Analysis of synthetic opioids in postmortem
blood, vitreous humor, and brain tissue. CUNY Academic
Works, 2018. https://academicworks.cuny.edu/jj_etds/88 (Mar 6,
2022).
337. Sharma, K.K., Hales, T.G., Rao, V.J., NicDaeid, N., McKenzie,
C. (2019) The search for the ‘next’ euphoric non-fentanil novel
synthetic opioids on the illicit drugs market: current status and
horizon scanning. Forensic Toxicology, 37, 1–16.
338. Cheney, B.V., Szmuszkovicz, J., Lahti, R.A., Zichi,
D.A. (1985) Factors affecting binding of trans-N-[2(methylamino)cyclohexyl]benzamides at the primary morphine
receptor. Journal of Medicinal Chemistry, 28, 1853–1864.
339. Szmuszkovicz, J., Von Voigtlander, P.F. (1982) Benzeneacetamide
amines: structurally novel non-mu opioids. Journal of Medicinal
Chemistry, 25, 1125–1126.
340. Baumann, M.H., Tocco, G., Papsun, D.M., Mohr, A.L., Fogarty, M.F., Krotulski, A.J. (2020) U-47700 and its analogs:
non-fentanyl synthetic opioids impacting the recreational drug
market. Brain Sciences, 10, 895.
341. Carroll, F.I., Lewin, A.H., Mascarella, S.W., Seltzman, H.H.,
Reddy, P.A. (2020) Designer drugs: a medicinal chemistry perspective (II). Annals of the New York Academy of Sciences, 1248,
18–38.
342. Moolten, M.S., Fishman, J.B., Chen, J.C., Carlson, K.R. (1993)
Etonitazene: an opioid selective for the mu receptor types. Life
Sciences, 52, PL199–203.
343. Hunger, A., Kebrle, J., Rossi, A., Hoffmann, K. (1957) Synthese basisch substituierter, analgetisch wirksamer BenzimidazolDerivate. Experientia, 13, 400–401.
344. Blanckaert, P., Cannaert, A., Uytfanghe, K.V., Hulpia, F., Deconinck, E., Calenbergh, S.V., et al. (2020) Report on a novel emerging class of highly potent benzimidazole NPS opioids: chemical
and in vitro functional characterization of isotonitazene. Drug
Testing and Analysis, 12, 422–430.
345. European Monitoring Centre for Drugs and Drug Addiction.
(2020) EMCDDA initial report on the new psychoactive
substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene). Publications Office of European Union, Luxembourg. https://www.
emcdda.europa.eu/system/files/publications/13028/EMCDDAInitial-report_Isotonitazene.pdf (Mar 6, 2022).
346. Krotulski, A.J., Papsun, D.M., Fogarty, M.F., Nelson, L.,
Logan, B.K. (2019) Public Health Alert: Isotonitazene.
NPS
Discovery.
https://www.npsdiscovery.org/wp-content/
uploads/2019/11/Public-Alert_Isotonitazene_NPS-Discovery_11
1919-1.pdf (Jan 10, 2021).
347. Shover, C.L., Falasinnu, T.O., Freedman, R.B., Humphreys, K.
(2021) Emerging characteristics of isotonitazene-involved overdose deaths: a case-control study. Journal of Addiction Medicine,
15, 429–431.
348. Drug Enforcement Administration. (2020) Temporary placement of isotonitazene in Schedule I. Federal Register, 85,
36819–36823.
349. Zagorski, C.M., Myslinski, J.M., Hill, L.G. (2020) Isotonitazene
as a contaminant of concern in the illegal opioid supply: a practical synthesis and cost perspective. International Journal of Drug
Policy, 86, 102939.
350. Siczek, M., Zawadzki, M., Siczek, M., Chłopaś-Konowałek,
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